{"ID": "DDI-DrugBank.d64.s87.p847", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;@DRUG$;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;@DRUG$, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["disulfiram", "drug", "352-361"], "DRUGB": ["sulfonamides", "group", "832-843"]}
{"ID": "DDI-DrugBank.d411.s4.p314", "TEXT1": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "LBL": "0", "DRUGA": ["diazepam", "drug", "462-469"], "DRUGB": ["iodine-containing compounds", "group", "611-637"]}
{"ID": "DDI-DrugBank.d482.s14.p37", "TEXT1": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other @DRUG$ metoprolol antihistamines carbamazepine (Tegretol) @DRUG$ (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "LBL": "0", "DRUGA": ["antidepressants", "group", "95-109"], "DRUGB": ["cimetidine", "drug", "162-171"]}
{"ID": "DDI-DrugBank.d86.s1.p99", "TEXT1": "Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, @DRUG$ pain medication (e.g., @DRUG$), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.", "LBL": "0", "DRUGA": ["narcotic", "group", "252-259"], "DRUGB": ["codeine", "drug", "284-290"]}
{"ID": "DDI-DrugBank.d357.s3.p29", "TEXT1": "Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that @DRUG$, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of @DRUG$.", "LBL": "0", "DRUGA": ["dopamine antagonists", "group", "83-102"], "DRUGB": ["APOKYN", "brand", "231-236"]}
{"ID": "DDI-DrugBank.d521.s3.p4", "TEXT1": "- a sulfa-based drug such as @DRUG$-trimethoprim (Bactrim, Septra), sulfisoxazole (@DRUG$), or sulfasalazine (Azulfidine);", "LBL": "0", "DRUGA": ["sulfamethoxazole", "drug", "29-44"], "DRUGB": ["Gantrisin", "brand", "93-101"]}
{"ID": "DDI-DrugBank.d446.s0.p82", "TEXT1": "Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, @DRUG$, nicotine, @DRUG$, tamoxifen, and warfarin.", "LBL": "0", "DRUGA": ["dantrolene", "drug", "157-166"], "DRUGB": ["somatropin", "drug", "179-188"]}
{"ID": "DDI-DrugBank.d225.s0.p24", "TEXT1": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, @DRUG$, @DRUG$, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.", "LBL": "0", "DRUGA": ["salicylates", "group", "224-234"], "DRUGB": ["sulfonamides", "group", "237-248"]}
{"ID": "DDI-DrugBank.d94.s11.p94", "TEXT1": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "LBL": "0", "DRUGA": ["alprazolam", "drug", "172-181"], "DRUGB": ["clonazepam", "drug", "243-252"]}
{"ID": "DDI-DrugBank.d410.s10.p3", "TEXT1": "Oral Contraceptives: The effect of oral @DRUG$ on the pharmacokinetics of @DRUG$  (dihydroergotamine mesylate) Injection, USP has not been studied.", "LBL": "0", "DRUGA": ["contraceptives", "group", "40-53"], "DRUGB": ["D.H.E. 45", "brand", "82-90"]}
{"ID": "DDI-DrugBank.d212.s11.p48", "TEXT1": "Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, @DRUG$, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these @DRUG$ during placebo-controlled clinical studies.", "LBL": "0", "DRUGA": ["phenytoin", "drug", "115-123"], "DRUGB": ["AEDs", "group", "236-239"]}
{"ID": "DDI-DrugBank.d183.s1.p9", "TEXT1": "INOmax has been administered with tolazoline, @DRUG$, @DRUG$, steroids, surfactant, and high-frequency ventilation.", "LBL": "0", "DRUGA": ["dopamine", "drug", "46-53"], "DRUGB": ["dobutamine", "drug", "56-65"]}
{"ID": "DDI-DrugBank.d415.s1.p9", "TEXT1": "However, because bleeding has been reported when ibuprofen and other nonsteroidal anti-inflammatory agents have been administered to patients on coumarin-type anticoagulants, the physician should be cautious when administering @DRUG$ to patients on @DRUG$.", "LBL": "DDI-advise", "DRUGA": ["ibuprofen", "drug", "227-235"], "DRUGB": ["anticoagulants", "group", "252-265"]}
{"ID": "DDI-DrugBank.d400.s14.p25", "TEXT1": "Antacids: In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including @DRUG$, @DRUG$ and trimethoprim.", "LBL": "0", "DRUGA": ["fluconazole", "drug", "271-281"], "DRUGB": ["lovastatin", "drug", "284-293"]}
{"ID": "DDI-DrugBank.d443.s9.p2", "TEXT1": "Antacids: Enteric Coated @DRUG$ should not be given concurrently with @DRUG$, since an increase in the pH of the stomach may effect the enteric coating of the tablets.", "LBL": "DDI-advise", "DRUGA": ["Aspirin", "brand", "25-31"], "DRUGB": ["antacids", "group", "71-78"]}
{"ID": "DDI-DrugBank.d64.s87.p445", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;@DRUG$*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;@DRUG$;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["chloral hydrate", "drug", "208-222"], "DRUGB": ["tolbutamide", "drug", "881-891"]}
{"ID": "DDI-MedLine.d8.s1.p0", "TEXT1": "The antimicrobial effect of a @DRUG$, @DRUG$, either alone or in combination with ofloxacin, was evaluated in vitro against two type strains and six clinical isolates of Mycobacterium ulcerans.", "LBL": "0", "DRUGA": ["benzoxazinorifamycin", "drug_n", "30-49"], "DRUGB": ["KRM-1648", "drug_n", "52-59"]}
{"ID": "DDI-DrugBank.d350.s5.p0", "TEXT1": "@DRUG$ reduced the blood AUC0-12 of @DRUG$ by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.", "LBL": "DDI-mechanism", "DRUGA": ["CANCIDAS", "brand", "0-7"], "DRUGB": ["tacrolimus", "drug", "38-47"]}
{"ID": "DDI-DrugBank.d565.s26.p0", "TEXT1": "In renal and cardiac transplant recipients, a reduction of @DRUG$ dose ranging from 15% to 48% was necessary to maintain @DRUG$ trough concentrations similar to those seen prior to the addition of diltiazem.", "LBL": "0", "DRUGA": ["cyclosporine", "drug", "59-70"], "DRUGB": ["cyclosporine", "drug", "127-138"]}
{"ID": "DDI-DrugBank.d5.s17.p110", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., @DRUG$, risperidone, thioridazine), @DRUG$ (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["haloperidol", "drug", "234-244"], "DRUGB": ["beta-blockers", "group", "275-287"]}
{"ID": "DDI-DrugBank.d246.s0.p1", "TEXT1": "Concurrent use of @DRUG$ with central nervous system depressants (e.g., @DRUG$, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.", "LBL": "DDI-effect", "DRUGA": ["butorphanol", "drug", "18-28"], "DRUGB": ["alcohol", "drug", "77-83"]}
{"ID": "DDI-MedLine.d105.s1.p2", "TEXT1": "Two studies were conducted in HIV-infected subjects to assess the potential for azithromycin to interact with @DRUG$ and @DRUG$.", "LBL": "0", "DRUGA": ["zidovudine", "drug", "110-119"], "DRUGB": ["dideoxyinosine", "drug", "125-138"]}
{"ID": "DDI-DrugBank.d64.s87.p757", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;@DRUG$;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;@DRUG$;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["diazoxide", "drug", "310-318"], "DRUGB": ["miconazole", "drug", "574-583"]}
{"ID": "DDI-DrugBank.d208.s0.p18", "TEXT1": "Benzthiazide may interact with alcohol, @DRUG$s, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, @DRUG$ like Aleve or Ibuprofen, and high blood pressure medications.", "LBL": "0", "DRUGA": ["blood thinner", "group", "40-52"], "DRUGB": ["NSAIDs", "group", "154-159"]}
{"ID": "DDI-DrugBank.d521.s1.p25", "TEXT1": "Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another @DRUG$ such as magnesium/choline salicylate (Trilisate), @DRUG$ (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);", "LBL": "0", "DRUGA": ["salicylate", "group", "115-124"], "DRUGB": ["salsalate", "drug", "176-184"]}
{"ID": "DDI-DrugBank.d488.s2.p23", "TEXT1": "Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, @DRUG$, ibuprofen, indomethacin, @DRUG$, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.", "LBL": "0", "DRUGA": ["phenylbutazone", "drug", "66-79"], "DRUGB": ["dipyridamole", "drug", "107-118"]}
{"ID": "DDI-DrugBank.d537.s0.p57", "TEXT1": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., @DRUG$), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., @DRUG$), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "LBL": "0", "DRUGA": ["Chloromycetin", "brand", "84-96"], "DRUGB": ["Pronestyl", "brand", "269-277"]}
{"ID": "DDI-DrugBank.d143.s18.p3", "TEXT1": "@DRUG$ may suppress certain CYP450 enzymes, including CYP1A2, CYP2C9, CYP2D6, and @DRUG$.", "LBL": "0", "DRUGA": ["Amiodarone", "drug", "0-9"], "DRUGB": ["CYP3A4", "drug", "86-91"]}
{"ID": "DDI-DrugBank.d522.s12.p3", "TEXT1": "Theophylline: Following co-administration of two 250-mg @DRUG$ tablets administered once daily with 200-mg @DRUG$ tablets administered twice daily for 10 days to 14 healthy subjects, the steady-state plasma concentration of theophylline was not significantly altered.", "LBL": "0", "DRUGA": ["dirithromycin", "drug", "56-68"], "DRUGB": ["theophylline", "drug", "114-125"]}
{"ID": "DDI-DrugBank.d501.s10.p14", "TEXT1": "In vitro studies evaluating the minimum inhibitory concentration (MIC) of vancomycin, @DRUG$, ampicillin, ampicillin/flucoxacillin, ceftazidime, gentamicin, and amphotericin demonstrated no evidence of incompatibility of these antibiotics with @DRUG$.", "LBL": "0", "DRUGA": ["cefazolin", "drug", "86-94"], "DRUGB": ["EXTRANEAL", "brand", "247-255"]}
{"ID": "DDI-DrugBank.d64.s87.p767", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;@DRUG$;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;@DRUG$;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["diazoxide", "drug", "310-318"], "DRUGB": ["prolonged narcotics", "group", "743-761"]}
{"ID": "DDI-DrugBank.d318.s14.p2", "TEXT1": "Leukocyte transfusions: acute pulmonary toxicity has been reported in patients receiving intravenous @DRUG$ and @DRUG$.", "LBL": "DDI-effect", "DRUGA": ["amphotericin B", "drug", "101-114"], "DRUGB": ["leukocyte transfusions", "drug_n", "120-141"]}
{"ID": "DDI-MedLine.d56.s1.p0", "TEXT1": "@DRUG$ (@DRUG$), C129H223N3O54, isolated from marine coelenterates of Palythoa tuberculosa, caused a first rapid contraction followed by the slow phasic contraction of guinea-pig vas deferens.", "LBL": "0", "DRUGA": ["Palytoxin", "drug_n", "0-8"], "DRUGB": ["PTX", "drug_n", "11-13"]}
{"ID": "DDI-DrugBank.d527.s2.p76", "TEXT1": "The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, @DRUG$, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral @DRUG$).", "LBL": "0", "DRUGA": ["albuterol", "drug", "183-191"], "DRUGB": ["contraceptives", "group", "315-328"]}
{"ID": "DDI-DrugBank.d363.s2.p1", "TEXT1": "Like @DRUG$, desflurane does not predispose to premature ventricular arrhythmias in the presence of exogenously infused @DRUG$ in swine.", "LBL": "0", "DRUGA": ["isoflurane", "drug", "5-14"], "DRUGB": ["epinephrine", "drug", "124-134"]}
{"ID": "DDI-DrugBank.d115.s0.p18", "TEXT1": "Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, @DRUG$, clarithromycin).", "LBL": "0", "DRUGA": ["itraconazole", "drug", "216-227"], "DRUGB": ["erythromycin", "drug", "230-241"]}
{"ID": "DDI-MedLine.d111.s5.p64", "TEXT1": "acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.", "LBL": "0", "DRUGA": ["phenobarbital", "drug", "78-90"], "DRUGB": ["quinidine", "drug", "107-115"]}
{"ID": "DDI-DrugBank.d484.s0.p383", "TEXT1": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, @DRUG$, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (@DRUG$, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "LBL": "0", "DRUGA": ["Tegretol", "brand", "174-181"], "DRUGB": ["Astramorph", "brand", "466-475"]}
{"ID": "DDI-DrugBank.d484.s0.p947", "TEXT1": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, @DRUG$), phenylbutazone, prednisolone (@DRUG$), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "LBL": "0", "DRUGA": ["MS Contin", "brand", "486-494"], "DRUGB": ["Prelone", "brand", "528-534"]}
{"ID": "DDI-DrugBank.d367.s9.p25", "TEXT1": "Analgesic/anti-inflammatory (e.g., acetaminophen, aspirin, codeine and @DRUG$ combinations, @DRUG$, indomethacin).", "LBL": "0", "DRUGA": ["codeine", "drug", "71-77"], "DRUGB": ["ibuprofen", "drug", "93-101"]}
{"ID": "DDI-DrugBank.d568.s18.p5", "TEXT1": "Theophylline - Combined administration of racemic citalopram (40 mg/day for 21 days) and the CYP1A2 substrate @DRUG$ (single dose of 300 mg) did not affect the pharmacokinetics of @DRUG$.", "LBL": "0", "DRUGA": ["theophylline", "drug", "110-121"], "DRUGB": ["theophylline", "drug", "186-197"]}
{"ID": "DDI-DrugBank.d411.s4.p552", "TEXT1": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.", "LBL": "0", "DRUGA": ["rifampin", "drug", "768-775"], "DRUGB": ["sulfonamides", "group", "800-811"]}
{"ID": "DDI-DrugBank.d485.s17.p33", "TEXT1": "Benzodiazepines: Combination hormonal contraceptives may decrease the clearance of some benzodiazepines (alprazolam, chlordiazepoxide, diazepam) and increase the clearance of others (@DRUG$, @DRUG$, temazepam).", "LBL": "0", "DRUGA": ["lorazepam", "drug", "183-191"], "DRUGB": ["oxazepam", "drug", "194-201"]}
{"ID": "DDI-DrugBank.d561.s4.p3", "TEXT1": "@DRUG$ (spironolactone, amiloride, triamterene, and others) or @DRUG$ supplements can increase the risk of hyperkalemia.", "LBL": "0", "DRUGA": ["Potassium-sparing diuretics", "group", "0-26"], "DRUGB": ["potassium", "drug", "84-92"]}
{"ID": "DDI-DrugBank.d549.s4.p0", "TEXT1": "Intravenous infusion of @DRUG$ had no effect on the pharmacokinetics of @DRUG$.", "LBL": "0", "DRUGA": ["iloprost", "drug", "24-31"], "DRUGB": ["digoxin", "drug", "74-80"]}
{"ID": "DDI-DrugBank.d225.s11.p0", "TEXT1": "The effect of concomitant administration of @DRUG$ and @DRUG$ has been demonstrated in a placebo-controlled crossover study in normal volunteers.", "LBL": "DDI-int", "DRUGA": ["fluconazole", "drug", "44-54"], "DRUGB": ["glipizide", "drug", "60-68"]}
{"ID": "DDI-DrugBank.d274.s3.p34", "TEXT1": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, @DRUG$, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, @DRUG$, and acetaminophen.", "LBL": "0", "DRUGA": ["furosemide", "drug", "165-174"], "DRUGB": ["folic acid", "drug", "307-316"]}
{"ID": "DDI-DrugBank.d196.s6.p5", "TEXT1": "Stavudine and @DRUG$ Ribavirin can antagonize the in vitro antiviral activity of @DRUG$ and zidovudine against HIV.", "LBL": "0", "DRUGA": ["Zidovudine", "drug", "14-23"], "DRUGB": ["stavudine", "drug", "85-93"]}
{"ID": "DDI-DrugBank.d64.s87.p536", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;@DRUG$;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;@DRUG$/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["chymotrypsin", "drug", "240-251"], "DRUGB": ["trimethoprim", "drug", "910-921"]}
{"ID": "DDI-DrugBank.d47.s5.p1", "TEXT1": "@DRUG$ salts may reduce the bioavailability of carbidopa and @DRUG$.", "LBL": "DDI-mechanism", "DRUGA": ["Iron", "drug", "0-3"], "DRUGB": ["levodopa", "drug", "59-66"]}
{"ID": "DDI-DrugBank.d446.s0.p52", "TEXT1": "Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, @DRUG$, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, @DRUG$, tamoxifen, and warfarin.", "LBL": "0", "DRUGA": ["bromocriptine", "drug", "75-87"], "DRUGB": ["somatropin", "drug", "179-188"]}
{"ID": "DDI-DrugBank.d324.s35.p5", "TEXT1": "Warfarin: Multiple oral doses of Sonata (20 mg q24h for 13 days) did not affect the pharmacokinetics of @DRUG$ (R+)- or (S-)-enantiomers or the pharmacodynamics (prothrombin time) following a single 25-mg oral dose of @DRUG$.", "LBL": "0", "DRUGA": ["warfarin", "drug", "104-111"], "DRUGB": ["warfarin", "drug", "220-227"]}
{"ID": "DDI-DrugBank.d46.s7.p17", "TEXT1": "- Cholestyramine and colestipol @DRUG$: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing @DRUG$ absorption from the gastrointestinal tract", "LBL": "0", "DRUGA": ["resins", "group", "32-37"], "DRUGB": ["diuretic", "group", "139-146"]}
{"ID": "DDI-DrugBank.d17.s9.p2", "TEXT1": "@DRUG$ or Corticosteroids or Corticotropin (@DRUG$)", "LBL": "0", "DRUGA": ["Amphotericin B", "drug", "0-13"], "DRUGB": ["ACTH", "drug", "52-55"]}
{"ID": "DDI-DrugBank.d547.s0.p6", "TEXT1": "No significant drug interactions have been reported in studies of @DRUG$ given with other drugs such as glyburide, nifedipine, digoxin, warfarin, hydrochlorothiazide, and oral contraceptives in healthy volunteers, or given with @DRUG$ to patients with heart failure (NYHA class II and III).", "LBL": "0", "DRUGA": ["candesartan cilexetil", "drug", "66-86"], "DRUGB": ["enalapril", "drug", "243-251"]}
{"ID": "DDI-DrugBank.d277.s12.p7", "TEXT1": "Phenobarbital (@DRUG$): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (@DRUG$) with or without other enzyme-inducing AEDs.", "LBL": "0", "DRUGA": ["Primidone", "drug", "15-23"], "DRUGB": ["primidone", "drug", "146-154"]}
{"ID": "DDI-DrugBank.d299.s10.p2", "TEXT1": "Coadministration of almotriptan and the potent CYP3A4 inhibitor @DRUG$ (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of @DRUG$.", "LBL": "0", "DRUGA": ["ketoconazole", "drug", "64-75"], "DRUGB": ["almotriptan", "drug", "235-245"]}
{"ID": "DDI-MedLine.d132.s1.p4", "TEXT1": "The availability of potent non-nucleoside reverse transcriptase inhibitor (@DRUG$)-based regimens for @DRUG$ therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.", "LBL": "0", "DRUGA": ["NNRTI", "group", "75-79"], "DRUGB": ["antiretroviral", "group", "101-114"]}
{"ID": "DDI-DrugBank.d53.s7.p11", "TEXT1": "When used in therapeutic doses, @DRUG$ had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), @DRUG$, trimethoprim/sulfamethoxazole or zidovudine.", "LBL": "DDI-mechanism", "DRUGA": ["azithromycin", "drug", "32-43"], "DRUGB": ["triazolam", "drug", "251-259"]}
{"ID": "DDI-DrugBank.d482.s14.p58", "TEXT1": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants @DRUG$ antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (@DRUG$) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "LBL": "0", "DRUGA": ["metoprolol", "drug", "111-120"], "DRUGB": ["Nizoral", "brand", "252-258"]}
{"ID": "DDI-DrugBank.d313.s2.p93", "TEXT1": "The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, @DRUG$, somatropin, thyroid hormones, estrogens, @DRUG$ (e.g., in oral contraceptives).", "LBL": "0", "DRUGA": ["phenothiazine derivatives", "group", "217-241"], "DRUGB": ["progestogens", "group", "285-296"]}
{"ID": "DDI-DrugBank.d370.s1.p2", "TEXT1": "Particular caution should be exercised in using preparations containing @DRUG$, resorcinol, or salicylic acid in combination with @DRUG$ Gel.", "LBL": "0", "DRUGA": ["sulfur", "drug", "72-77"], "DRUGB": ["DIFFERIN", "brand", "130-137"]}
{"ID": "DDI-DrugBank.d484.s0.p246", "TEXT1": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and @DRUG$, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, @DRUG$ (Theo-Dur), and vitamin C.", "LBL": "0", "DRUGA": ["tetracycline", "drug", "118-129"], "DRUGB": ["theophylline", "drug", "585-596"]}
{"ID": "DDI-DrugBank.d455.s11.p2", "TEXT1": "No interaction with the @DRUG$ imipramine was shown in a single-dose study with entacapone without coadministered @DRUG$/dopa-decarboxylase inhibitor.", "LBL": "0", "DRUGA": ["tricyclic antidepressant", "group", "24-47"], "DRUGB": ["levodopa", "drug", "132-139"]}
{"ID": "DDI-DrugBank.d123.s15.p5", "TEXT1": "Probenecid: Probenecid interferes with renal tubular secretion of @DRUG$ and produces an increase in the level of @DRUG$ in serum.", "LBL": "0", "DRUGA": ["ciprofloxacin", "drug", "66-78"], "DRUGB": ["ciprofloxacin", "drug", "121-133"]}
{"ID": "DDI-DrugBank.d297.s2.p45", "TEXT1": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, @DRUG$, @DRUG$, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.", "LBL": "0", "DRUGA": ["azathioprine", "drug", "175-186"], "DRUGB": ["chloroquine", "drug", "189-199"]}
{"ID": "DDI-DrugBank.d213.s3.p1", "TEXT1": "@DRUG$ may decrease thyroidal uptake of sodium iodide I131, a rebound in uptake may occur up to 5 days after sudden withdrawal of @DRUG$.", "LBL": "0", "DRUGA": ["Antithyroid agents", "group", "0-17"], "DRUGB": ["Carbimazole", "drug", "142-152"]}
{"ID": "DDI-DrugBank.d509.s19.p4", "TEXT1": "Carbamazepine: Coadministration of @DRUG$ (200 mg BID), a potent CYP3A4 inducer, with @DRUG$ (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole.", "LBL": "DDI-mechanism", "DRUGA": ["carbamazepine", "drug", "35-47"], "DRUGB": ["aripiprazole", "drug", "93-104"]}
{"ID": "DDI-DrugBank.d94.s11.p349", "TEXT1": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "LBL": "0", "DRUGA": ["clonazepam", "drug", "243-252"], "DRUGB": ["midazolam", "drug", "470-478"]}
{"ID": "DDI-DrugBank.d202.s16.p8", "TEXT1": "Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other @DRUG$, @DRUG$, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.", "LBL": "0", "DRUGA": ["antidepressants", "group", "131-145"], "DRUGB": ["phenothiazines", "group", "148-161"]}
{"ID": "DDI-DrugBank.d48.s15.p23", "TEXT1": "Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, @DRUG$, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, @DRUG$) should be administered with caution in patients receiving SPRYCEL.", "LBL": "0", "DRUGA": ["astemizole", "drug", "90-99"], "DRUGB": ["dihydroergotamine", "drug", "226-242"]}
{"ID": "DDI-DrugBank.d64.s87.p680", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;@DRUG$;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;@DRUG$;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["dextran", "drug", "286-292"], "DRUGB": ["miconazole", "drug", "574-583"]}
{"ID": "DDI-DrugBank.d167.s1.p1", "TEXT1": "@DRUG$ (neostgmine, physostigmine), @DRUG$, quinine, procainamide can enhance toxicity and cause cardio respiratory depression.", "LBL": "0", "DRUGA": ["Anticholinesterases", "group", "0-18"], "DRUGB": ["lignocaine", "drug", "49-58"]}
{"ID": "DDI-DrugBank.d291.s0.p0", "TEXT1": "When @DRUG$ or @DRUG$ is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip retard may enhance the action of anticoagulants of the coumarin type.", "LBL": "0", "DRUGA": ["Bezalip", "brand", "5-11"], "DRUGB": ["Bezalip retard", "brand", "16-29"]}
{"ID": "DDI-DrugBank.d219.s10.p2", "TEXT1": "Diuretics: Etodolac has no apparent pharmacokinetic interaction when administered with @DRUG$ or @DRUG$.", "LBL": "0", "DRUGA": ["furosemide", "drug", "87-96"], "DRUGB": ["hydrochlorothiazide", "drug", "101-119"]}
{"ID": "DDI-DrugBank.d274.s3.p37", "TEXT1": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, @DRUG$, lidocaine, @DRUG$, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.", "LBL": "0", "DRUGA": ["spironolactone", "drug", "177-190"], "DRUGB": ["glyceryl trinitrate", "drug", "204-222"]}
{"ID": "DDI-DrugBank.d487.s8.p0", "TEXT1": "There are reports of enhanced as well as diminished effects of @DRUG$ when given concurrently with @DRUG$.", "LBL": "DDI-effect", "DRUGA": ["anticoagulants", "group", "63-76"], "DRUGB": ["corticosteroids", "group", "107-121"]}
{"ID": "DDI-DrugBank.d263.s22.p17", "TEXT1": "Magnesium/Aluminum-containing Antacid Products: Absorption of @DRUG$ is moderately reduced (approximately 25%) when coadministered with magnesium/aluminum-containing @DRUG$.", "LBL": "0", "DRUGA": ["zalcitabine", "drug", "62-72"], "DRUGB": ["antacid products", "group", "171-186"]}
{"ID": "DDI-DrugBank.d245.s0.p35", "TEXT1": "The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, @DRUG$, and @DRUG$.", "LBL": "0", "DRUGA": ["monoamine oxidase inhibitors", "group", "238-265"], "DRUGB": ["beta adrenergic blocking agents", "group", "272-302"]}
{"ID": "DDI-DrugBank.d94.s4.p262", "TEXT1": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, @DRUG$, ketoconazole, loratadine, @DRUG$, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "LBL": "0", "DRUGA": ["itraconazole", "drug", "314-325"], "DRUGB": ["nefazodone", "drug", "354-363"]}
{"ID": "DDI-DrugBank.d480.s8.p2", "TEXT1": "Although it has not been established that there is an interaction between @DRUG$ and benzodiazepines or other psychotropics, caution is advised when @DRUG$ is initiated in patients taking a benzodiazepine or any other psychotropic drug.", "LBL": "0", "DRUGA": ["Clozapine", "drug", "74-82"], "DRUGB": ["clozapine", "drug", "152-160"]}
{"ID": "DDI-DrugBank.d373.s2.p9", "TEXT1": "Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between @DRUG$ and @DRUG$, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.", "LBL": "DDI-int", "DRUGA": ["digoxin", "drug", "164-170"], "DRUGB": ["nifedipine", "drug", "176-185"]}
{"ID": "DDI-DrugBank.d165.s3.p0", "TEXT1": "Coadministration of @DRUG$ with @DRUG$ has led to elevated plasma concentrations of terfenadine, resulting in rare instances of life- threatening cardiac dysrhythmias and one death.", "LBL": "DDI-mechanism", "DRUGA": ["terfenadine", "drug", "20-30"], "DRUGB": ["Itraconazole", "drug", "37-48"]}
{"ID": "DDI-DrugBank.d97.s60.p5", "TEXT1": "Anticonvulsants: carbamazepine, @DRUG$, @DRUG$", "LBL": "0", "DRUGA": ["phenobarbital", "drug", "32-44"], "DRUGB": ["phenytoin", "drug", "47-55"]}
{"ID": "DDI-DrugBank.d521.s8.p8", "TEXT1": "- a @DRUG$ such as chlorpromazine (Thorazine), fluphenazine (Prolixin, Permitil), prochlorperazine (Compazine), promethazine (@DRUG$), and others;", "LBL": "0", "DRUGA": ["phenothiazine", "group", "4-16"], "DRUGB": ["Phenergan", "brand", "133-141"]}
{"ID": "DDI-DrugBank.d274.s3.p46", "TEXT1": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, @DRUG$, @DRUG$, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.", "LBL": "0", "DRUGA": ["lidocaine", "drug", "193-201"], "DRUGB": ["glyceryl trinitrate", "drug", "204-222"]}
{"ID": "DDI-DrugBank.d18.s1.p5", "TEXT1": "Injection: @DRUG$ injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other @DRUG$.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.", "LBL": "DDI-effect", "DRUGA": ["Lorazepam", "drug", "11-19"], "DRUGB": ["antidepressants", "group", "215-229"]}
{"ID": "DDI-DrugBank.d389.s0.p3", "TEXT1": "@DRUG$ may enhance the effects of tricyclic antidepressants, barbiturates, alcohol, and other @DRUG$.", "LBL": "DDI-effect", "DRUGA": ["Antihistamines", "group", "0-13"], "DRUGB": ["CNS depressants", "group", "102-116"]}
{"ID": "DDI-DrugBank.d558.s25.p8", "TEXT1": "Inhibitors of this isoenzyme (e.g., @DRUG$, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, @DRUG$, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.", "LBL": "0", "DRUGA": ["macrolide antibiotics", "group", "36-56"], "DRUGB": ["quinine", "drug", "216-222"]}
{"ID": "DDI-DrugBank.d51.s0.p3", "TEXT1": "ATROVENT Inhalation Aerosol has been used concomitantly with other drugs, including @DRUG$, @DRUG$, and steroids, commonly used in the treatment of chronic obstructive pulmonary disease.", "LBL": "0", "DRUGA": ["sympathomimetic bronchodilators", "group", "84-114"], "DRUGB": ["methylxanthines", "group", "117-131"]}
{"ID": "DDI-DrugBank.d431.s12.p7", "TEXT1": "therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, @DRUG$ esters, @DRUG$ salts, digoxin).", "LBL": "0", "DRUGA": ["ampicillin", "drug", "185-194"], "DRUGB": ["iron", "drug", "204-207"]}
{"ID": "DDI-DrugBank.d209.s3.p5", "TEXT1": "Other concomitant therapy Although specific interaction studies were not performed, @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, @DRUG$, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.", "LBL": "0", "DRUGA": ["finasteride", "drug", "84-94"], "DRUGB": ["benzodiazepines", "group", "293-307"]}
{"ID": "DDI-DrugBank.d13.s0.p57", "TEXT1": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ and Ethanol cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of Tricyclic antidepressants", "LBL": "0", "DRUGA": ["Flupenthixol", "drug", "203-214"], "DRUGB": ["Tricyclic antidepressants", "group", "260-284"]}
{"ID": "DDI-MedLine.d69.s0.p1", "TEXT1": "Differential regulation of tyrosine phosphorylation in tumor cells by @DRUG$, a homodimeric disintegrin, and monomeric disintegrins echistatin and @DRUG$.", "LBL": "0", "DRUGA": ["contortrostatin", "drug_n", "70-84"], "DRUGB": ["flavoridin", "drug_n", "156-165"]}
{"ID": "DDI-DrugBank.d526.s24.p0", "TEXT1": "When @DRUG$ therapy is initiated, a reduction in @DRUG$ dosage may be required, and increased amounts may be required when estrogen is terminated.", "LBL": "0", "DRUGA": ["estrogen", "group", "5-12"], "DRUGB": ["corticosteroid", "group", "51-64"]}
{"ID": "DDI-DrugBank.d179.s21.p23", "TEXT1": "- @DRUG$ (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., @DRUG$]) or", "LBL": "0", "DRUGA": ["Phenothiazines", "group", "2-15"], "DRUGB": ["Temaril", "brand", "390-396"]}
{"ID": "DDI-DrugBank.d208.s0.p25", "TEXT1": "Benzthiazide may interact with alcohol, blood thinners, @DRUG$ (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or @DRUG$, and high blood pressure medications.", "LBL": "0", "DRUGA": ["decongestant drugs", "group", "56-73"], "DRUGB": ["Ibuprofen", "drug", "175-183"]}
{"ID": "DDI-DrugBank.d484.s0.p655", "TEXT1": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (@DRUG$), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, @DRUG$), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "LBL": "0", "DRUGA": ["Lipitor", "brand", "272-278"], "DRUGB": ["MS Contin", "brand", "486-494"]}
{"ID": "DDI-DrugBank.d404.s0.p15", "TEXT1": "Interactions for vitamin D analogues (Vitamin D2, @DRUG$, Calcitriol, and Calcidiol): @DRUG$: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;", "LBL": "0", "DRUGA": ["Vitamin D3", "drug", "50-59"], "DRUGB": ["Cholestyramine", "drug", "90-103"]}
{"ID": "DDI-DrugBank.d464.s0.p14", "TEXT1": "Codeine in combination with other narcotic analgesics, general @DRUG$, phenothiazines, @DRUG$, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.", "LBL": "0", "DRUGA": ["anesthetics", "group", "63-73"], "DRUGB": ["tranquilizers", "group", "92-104"]}
{"ID": "DDI-DrugBank.d484.s0.p962", "TEXT1": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, @DRUG$ (@DRUG$), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "LBL": "0", "DRUGA": ["prednisolone", "drug", "514-525"], "DRUGB": ["Prelone", "brand", "528-534"]}
{"ID": "DDI-DrugBank.d76.s19.p0", "TEXT1": "@DRUG$: The co-administration of @DRUG$ Tablets and diazepam is generally not advisable.", "LBL": "0", "DRUGA": ["Diazepam", "drug", "0-7"], "DRUGB": ["Fluvoxamine", "drug", "35-45"]}
{"ID": "DDI-DrugBank.d198.s7.p0", "TEXT1": "@DRUG$ (200 mg once daily) produced a 10-fold increase in @DRUG$ AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.", "LBL": "DDI-mechanism", "DRUGA": ["Ketoconazole", "drug", "0-11"], "DRUGB": ["vardenafil", "drug", "64-73"]}
{"ID": "DDI-DrugBank.d411.s3.p14", "TEXT1": "Binding to Serum Proteins: The following agents may either inhibit @DRUG$ binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, @DRUG$, salicylates, tamoxifen.", "LBL": "DDI-mechanism", "DRUGA": ["levothyroxine sodium", "drug", "67-86"], "DRUGB": ["phenytoin", "drug", "402-410"]}
{"ID": "DDI-DrugBank.d87.s13.p2", "TEXT1": "Limited data in patients receiving known enzyme inducers ( @DRUG$, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of @DRUG$ elimination.", "LBL": "DDI-mechanism", "DRUGA": ["phenytoin", "drug", "59-67"], "DRUGB": ["flecainide", "drug", "145-154"]}
{"ID": "DDI-DrugBank.d167.s2.p24", "TEXT1": "In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like lidocaine, procaine, @DRUG$, metaclopramide, lithium carbonate, and @DRUG$.", "LBL": "0", "DRUGA": ["beta-blockers", "group", "123-135"], "DRUGB": ["terbutaline", "drug", "177-187"]}
{"ID": "DDI-DrugBank.d176.s12.p32", "TEXT1": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, @DRUG$, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of @DRUG$ was not altered by coadministration of fosinopril with any one of these drugs.", "LBL": "0", "DRUGA": ["hydrochlorothiazide", "drug", "117-135"], "DRUGB": ["fosinoprilat", "drug_n", "227-238"]}
{"ID": "DDI-DrugBank.d48.s15.p80", "TEXT1": "Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, @DRUG$, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving @DRUG$.", "LBL": "DDI-advise", "DRUGA": ["sirolimus", "drug", "171-179"], "DRUGB": ["SPRYCEL", "brand", "303-309"]}
{"ID": "DDI-DrugBank.d446.s0.p7", "TEXT1": "@DRUG$ may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, @DRUG$, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.", "LBL": "DDI-int", "DRUGA": ["Chlorotrianisene", "drug", "0-15"], "DRUGB": ["cyclosporine", "drug", "143-154"]}
{"ID": "DDI-DrugBank.d143.s43.p4", "TEXT1": "@DRUG$: Potentiation of warfarin-type (CYP2C9 and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving @DRUG$ and can result in serious or fatal bleeding.", "LBL": "0", "DRUGA": ["Anticoagulants", "drug", "0-13"], "DRUGB": ["amiodarone", "drug", "143-152"]}
{"ID": "DDI-DrugBank.d64.s87.p91", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:@DRUG$*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;@DRUG$;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["alcohol", "drug", "115-121"], "DRUGB": ["phenytoin", "drug", "711-719"]}
{"ID": "DDI-DrugBank.d293.s0.p7", "TEXT1": "May interact with thyroid medication (e.g., @DRUG$), iodine-containing products, antacids, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, @DRUG$).", "LBL": "0", "DRUGA": ["levothyroxine", "drug", "44-56"], "DRUGB": ["omeprazole", "drug", "193-202"]}
{"ID": "DDI-MedLine.d83.s5.p5", "TEXT1": "In the first double-blind comparative study (28-week) of olanzapine and risperidone, @DRUG$ 10 to 20 mg/day proved to be significantly more effective than @DRUG$ 4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms.", "LBL": "0", "DRUGA": ["olanzapine", "drug", "85-94"], "DRUGB": ["risperidone", "drug", "159-169"]}
{"ID": "DDI-DrugBank.d64.s87.p102", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:@DRUG$*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;@DRUG$;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["alcohol", "drug", "115-121"], "DRUGB": ["tolbutamide", "drug", "881-891"]}
{"ID": "DDI-DrugBank.d94.s11.p229", "TEXT1": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "LBL": "0", "DRUGA": ["buspirone", "drug", "210-218"], "DRUGB": ["haloperidol", "drug", "393-403"]}
{"ID": "DDI-DrugBank.d531.s90.p41", "TEXT1": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, @DRUG$, famotidine, fluconazole, lamivudine, @DRUG$, nelfinavir, paroxetine, and zidovudine.", "LBL": "0", "DRUGA": ["cetirizine", "drug", "206-215"], "DRUGB": ["lorazepam", "drug", "255-263"]}
{"ID": "DDI-DrugBank.d53.s7.p98", "TEXT1": "When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, @DRUG$, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or @DRUG$.", "LBL": "0", "DRUGA": ["midazolam", "drug", "180-188"], "DRUGB": ["zidovudine", "drug", "295-304"]}
{"ID": "DDI-DrugBank.d484.s0.p107", "TEXT1": "Etonogestrel may interact with the following medications: acetaminophen (@DRUG$), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, @DRUG$), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "LBL": "0", "DRUGA": ["Tylenol", "brand", "73-79"], "DRUGB": ["Sandimmune", "brand", "328-337"]}
{"ID": "DDI-DrugBank.d484.s0.p207", "TEXT1": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as @DRUG$ and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, @DRUG$ (Theo-Dur), and vitamin C.", "LBL": "0", "DRUGA": ["ampicillin", "drug", "103-112"], "DRUGB": ["theophylline", "drug", "585-596"]}
{"ID": "DDI-DrugBank.d531.s90.p62", "TEXT1": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, @DRUG$, nelfinavir, paroxetine, and @DRUG$.", "LBL": "0", "DRUGA": ["lorazepam", "drug", "255-263"], "DRUGB": ["zidovudine", "drug", "294-303"]}
{"ID": "DDI-DrugBank.d94.s4.p177", "TEXT1": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, @DRUG$, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, @DRUG$(1), verapamil, zileuton.", "LBL": "0", "DRUGA": ["delavirdine", "drug", "219-229"], "DRUGB": ["valproate", "drug", "467-475"]}
{"ID": "DDI-MedLine.d111.s5.p6", "TEXT1": "@DRUG$/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.", "LBL": "0", "DRUGA": ["acetaminophen", "drug", "0-12"], "DRUGB": ["valproic acid", "drug", "92-104"]}
{"ID": "DDI-DrugBank.d238.s23.p1", "TEXT1": "It is desirable to monitor @DRUG$plasma levels whenever an agent of the tricyclic antidepressant class including @DRUG$ is going to be co-administered with another drug known to be an inhibitor of P450 2D6 (and/or P450 1A2).", "LBL": "0", "DRUGA": ["TCA", "group", "27-29"], "DRUGB": ["Anafranil", "brand", "110-118"]}
{"ID": "DDI-DrugBank.d568.s24.p5", "TEXT1": "Triazolam - Combined administration of racemic @DRUG$ (titrated to 40 mg/day for 28 days) and the CYP3A4 substrate triazolam (single dose of 0.25 mg) did not significantly affect the pharmacokinetics of either @DRUG$ or triazolam.", "LBL": "0", "DRUGA": ["citalopram", "drug", "47-56"], "DRUGB": ["citalopram", "drug", "214-223"]}
{"ID": "DDI-DrugBank.d64.s87.p379", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;@DRUG$;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;@DRUG$;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["bromelains", "drug", "197-206"], "DRUGB": ["miconazole", "drug", "574-583"]}
{"ID": "DDI-MedLine.d12.s7.p2", "TEXT1": "These results suggest that both @DRUG$ and retinyl acetate, and possibly other glucocorticoids and @DRUG$, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.", "LBL": "0", "DRUGA": ["dexamethasone", "drug", "32-44"], "DRUGB": ["retinoids", "group", "106-114"]}
{"ID": "DDI-DrugBank.d87.s8.p0", "TEXT1": "Nevertheless, the possibility of additive negative inotropic effects of @DRUG$ and @DRUG$ should be recognized.", "LBL": "DDI-effect", "DRUGA": ["beta blockers", "group", "72-84"], "DRUGB": ["flecainide", "drug", "90-99"]}
{"ID": "DDI-DrugBank.d63.s0.p27", "TEXT1": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., @DRUG$), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and @DRUG$ (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.", "LBL": "0", "DRUGA": ["Marplan", "brand", "64-70"], "DRUGB": ["tranylcypromine", "drug", "165-179"]}
{"ID": "DDI-DrugBank.d411.s3.p58", "TEXT1": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, @DRUG$, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, @DRUG$, phenytoin, salicylates, tamoxifen.", "LBL": "0", "DRUGA": ["asparaginase", "drug", "210-221"], "DRUGB": ["phenylbutazone", "drug", "386-399"]}
{"ID": "DDI-DrugBank.d484.s0.p80", "TEXT1": "Etonogestrel may interact with the following medications: @DRUG$ (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (@DRUG$), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "LBL": "0", "DRUGA": ["acetaminophen", "drug", "58-70"], "DRUGB": ["Prelone", "brand", "528-534"]}
{"ID": "DDI-DrugBank.d94.s11.p886", "TEXT1": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "LBL": "0", "DRUGA": ["nortriptyline", "drug", "494-506"], "DRUGB": ["praziquantel", "drug", "574-585"]}
{"ID": "DDI-DrugBank.d124.s26.p74", "TEXT1": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;", "LBL": "0", "DRUGA": ["quinidine", "drug", "192-200"], "DRUGB": ["pimozide", "drug", "258-265"]}
{"ID": "DDI-DrugBank.d395.s22.p2", "TEXT1": "Theophylline-related adverse effects have occurred in patients when @DRUG$ and @DRUG$ were coadministered.", "LBL": "DDI-effect", "DRUGA": ["theophylline", "drug", "68-79"], "DRUGB": ["enoxacin", "drug", "85-92"]}
{"ID": "DDI-DrugBank.d353.s1.p5", "TEXT1": "Glibenclamide: In a study of 7 healthy male volunteers, @DRUG$ treatment potentiated the blood glucose lowering effect of glibenclamide (a @DRUG$ similar to chlorpropamide) in 3 of the 7 subjects.", "LBL": "0", "DRUGA": ["acitretin", "drug", "56-64"], "DRUGB": ["sulfonylurea", "group", "142-153"]}
{"ID": "DDI-DrugBank.d241.s0.p0", "TEXT1": "Additional reductions in blood pressure may occur when @DRUG$ is administered with @DRUG$, antihypertensive agents, or other vasodilators.", "LBL": "DDI-effect", "DRUGA": ["FLOLAN", "brand", "55-60"], "DRUGB": ["diuretics", "group", "83-91"]}
{"ID": "DDI-DrugBank.d94.s11.p554", "TEXT1": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "LBL": "0", "DRUGA": ["dicumarol", "drug", "315-323"], "DRUGB": ["contraceptives", "group", "526-539"]}
{"ID": "DDI-DrugBank.d189.s0.p39", "TEXT1": "No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin, @DRUG$, @DRUG$, ethanol or itraconazole.", "LBL": "0", "DRUGA": ["isosorbide mononitrate", "drug", "173-194"], "DRUGB": ["carvedilol", "drug", "197-206"]}
{"ID": "DDI-DrugBank.d484.s0.p782", "TEXT1": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as @DRUG$ (Agenerase, Crixivan, @DRUG$, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "LBL": "0", "DRUGA": ["protease inhibitors", "group", "365-383"], "DRUGB": ["Fortovase", "brand", "407-415"]}
{"ID": "DDI-DrugBank.d64.s87.p6", "TEXT1": "Drugs that reportedly may increase oral @DRUG$ response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;@DRUG$;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "DDI-effect", "DRUGA": ["anticoagulant", "group", "40-52"], "DRUGB": ["bromelains", "drug", "197-206"]}
{"ID": "DDI-DrugBank.d154.s1.p2", "TEXT1": "Although the mechanism of interaction between fenoprofen and @DRUG$ is not totally known, enzyme induction and displacement of @DRUG$ from plasma albumin binding sites are possibilities.", "LBL": "0", "DRUGA": ["aspirin", "brand", "61-67"], "DRUGB": ["fenoprofen", "drug", "128-137"]}
{"ID": "DDI-MedLine.d84.s3.p11", "TEXT1": "To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (@DRUG$, cefazolin, oxytetracycline and @DRUG$), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain.", "LBL": "0", "DRUGA": ["ampicillin", "drug", "95-104"], "DRUGB": ["chloramphenicol", "drug", "138-152"]}
{"ID": "DDI-DrugBank.d484.s0.p576", "TEXT1": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, @DRUG$, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, @DRUG$ (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "LBL": "0", "DRUGA": ["Nizoral", "brand", "238-244"], "DRUGB": ["prednisolone", "drug", "514-525"]}
{"ID": "DDI-DrugBank.d480.s30.p26", "TEXT1": "Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and @DRUG$ (e.g., @DRUG$, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.", "LBL": "0", "DRUGA": ["Type 1C antiarrhythmics", "group", "159-181"], "DRUGB": ["propafenone", "drug", "190-200"]}
{"ID": "DDI-DrugBank.d94.s11.p387", "TEXT1": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "LBL": "0", "DRUGA": ["clozapine", "drug", "255-263"], "DRUGB": ["nortriptyline", "drug", "494-506"]}
{"ID": "DDI-DrugBank.d484.s0.p716", "TEXT1": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), @DRUG$ (Neoral, Sandimmune), HIV drugs classified as @DRUG$ (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "LBL": "0", "DRUGA": ["cyclosporine", "drug", "306-317"], "DRUGB": ["protease inhibitors", "group", "365-383"]}
{"ID": "DDI-DrugBank.d530.s3.p2", "TEXT1": "Neuroleptic Drugs - @DRUG$ may potentiate the tardive dyskinesia side reactions of @DRUG$ if used concomitantly with them.", "LBL": "0", "DRUGA": ["L-phenylalanine", "drug", "20-34"], "DRUGB": ["neuroleptic drugs", "group", "92-108"]}
{"ID": "DDI-DrugBank.d334.s12.p0", "TEXT1": "No clinically important pharmacokinetic interactions occurred when @DRUG$ was used concomitantly with @DRUG$ or hydrochlorothiazide.", "LBL": "0", "DRUGA": ["PRINIVIL", "brand", "67-74"], "DRUGB": ["propranolol", "drug", "104-114"]}
{"ID": "DDI-DrugBank.d411.s4.p208", "TEXT1": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.", "LBL": "0", "DRUGA": ["pertechnetate", "drug", "365-377"], "DRUGB": ["sulfonylureas", "group", "814-826"]}
{"ID": "DDI-DrugBank.d64.s87.p1324", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;@DRUG$;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;@DRUG$, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["pentoxifylline", "drug", "668-681"], "DRUGB": ["sulfonamides", "group", "832-843"]}
{"ID": "DDI-DrugBank.d94.s11.p987", "TEXT1": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.", "LBL": "0", "DRUGA": ["quetiapine", "drug", "609-618"], "DRUGB": ["warfarin", "drug", "703-710"]}
{"ID": "DDI-DrugBank.d64.s87.p899", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;@DRUG$;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;@DRUG$;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["fenoprofen", "drug", "410-419"], "DRUGB": ["miconazole", "drug", "574-583"]}
{"ID": "DDI-DrugBank.d482.s14.p39", "TEXT1": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other @DRUG$ metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) @DRUG$ fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "LBL": "0", "DRUGA": ["antidepressants", "group", "95-109"], "DRUGB": ["estrogens", "group", "183-191"]}
{"ID": "DDI-MedLine.d120.s1.p0", "TEXT1": "Among the @DRUG$, many, like @DRUG$, cannot be used clinically because they are toxic;", "LBL": "0", "DRUGA": ["polyene antibiotics", "group", "10-28"], "DRUGB": ["filipin", "drug_n", "42-48"]}
{"ID": "DDI-DrugBank.d212.s17.p1", "TEXT1": "@DRUG$ Keppra  (1000 mg twice daily) did not influence the pharmacokinetics and pharmacodynamics (ECG) of @DRUG$ given as a 0.25 mg dose every day.", "LBL": "0", "DRUGA": ["Digoxin", "drug", "0-6"], "DRUGB": ["digoxin", "drug", "107-113"]}
{"ID": "DDI-DrugBank.d527.s1.p18", "TEXT1": "The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetes products, ACE inhibitors, disopyramide, @DRUG$, fluoxetine, @DRUG$, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.", "LBL": "0", "DRUGA": ["fibrates", "group", "187-194"], "DRUGB": ["MAO inhibitors", "group", "209-222"]}
{"ID": "DDI-DrugBank.d94.s11.p604", "TEXT1": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "LBL": "0", "DRUGA": ["ethosuximide", "drug", "339-350"], "DRUGB": ["itraconazole", "drug", "406-417"]}
{"ID": "DDI-DrugBank.d413.s6.p2", "TEXT1": "@DRUG$: It has been reported that allopurinol prolongs the half-life of the anticoagulant, @DRUG$.", "LBL": "0", "DRUGA": ["Dicumarol", "drug", "0-8"], "DRUGB": ["dicumarol", "drug", "94-102"]}
{"ID": "DDI-DrugBank.d291.s0.p5", "TEXT1": "When Bezalip or @DRUG$ is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and @DRUG$ may enhance the action of anticoagulants of the coumarin type.", "LBL": "0", "DRUGA": ["Bezalip retard", "brand", "16-29"], "DRUGB": ["Bezalip retard", "brand", "158-171"]}
{"ID": "DDI-DrugBank.d543.s0.p14", "TEXT1": "The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine @DRUG$ of class (e.g. quinidine), @DRUG$ antipsychotic agents (e.g. phenothiazines), benzodiazepines.", "LBL": "0", "DRUGA": ["antiarrhythmic agents", "group", "103-123"], "DRUGB": ["antihistamines", "group", "152-165"]}
{"ID": "DDI-DrugBank.d64.s87.p669", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;@DRUG$;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;@DRUG$;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["dextran", "drug", "286-292"], "DRUGB": ["ethacrynic acid", "drug", "394-408"]}
{"ID": "DDI-DrugBank.d318.s8.p5", "TEXT1": "@DRUG$ (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and @DRUG$ suggest that imidazoles may induce fungal resistance to amphotericin B.", "LBL": "0", "DRUGA": ["Imidazoles", "group", "0-9"], "DRUGB": ["imidazoles", "group", "150-159"]}
{"ID": "DDI-DrugBank.d521.s8.p21", "TEXT1": "- a phenothiazine such as chlorpromazine (@DRUG$), fluphenazine (Prolixin, Permitil), prochlorperazine (@DRUG$), promethazine (Phenergan), and others;", "LBL": "0", "DRUGA": ["Thorazine", "brand", "42-50"], "DRUGB": ["Compazine", "brand", "107-115"]}
{"ID": "DDI-DrugBank.d484.s0.p256", "TEXT1": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, @DRUG$ (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (@DRUG$, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "LBL": "0", "DRUGA": ["anticonvulsants", "group", "132-146"], "DRUGB": ["Gris-PEG", "brand", "228-235"]}
{"ID": "DDI-DrugBank.d179.s21.p16", "TEXT1": "- @DRUG$ (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], @DRUG$ [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or", "LBL": "0", "DRUGA": ["Phenothiazines", "group", "2-15"], "DRUGB": ["thioridazine", "drug", "271-282"]}
{"ID": "DDI-DrugBank.d64.s87.p1005", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;@DRUG$;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;@DRUG$;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["indomethacin", "drug", "458-469"], "DRUGB": ["prolonged narcotics", "group", "743-761"]}
{"ID": "DDI-DrugBank.d285.s1.p7", "TEXT1": "A similar association, though less marked, has been suggested with barbiturates, phenyl-butazone, @DRUG$, carbamazepine and possibly with griseofulvin, @DRUG$, and tetracyclines (72)", "LBL": "0", "DRUGA": ["phenytoin sodium", "drug", "98-113"], "DRUGB": ["ampicillin", "drug", "162-171"]}
{"ID": "DDI-MedLine.d30.s1.p4", "TEXT1": "The behavioral effects of the stereoisomers of N-allylnormetazocine (@DRUG$) were compared with those of phencyclidine (@DRUG$) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation.", "LBL": "0", "DRUGA": ["NANM", "drug_n", "69-72"], "DRUGB": ["PCP", "drug_n", "118-120"]}
{"ID": "DDI-DrugBank.d521.s1.p24", "TEXT1": "Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another @DRUG$ such as magnesium/choline salicylate (@DRUG$), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);", "LBL": "0", "DRUGA": ["salicylate", "group", "115-124"], "DRUGB": ["Trilisate", "brand", "164-172"]}
{"ID": "DDI-DrugBank.d121.s0.p0", "TEXT1": "Nephrotoxicity has been reported following concomitant administration of @DRUG$ and @DRUG$.", "LBL": "DDI-effect", "DRUGA": ["aminoglycoside antibiotics", "group", "73-98"], "DRUGB": ["cephalosporin antibiotics", "group", "104-128"]}
{"ID": "DDI-DrugBank.d396.s2.p8", "TEXT1": "The use of MAO inhibitors or tricyclic antidepressants with @DRUG$ preparations may increase the effect of either the antidepressant or @DRUG$.", "LBL": "0", "DRUGA": ["hydrocodone", "drug", "60-70"], "DRUGB": ["hydrocodone", "drug", "141-151"]}
{"ID": "DDI-DrugBank.d357.s3.p14", "TEXT1": "Dopamine Antagonists: Since @DRUG$ is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, @DRUG$) or metoclopramide, may diminish the effectiveness of APOKYN.", "LBL": "0", "DRUGA": ["apomorphine", "drug", "28-38"], "DRUGB": ["thioxanthenes", "group", "163-175"]}
{"ID": "DDI-DrugBank.d64.s87.p613", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;@DRUG$;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;@DRUG$*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["cinchophen", "drug", "264-273"], "DRUGB": ["ranitidine", "drug", "793-802"]}
{"ID": "DDI-MedLine.d111.s5.p30", "TEXT1": "acetaminophen/theophylline, @DRUG$/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.", "LBL": "0", "DRUGA": ["lidocaine", "drug", "28-36"], "DRUGB": ["quinidine", "drug", "107-115"]}
{"ID": "DDI-DrugBank.d64.s87.p801", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;@DRUG$;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;@DRUG$;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["diflunisal", "drug", "341-350"], "DRUGB": ["phenylbutazone", "drug", "683-696"]}
{"ID": "DDI-DrugBank.d424.s3.p1", "TEXT1": "@DRUG$: Coadministration of rifampin and @DRUG$ Suspension results in a significant decrease in average steady- state plasma atovaquone concentrations.", "LBL": "0", "DRUGA": ["Rifampin", "drug", "0-7"], "DRUGB": ["MEPRON", "brand", "43-48"]}
{"ID": "DDI-DrugBank.d94.s11.p590", "TEXT1": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "LBL": "0", "DRUGA": ["doxycycline", "drug", "326-336"], "DRUGB": ["risperidone", "drug", "621-631"]}
{"ID": "DDI-DrugBank.d72.s1.p11", "TEXT1": "Fluconazole, and the 5-HT3 antiemetics @DRUG$ (@DRUG$) and granisetron (Kytril) have all been used with BUSULFEX.", "LBL": "0", "DRUGA": ["ondansetron", "drug", "39-49"], "DRUGB": ["Zofran", "brand", "52-57"]}
{"ID": "DDI-DrugBank.d46.s19.p2", "TEXT1": "- @DRUG$: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, @DRUG$.", "LBL": "0", "DRUGA": ["Non-steroidal Anti-inflammatory Drugs", "group", "2-38"], "DRUGB": ["potassium-sparing diuretics", "group", "197-213;228-236"]}
{"ID": "DDI-DrugBank.d47.s2.p8", "TEXT1": "Dopamine D2 receptor antagonists (e.g., @DRUG$, butyrophenones, risperidone) and isoniazid may reduce the therapeutic effects of @DRUG$.", "LBL": "DDI-effect", "DRUGA": ["phenothiazines", "group", "40-53"], "DRUGB": ["levodopa", "drug", "137-144"]}
{"ID": "DDI-DrugBank.d404.s0.p10", "TEXT1": "Interactions for vitamin D analogues (@DRUG$, Vitamin D3, Calcitriol, and Calcidiol): @DRUG$: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;", "LBL": "0", "DRUGA": ["Vitamin D2", "drug", "38-47"], "DRUGB": ["Cholestyramine", "drug", "90-103"]}
{"ID": "DDI-DrugBank.d434.s30.p16", "TEXT1": "Effects of Other Antiepileptic Drugs on Felbatol  @DRUG$: Phenytoin causes an approximate doubling of the clearance of @DRUG$  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "LBL": "0", "DRUGA": ["Phenytoin", "drug", "50-58"], "DRUGB": ["Felbatol", "brand", "122-129"]}
{"ID": "DDI-DrugBank.d178.s4.p44", "TEXT1": "These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, @DRUG$, and @DRUG$.", "LBL": "0", "DRUGA": ["calcium channel blocking drugs", "group", "185-214"], "DRUGB": ["isoniazid", "drug", "221-229"]}
{"ID": "DDI-DrugBank.d220.s11.p10", "TEXT1": "In patients taking an anticonvulsant (eg, @DRUG$, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the @DRUG$.", "LBL": "0", "DRUGA": ["valproic acid", "drug", "42-54"], "DRUGB": ["anticonvulsant", "group", "199-212"]}
{"ID": "DDI-DrugBank.d249.s18.p4", "TEXT1": "Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of @DRUG$ (20% decrease in binding), @DRUG$, prednisolone (10% decrease in binding), or warfarin.", "LBL": "0", "DRUGA": ["salicylic acid", "drug", "100-113"], "DRUGB": ["tolbutamide", "drug", "142-152"]}
{"ID": "DDI-DrugBank.d460.s9.p0", "TEXT1": "@DRUG$: Administration of morning and lunch doses of @DRUG$ 120 mg in combination with a single 75-mg dose of diclofenac in healthy volunteers resulted in no significant changes to the pharmacokinetics of either agent.", "LBL": "0", "DRUGA": ["Diclofenac", "drug", "0-9"], "DRUGB": ["Starlix", "brand", "57-63"]}
{"ID": "DDI-DrugBank.d297.s2.p26", "TEXT1": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, @DRUG$, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, @DRUG$, leflunomide, sulfasalazine, and anakinra.", "LBL": "0", "DRUGA": ["NSAIDs", "group", "129-134"], "DRUGB": ["hydroxychloroquine", "drug", "208-225"]}
{"ID": "DDI-DrugBank.d564.s0.p6", "TEXT1": "The administration of local anesthetic solutions containing @DRUG$ or norepinephrine to patients receiving monoamine oxidase inhibitors or @DRUG$ may produce severe, prolonged hypertension.", "LBL": "DDI-effect", "DRUGA": ["epinephrine", "drug", "60-70"], "DRUGB": ["tricyclic antidepressants", "group", "144-168"]}
{"ID": "DDI-DrugBank.d124.s26.p39", "TEXT1": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;", "LBL": "0", "DRUGA": ["disopyramide", "drug", "157-168"], "DRUGB": ["carbamazepine", "drug", "268-280"]}
{"ID": "DDI-DrugBank.d431.s1.p3", "TEXT1": "Studies have shown that @DRUG$ does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, @DRUG$, phenytoin, propranolol, prednisone, diazepam, clarithromycin, or terfenadine in healthy subjects.", "LBL": "0", "DRUGA": ["lansoprazole", "drug", "24-35"], "DRUGB": ["ibuprofen", "drug", "191-199"]}
{"ID": "DDI-DrugBank.d94.s11.p853", "TEXT1": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "LBL": "0", "DRUGA": ["midazolam", "drug", "470-478"], "DRUGB": ["quetiapine", "drug", "609-618"]}
{"ID": "DDI-DrugBank.d66.s2.p2", "TEXT1": "@DRUG$ - Concomitant use of L-glutamine and indomethacin may ameliorate increased intestinal permeability caused by @DRUG$.", "LBL": "0", "DRUGA": ["Indomethacin", "drug", "0-11"], "DRUGB": ["indomethacin", "drug", "122-133"]}
{"ID": "DDI-DrugBank.d143.s18.p6", "TEXT1": "Amiodarone may suppress certain CYP450 enzymes, including @DRUG$, CYP2C9, CYP2D6, and @DRUG$.", "LBL": "0", "DRUGA": ["CYP1A2", "drug", "58-63"], "DRUGB": ["CYP3A4", "drug", "86-91"]}
{"ID": "DDI-DrugBank.d549.s3.p19", "TEXT1": "During clinical trials, iloprost was used concurrently with anticoagulants, @DRUG$, cardiac glycosides, calcium channel blockers, analgesics, antipyretics, @DRUG$, corticosteroids, and other medications.", "LBL": "0", "DRUGA": ["diuretics", "group", "76-84"], "DRUGB": ["nonsteroidal antiinflammatories", "group", "159-189"]}
{"ID": "DDI-DrugBank.d448.s2.p0", "TEXT1": "When @DRUG$ are given to patients receiving @DRUG$, hypertensive reactions, including hypertensive crises, may occur.", "LBL": "DDI-effect", "DRUGA": ["sympathomimetic drugs", "group", "5-25"], "DRUGB": ["monoamine oxidase inhibitors", "group", "59-86"]}
{"ID": "DDI-DrugBank.d64.s87.p1442", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;@DRUG$;sulfinpyrazone;sulfonamides, long acting;@DRUG$;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["salicylates", "group", "805-815"], "DRUGB": ["sulindac", "drug", "858-865"]}
{"ID": "DDI-DrugBank.d521.s8.p17", "TEXT1": "- a phenothiazine such as chlorpromazine (@DRUG$), @DRUG$ (Prolixin, Permitil), prochlorperazine (Compazine), promethazine (Phenergan), and others;", "LBL": "0", "DRUGA": ["Thorazine", "brand", "42-50"], "DRUGB": ["fluphenazine", "drug", "54-65"]}
{"ID": "DDI-DrugBank.d66.s7.p2", "TEXT1": "@DRUG$ - In one report, L-glutamine at a dose of 10 grams three times daily, given 24 hours after receiving paclitaxel, appeared to prevent the development of myalgia and arthralgia, adverse reactions of @DRUG$.", "LBL": "0", "DRUGA": ["Paclitaxel", "drug", "0-9"], "DRUGB": ["paclitaxel", "drug", "208-217"]}
{"ID": "DDI-DrugBank.d558.s13.p1", "TEXT1": "@DRUG$ 50 mg QD or HCTZ/@DRUG$ 50/100 mg QD was co-administered with TIKOSYN (500 mcg BID) for 5 days (following 2 days of diuretic use at half dose).", "LBL": "0", "DRUGA": ["HCTZ", "drug", "0-3"], "DRUGB": ["triamterene", "drug", "22-32"]}
{"ID": "DDI-DrugBank.d124.s26.p125", "TEXT1": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;", "LBL": "DDI-mechanism", "DRUGA": ["carbamazepine", "drug", "268-280"], "DRUGB": ["saquinavir", "drug", "397-406"]}
{"ID": "DDI-DrugBank.d284.s8.p1", "TEXT1": "The concurrent use of intravenously or orally administered @DRUG$ (e.g., aminophylline, @DRUG$) by patients receiving BROVANA has not been completely evaluated.", "LBL": "0", "DRUGA": ["methylxanthines", "group", "59-73"], "DRUGB": ["theophylline", "drug", "97-108"]}
{"ID": "DDI-DrugBank.d64.s90.p10", "TEXT1": "Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic agents) or drugs which inhibit platelet function (eg, @DRUG$ and other non-steroidal anti-inflammatory drugs, dipyridamole, hydrochloroquine, @DRUG$, dextran) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations.", "LBL": "0", "DRUGA": ["aspirin", "brand", "160-166"], "DRUGB": ["clofibrate", "drug", "249-258"]}
{"ID": "DDI-DrugBank.d567.s21.p3", "TEXT1": "Digoxin: In patients with hypercholesterolemia, concomitant administration of @DRUG$ and @DRUG$ resulted in no effect on digoxin plasma concentrations.", "LBL": "0", "DRUGA": ["lovastatin", "drug", "78-87"], "DRUGB": ["digoxin", "drug", "93-99"]}
{"ID": "DDI-DrugBank.d257.s0.p50", "TEXT1": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other @DRUG$, general @DRUG$, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.", "LBL": "0", "DRUGA": ["opioids", "group", "154-160"], "DRUGB": ["anesthetics", "group", "171-181"]}
{"ID": "DDI-DrugBank.d63.s0.p46", "TEXT1": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), @DRUG$ (e.g., Matulane), @DRUG$ (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.", "LBL": "0", "DRUGA": ["procarbazine", "drug", "101-112"], "DRUGB": ["selegiline", "drug", "132-141"]}
{"ID": "DDI-DrugBank.d441.s6.p0", "TEXT1": "Spontaneous reports of serotonin syndrome associated with co-administration of @DRUG$ and @DRUG$, including antidepressants such as selective serotonin reuptake inhibitors (SSRIs), have been reported.", "LBL": "DDI-effect", "DRUGA": ["ZYVOX", "brand", "79-83"], "DRUGB": ["serotonergic agents", "group", "89-107"]}
{"ID": "DDI-DrugBank.d170.s5.p67", "TEXT1": "Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, @DRUG$ (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and @DRUG$, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.", "LBL": "0", "DRUGA": ["tranquilizers", "group", "213-225"], "DRUGB": ["alcohol", "drug", "320-326"]}
{"ID": "DDI-DrugBank.d179.s21.p17", "TEXT1": "- @DRUG$ (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., @DRUG$], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or", "LBL": "0", "DRUGA": ["Phenothiazines", "group", "2-15"], "DRUGB": ["Mellaril", "brand", "291-298"]}
{"ID": "DDI-DrugBank.d395.s9.p4", "TEXT1": "Non-steroidal anti-inflammatory agents: Seizures have been reported in patients taking @DRUG$ concomitantly with the nonsteroidal anti-inflammatory drug @DRUG$.", "LBL": "DDI-effect", "DRUGA": ["enoxacin", "drug", "87-94"], "DRUGB": ["fenbufen", "drug", "155-162"]}
{"ID": "DDI-DrugBank.d446.s0.p57", "TEXT1": "Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, @DRUG$ supplements, corticosteroids, corticotropin, @DRUG$, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.", "LBL": "0", "DRUGA": ["calcium", "drug", "90-96"], "DRUGB": ["cyclosporine", "drug", "143-154"]}
{"ID": "DDI-DrugBank.d484.s0.p830", "TEXT1": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, @DRUG$, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (@DRUG$), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "LBL": "0", "DRUGA": ["Crixivan", "brand", "397-404"], "DRUGB": ["Prelone", "brand", "528-534"]}
{"ID": "DDI-MedLine.d76.s9.p5", "TEXT1": "Formulation of fluorescence labelled bacitracin and insulin in unconjugated @DRUG$ (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) @DRUG$7.3 a significantly improved permeation was observed (R= 1.3).", "LBL": "0", "DRUGA": ["NaCMC", "drug_n", "76-80"], "DRUGB": ["CMC-Cys", "drug_n", "173-179"]}
{"ID": "DDI-DrugBank.d94.s11.p351", "TEXT1": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "LBL": "0", "DRUGA": ["clonazepam", "drug", "243-252"], "DRUGB": ["nortriptyline", "drug", "494-506"]}
{"ID": "DDI-DrugBank.d94.s8.p28", "TEXT1": "Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, @DRUG$, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on @DRUG$, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.", "LBL": "0", "DRUGA": ["doxorubicin HCL", "drug", "137-151"], "DRUGB": ["EQUETROTM", "brand", "305-313"]}
{"ID": "DDI-DrugBank.d397.s8.p89", "TEXT1": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, @DRUG$, terfenadine, and @DRUG$.", "LBL": "0", "DRUGA": ["valproate", "drug", "191-199"], "DRUGB": ["astemizole", "drug", "219-228"]}
{"ID": "DDI-DrugBank.d411.s3.p39", "TEXT1": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related @DRUG$, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, @DRUG$, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.", "LBL": "0", "DRUGA": ["anabolic hormones", "group", "191-207"], "DRUGB": ["glucocorticoids", "group", "309-323"]}
{"ID": "DDI-DrugBank.d289.s6.p14", "TEXT1": "Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of @DRUG$ and the oral hormonal contraceptive Ortho-Novum produced average decreases of norethindrone and @DRUG$ levels of 14% and 31%, respectively.", "LBL": "0", "DRUGA": ["bosentan", "drug", "158-165"], "DRUGB": ["ethinyl estradiol", "drug", "263-279"]}
{"ID": "DDI-DrugBank.d45.s5.p7", "TEXT1": "Concomitant Crohn s disease medications were antibiotics, antivirals, @DRUG$, @DRUG$/AZA and aminosalicylates.", "LBL": "0", "DRUGA": ["corticosteroids", "group", "70-84"], "DRUGB": ["6-MP", "drug", "87-90"]}
{"ID": "DDI-DrugBank.d94.s8.p39", "TEXT1": "Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, @DRUG$, phenobarbital, @DRUG$(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.", "LBL": "0", "DRUGA": ["rifampin", "drug", "165-172"], "DRUGB": ["Phenytoin", "drug", "190-198"]}
{"ID": "DDI-DrugBank.d260.s0.p22", "TEXT1": "Probenecid : @DRUG$ is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, @DRUG$, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).", "LBL": "DDI-mechanism", "DRUGA": ["Probenecid", "drug", "13-22"], "DRUGB": ["clofibrate", "drug", "245-254"]}
{"ID": "DDI-DrugBank.d64.s87.p295", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;@DRUG$;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;@DRUG$;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["anabolic steroids", "group", "167-183"], "DRUGB": ["pyrazolones", "group", "763-773"]}
{"ID": "DDI-DrugBank.d13.s0.p44", "TEXT1": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of @DRUG$", "LBL": "0", "DRUGA": ["flupenthixol", "drug", "136-147"], "DRUGB": ["Tricyclic antidepressants", "group", "324-348"]}
{"ID": "DDI-DrugBank.d411.s4.p125", "TEXT1": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.", "LBL": "0", "DRUGA": ["androgens", "group", "282-290"], "DRUGB": ["thiazide diuretics", "group", "829-846"]}
{"ID": "DDI-DrugBank.d320.s1.p0", "TEXT1": "In vitro studies indicate CYP3A4 isoform and CYP1A2 isoform mediate the metabolism of @DRUG$ to @DRUG$ and 3-hydroxy levobupivacaine, respectively.", "LBL": "0", "DRUGA": ["levobupivacaine", "drug", "86-100"], "DRUGB": ["desbutyl levobupivacaine", "drug_n", "105-128"]}
{"ID": "DDI-DrugBank.d246.s0.p2", "TEXT1": "Concurrent use of @DRUG$ with central nervous system depressants (e.g., alcohol, @DRUG$, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.", "LBL": "DDI-effect", "DRUGA": ["butorphanol", "drug", "18-28"], "DRUGB": ["barbiturates", "group", "86-97"]}
{"ID": "DDI-DrugBank.d208.s0.p3", "TEXT1": "@DRUG$ may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, @DRUG$, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.", "LBL": "DDI-int", "DRUGA": ["Benzthiazide", "drug", "0-11"], "DRUGB": ["lithium", "drug", "129-135"]}
{"ID": "DDI-DrugBank.d236.s14.p2", "TEXT1": "Antihistamines: @DRUG$ may counteract the sedative effect of @DRUG$.", "LBL": "DDI-effect", "DRUGA": ["Amphetamines", "group", "16-27"], "DRUGB": ["antihistamines", "group", "67-80"]}
{"ID": "DDI-DrugBank.d360.s1.p3", "TEXT1": "A similar association, though less marked, has been suggested with @DRUG$, phenylbutazone, phenytoin sodium, carbamazepine, @DRUG$, topiramate, and possibly with ampicillin and tetracyclines 72.", "LBL": "0", "DRUGA": ["barbiturates", "group", "67-78"], "DRUGB": ["griseofulvin", "drug", "130-141"]}
{"ID": "DDI-DrugBank.d411.s4.p60", "TEXT1": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "LBL": "0", "DRUGA": ["p-aminosalicylic acid", "drug", "247-267"], "DRUGB": ["rifampin", "drug", "768-775"]}
{"ID": "DDI-DrugBank.d165.s16.p0", "TEXT1": "@DRUG$, @DRUG$ and digoxin concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.", "LBL": "0", "DRUGA": ["Cyclosporine", "drug", "0-11"], "DRUGB": ["tacrolimus", "drug", "14-23"]}
{"ID": "DDI-DrugBank.d251.s0.p20", "TEXT1": "Antiacid, clarithromycin, Didanosine, @DRUG$, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, @DRUG$, Rifabutin, Rifampin, Ritanovir, Saquinavir.", "LBL": "0", "DRUGA": ["Fluconazole", "drug", "38-48"], "DRUGB": ["carbamazepine", "drug", "114-126"]}
{"ID": "DDI-DrugBank.d353.s5.p0", "TEXT1": "However, it has been established that @DRUG$ interferes with the contraceptive effect of microdosed @DRUG$ minipill preparations.", "LBL": "DDI-effect", "DRUGA": ["acitretin", "drug", "38-46"], "DRUGB": ["progestin", "drug", "103-111"]}
{"ID": "DDI-DrugBank.d484.s0.p473", "TEXT1": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, @DRUG$), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as @DRUG$ (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "LBL": "0", "DRUGA": ["Felbatol", "brand", "204-211"], "DRUGB": ["protease inhibitors", "group", "365-383"]}
{"ID": "DDI-DrugBank.d460.s3.p0", "TEXT1": "@DRUG$: In a randomized, multiple-dose crossover study, patients with Type 2 diabetes were administered 120 mg @DRUG$ three times a day before meals for 1 day in combination with glyburide 10 mg daily.", "LBL": "0", "DRUGA": ["Glyburide", "drug", "0-8"], "DRUGB": ["Starlix", "brand", "114-120"]}
{"ID": "DDI-DrugBank.d64.s87.p877", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;@DRUG$;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;@DRUG$;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["ethacrynic acid", "drug", "394-408"], "DRUGB": ["quinidine", "drug", "775-783"]}
{"ID": "DDI-DrugBank.d163.s2.p9", "TEXT1": "Tetracyclines: Concomitant treatment with Accutane and tetracyclines should be avoided because @DRUG$ use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of @DRUG$", "LBL": "DDI-effect", "DRUGA": ["Accutane", "brand", "95-102"], "DRUGB": ["tetracyclines", "group", "252-264"]}
{"ID": "DDI-DrugBank.d345.s13.p7", "TEXT1": "No depressant effect on blood levels in humans was noted when @DRUG$ was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, nicotinic acid (niacin), tolbutamide, @DRUG$ or warfarin.", "LBL": "0", "DRUGA": ["colestipol hydrochloride", "drug", "62-85"], "DRUGB": ["phenytoin", "drug", "221-229"]}
{"ID": "DDI-DrugBank.d64.s87.p1103", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;@DRUG$;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;@DRUG$;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["mefenamic acid", "drug", "518-531"], "DRUGB": ["triclofos sodium", "drug", "893-908"]}
{"ID": "DDI-DrugBank.d94.s11.p155", "TEXT1": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "LBL": "0", "DRUGA": ["amitriptyline", "drug", "184-196"], "DRUGB": ["mirtazapine", "drug", "481-491"]}
{"ID": "DDI-DrugBank.d64.s87.p1167", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;@DRUG$;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;@DRUG$;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["metronidazole", "drug", "560-572"], "DRUGB": ["phenylbutazone", "drug", "683-696"]}
{"ID": "DDI-DrugBank.d521.s5.p13", "TEXT1": "- a beta-blocker such as @DRUG$ (Inderal), atenolol (Tenormin), acebutolol (Sectral), @DRUG$ (Lopressor), and others;", "LBL": "0", "DRUGA": ["propranolol", "drug", "25-35"], "DRUGB": ["metoprolol", "drug", "91-100"]}
{"ID": "DDI-DrugBank.d329.s0.p3", "TEXT1": "When ertapenem is co-administered with @DRUG$ (500 mg p.o. every 6 hours), @DRUG$ competes for active tubular secretion and reduces the renal clearance of ertapenem.", "LBL": "0", "DRUGA": ["probenecid", "drug", "39-48"], "DRUGB": ["probenecid", "drug", "79-88"]}
{"ID": "DDI-DrugBank.d64.s87.p1364", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;@DRUG$;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;@DRUG$ overdosage.", "LBL": "0", "DRUGA": ["phenyramidol", "drug_n", "698-709"], "DRUGB": ["warfarin sodium", "drug", "983-997"]}
{"ID": "DDI-DrugBank.d332.s0.p0", "TEXT1": "Administration of @DRUG$ to patients who are receiving @DRUG$ or monoamine oxidase inhibiting drugs may result in an additive pressor effect .", "LBL": "DDI-effect", "DRUGA": ["doxapram", "drug", "18-25"], "DRUGB": ["sympathomimetic", "group", "57-71"]}
{"ID": "DDI-MedLine.d13.s8.p2", "TEXT1": "However, the absolute number of alcohol-related deaths is far greater than the number of deaths in @DRUG$ or @DRUG$ users.", "LBL": "0", "DRUGA": ["amphetamine", "drug", "99-109"], "DRUGB": ["heroin", "drug_n", "114-119"]}
{"ID": "DDI-DrugBank.d443.s0.p5", "TEXT1": "Uricosuric Agents: @DRUG$ may decrease the effects of probenecid, @DRUG$, and phenylbutazone.", "LBL": "DDI-effect", "DRUGA": ["Aspirin", "brand", "19-25"], "DRUGB": ["sulfinpyrazone", "drug", "67-80"]}
{"ID": "DDI-DrugBank.d484.s0.p50", "TEXT1": "Etonogestrel may interact with the following medications: @DRUG$ (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, @DRUG$, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "LBL": "0", "DRUGA": ["acetaminophen", "drug", "58-70"], "DRUGB": ["Phenobarbital", "drug", "159-171"]}
{"ID": "DDI-DrugBank.d64.s91.p0", "TEXT1": "The beneficial effects on arterial thrombus formation from combined therapy with @DRUG$@DRUG$ must be weighed against an increased risk of inducing hemorrhage.", "LBL": "DDI-advise", "DRUGA": ["antiplatelet medication", "group", "81-92;112-121"], "DRUGB": ["anticoagulant medication", "group", "98-121"]}
{"ID": "DDI-DrugBank.d209.s3.p82", "TEXT1": "Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, @DRUG$, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as @DRUG$), and quinolone anti-infectives without evidence of clinically significant adverse interactions.", "LBL": "0", "DRUGA": ["benzodiazepines", "group", "293-307"], "DRUGB": ["NSAIDs", "group", "483-488"]}
{"ID": "DDI-DrugBank.d15.s1.p12", "TEXT1": "In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin, acetylsalicylic acid, @DRUG$, and @DRUG$, nor the pharmacokinetics of digoxin at steady state.", "LBL": "0", "DRUGA": ["piroxicam", "drug", "101-109"], "DRUGB": ["digoxin", "drug", "116-122"]}
{"ID": "DDI-MedLine.d115.s2.p20", "TEXT1": "To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, @DRUG$, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.", "LBL": "0", "DRUGA": ["vincristine", "drug", "275-285"], "DRUGB": ["cyclophosphamide", "drug", "440-455"]}
{"ID": "DDI-DrugBank.d236.s5.p0", "TEXT1": "Urinary alkalinizing agents (@DRUG$, some @DRUG$) increase the concentration of the non-ionized species of the amphetamine molecule, thereby decreasing urinary excretion.", "LBL": "0", "DRUGA": ["acetazolamide", "drug", "29-41"], "DRUGB": ["thiazides", "group", "49-57"]}
{"ID": "DDI-DrugBank.d533.s7.p0", "TEXT1": "Co-administration of @DRUG$ did not significantly affect the pharmacokinetics of @DRUG$, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.", "LBL": "0", "DRUGA": ["aliskiren", "drug", "21-29"], "DRUGB": ["lovastatin", "drug", "84-93"]}
{"ID": "DDI-DrugBank.d312.s1.p1", "TEXT1": "In Study 1, patients with colorectal cancer were given @DRUG$/5-FU/@DRUG$ (bolus-IFL) with or without AVASTIN.", "LBL": "0", "DRUGA": ["irinotecan", "drug", "55-64"], "DRUGB": ["leucovorin", "drug", "71-80"]}
{"ID": "DDI-DrugBank.d411.s3.p127", "TEXT1": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, @DRUG$, mefenamic acid, methadone, @DRUG$, phenylbutazone, phenytoin, salicylates, tamoxifen.", "LBL": "0", "DRUGA": ["meclofenamic acid", "drug", "326-342"], "DRUGB": ["perphenazine", "drug", "372-383"]}
{"ID": "DDI-DrugBank.d46.s20.p2", "TEXT1": "Therefore, when chlorothiazide and @DRUG$ are used concomitantly, the patient should be observed closely to determine if the desired effect of the @DRUG$ is obtained", "LBL": "0", "DRUGA": ["non-steroidal anti-inflammatory agents", "group", "35-72"], "DRUGB": ["diuretic", "group", "179-186"]}
{"ID": "DDI-MedLine.d53.s4.p0", "TEXT1": "Our data suggest that @DRUG$ significantly potentiates the reduction in cell number induced by @DRUG$ alone.", "LBL": "DDI-effect", "DRUGA": ["TAM", "drug_n", "22-24"], "DRUGB": ["1,25(OH)2D3", "drug", "92-102"]}
{"ID": "DDI-DrugBank.d331.s6.p0", "TEXT1": "Thus, @DRUG$ should not be administered concurrently with @DRUG$.", "LBL": "DDI-advise", "DRUGA": ["probenecid", "drug", "6-15"], "DRUGB": ["bumetanide", "drug", "62-71"]}
{"ID": "DDI-DrugBank.d411.s3.p92", "TEXT1": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and @DRUG$, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, @DRUG$, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.", "LBL": "0", "DRUGA": ["estrogen-containing compounds", "group", "250-278"], "DRUGB": ["methadone", "drug", "361-369"]}
{"ID": "DDI-DrugBank.d347.s7.p38", "TEXT1": "Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), @DRUG$ containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after @DRUG$.", "LBL": "DDI-advise", "DRUGA": ["multivitamin preparations", "group", "92-116"], "DRUGB": ["FACTIVE", "brand", "307-313"]}
{"ID": "DDI-DrugBank.d306.s0.p3", "TEXT1": "The effectiveness of @DRUG$-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and @DRUG$, and the antituberculosis drug rifampin.", "LBL": "DDI-effect", "DRUGA": ["progestin", "group", "21-29"], "DRUGB": ["barbiturates", "group", "144-155"]}
{"ID": "DDI-DrugBank.d94.s4.p88", "TEXT1": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, @DRUG$, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, @DRUG$, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "LBL": "0", "DRUGA": ["cimetidine", "drug", "165-174"], "DRUGB": ["niacinamide", "drug", "366-376"]}
{"ID": "DDI-DrugBank.d411.s3.p144", "TEXT1": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, @DRUG$, phenylbutazone, @DRUG$, salicylates, tamoxifen.", "LBL": "0", "DRUGA": ["perphenazine", "drug", "372-383"], "DRUGB": ["phenytoin", "drug", "402-410"]}
{"ID": "DDI-DrugBank.d521.s2.p234", "TEXT1": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), @DRUG$ (@DRUG$), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "LBL": "0", "DRUGA": ["etodolac", "drug", "173-180"], "DRUGB": ["Lodine", "brand", "183-188"]}
{"ID": "DDI-DrugBank.d245.s0.p34", "TEXT1": "The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, @DRUG$, monoamine oxidase inhibitors, and @DRUG$.", "LBL": "0", "DRUGA": ["coumarins", "group", "227-235"], "DRUGB": ["beta adrenergic blocking agents", "group", "272-302"]}
{"ID": "DDI-DrugBank.d544.s0.p3", "TEXT1": "No dose adjustment is necessary when @DRUG$ is added to triple-immunosuppression regimens including cyclosporine, corticosteroids, and either azathioprine or @DRUG$.", "LBL": "0", "DRUGA": ["Simulect", "brand", "37-44"], "DRUGB": ["mycophenolate mofetil", "drug", "160-180"]}
{"ID": "DDI-DrugBank.d211.s2.p1", "TEXT1": "@DRUG$: Chloramphenicol, @DRUG$, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins.", "LBL": "0", "DRUGA": ["Bacteriostatic Antibiotics", "group", "0-25"], "DRUGB": ["erythromycins", "drug", "45-57"]}
{"ID": "DDI-DrugBank.d179.s21.p36", "TEXT1": "- Phenothiazines (@DRUG$ [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., @DRUG$], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or", "LBL": "0", "DRUGA": ["acetophenazine", "drug", "18-31"], "DRUGB": ["Sparine", "brand", "229-235"]}
{"ID": "DDI-DrugBank.d413.s16.p7", "TEXT1": "Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving @DRUG$ or @DRUG$ concurrently with allopurinol compared to patients who are not receiving both drugs.", "LBL": "0", "DRUGA": ["ampicillin", "drug", "109-118"], "DRUGB": ["amoxicillin", "drug", "123-133"]}
{"ID": "DDI-DrugBank.d412.s10.p0", "TEXT1": "If @DRUG$ is used with @DRUG$ in patients with angina pectoris, additional antihypertensive effects may occur.", "LBL": "DDI-effect", "DRUGA": ["labetalol HCl", "drug", "3-15"], "DRUGB": ["nitroglycerin", "drug", "30-42"]}
{"ID": "DDI-DrugBank.d297.s2.p10", "TEXT1": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and @DRUG$.", "LBL": "0", "DRUGA": ["ORENCIA", "brand", "115-121"], "DRUGB": ["anakinra", "drug", "260-267"]}
{"ID": "DDI-DrugBank.d64.s87.p1455", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;@DRUG$;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/@DRUG$;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["sulfinpyrazone", "drug", "817-830"], "DRUGB": ["sulfamethoxazole", "drug", "923-938"]}
{"ID": "DDI-DrugBank.d94.s11.p386", "TEXT1": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "LBL": "0", "DRUGA": ["clozapine", "drug", "255-263"], "DRUGB": ["mirtazapine", "drug", "481-491"]}
{"ID": "DDI-DrugBank.d64.s29.p22", "TEXT1": "Drugs that have been reported to diminish oral @DRUG$ response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;@DRUG$ under-dosage.", "LBL": "DDI-effect", "DRUGA": ["anticoagulant", "group", "47-59"], "DRUGB": ["warfarin sodium", "drug", "490-504"]}
{"ID": "DDI-DrugBank.d64.s87.p766", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;@DRUG$;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;@DRUG$;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["diazoxide", "drug", "310-318"], "DRUGB": ["phenytoin", "drug", "711-719"]}
{"ID": "DDI-DrugBank.d20.s7.p3", "TEXT1": "In a study in diabetics with microalbuminuria INSPRA 200 mg combined with the @DRUG$ @DRUG$ 10 mg increased the frequency of hyperkalemia (serum potassium  5.5 mEq/L) from 17% on enalapril alone to 38%.", "LBL": "0", "DRUGA": ["ACE inhibitor", "group", "78-90"], "DRUGB": ["enalapril", "drug", "92-100"]}
{"ID": "DDI-DrugBank.d426.s3.p5", "TEXT1": "@DRUG$ (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$.", "LBL": "DDI-effect", "DRUGA": ["Selective serotonin reuptake inhibitors", "group", "0-38"], "DRUGB": ["5-HT1 agonists", "group", "210-223"]}
{"ID": "DDI-DrugBank.d64.s87.p1263", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;@DRUG$;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;@DRUG$;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["naproxen", "drug", "629-636"], "DRUGB": ["quinine", "drug", "785-791"]}
{"ID": "DDI-DrugBank.d197.s3.p3", "TEXT1": "No pharmacokinetic interactions between @DRUG$ and isoflurane, propofol, alfentanil, and @DRUG$ have been demonstrated.", "LBL": "0", "DRUGA": ["dexmedetomidine", "drug", "40-54"], "DRUGB": ["midazolam", "drug", "98-106"]}
{"ID": "DDI-DrugBank.d64.s87.p812", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;@DRUG$;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;@DRUG$;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["diflunisal", "drug", "341-350"], "DRUGB": ["sulindac", "drug", "858-865"]}
{"ID": "DDI-DrugBank.d536.s1.p40", "TEXT1": "These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, @DRUG$, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid.", "LBL": "0", "DRUGA": ["thyroid products", "group", "88-103"], "DRUGB": ["phenytoin", "drug", "138-146"]}
{"ID": "DDI-DrugBank.d64.s87.p492", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;@DRUG$;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;@DRUG$/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["chlorpropamide", "drug", "225-238"], "DRUGB": ["trimethoprim", "drug", "910-921"]}
{"ID": "DDI-DrugBank.d225.s3.p1", "TEXT1": "In vitro binding studies with human serum proteins indicate that @DRUG$ binds differently than tolbutamide and does not interact with @DRUG$ or dicumarol.", "LBL": "0", "DRUGA": ["glipizide", "drug", "65-73"], "DRUGB": ["salicylate", "group", "137-146"]}
{"ID": "DDI-DrugBank.d328.s48.p0", "TEXT1": "Plasma exposure of @DRUG$ (10 mg BID) was increased by 28% following administration of @DRUG$ (40 mg BID) for 12 days, while plasma exposure of valdecoxib (40 mg BID) was not substantially increased following administration of diazepam (10 mg BID) for 12 days.", "LBL": "DDI-mechanism", "DRUGA": ["diazepam", "drug", "19-26"], "DRUGB": ["valdecoxib", "drug", "89-98"]}
{"ID": "DDI-DrugBank.d347.s7.p44", "TEXT1": "Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after @DRUG$.", "LBL": "DDI-advise", "DRUGA": ["didanosine", "drug", "168-177"], "DRUGB": ["FACTIVE", "brand", "307-313"]}
{"ID": "DDI-DrugBank.d99.s17.p1", "TEXT1": "@DRUG$, barbiturates and other @DRUG$;", "LBL": "0", "DRUGA": ["alcohol", "drug", "0-6"], "DRUGB": ["CNS depressants", "drug", "32-46"]}
{"ID": "DDI-DrugBank.d373.s7.p0", "TEXT1": "Since there have been isolated reports of patients with elevated @DRUG$ levels, it is recommended that @DRUG$ levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.", "LBL": "0", "DRUGA": ["digoxin", "drug", "65-71"], "DRUGB": ["digoxin", "drug", "104-110"]}
{"ID": "DDI-DrugBank.d528.s0.p8", "TEXT1": "Acetaminophen and methotrexate - @DRUG$ may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking @DRUG$.", "LBL": "DDI-effect", "DRUGA": ["L-methionine", "drug", "33-44"], "DRUGB": ["methotrexate", "drug", "134-145"]}
{"ID": "DDI-DrugBank.d476.s2.p0", "TEXT1": "In patients receiving concurrent therapy with @DRUG$, if therapy is to be discontinued, it is suggested that @DRUG$ be discontinued for several days before the withdrawal of clonidine.", "LBL": "0", "DRUGA": ["clonidine", "drug", "46-54"], "DRUGB": ["ZEBETA", "brand", "112-117"]}
{"ID": "DDI-DrugBank.d475.s3.p2", "TEXT1": "In patients given very high doses (3900 mg) of aspirin daily, increases in serum @DRUG$ levels were seen when @DRUG$, 150 mg b.i.d., was administered concurrently.", "LBL": "0", "DRUGA": ["salicylate", "group", "81-90"], "DRUGB": ["nizatidine", "drug", "114-123"]}
{"ID": "DDI-DrugBank.d239.s2.p4", "TEXT1": "The co-administration of @DRUG$ with IV vasodilators such as nitroglycerin, nitroprusside, milrinone, or IV @DRUG$ has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).", "LBL": "0", "DRUGA": ["Natrecor", "brand", "25-32"], "DRUGB": ["ACE inhibitors", "group", "110-123"]}
{"ID": "DDI-DrugBank.d484.s0.p2", "TEXT1": "@DRUG$ may interact with the following medications: acetaminophen (Tylenol), @DRUG$ such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "LBL": "DDI-int", "DRUGA": ["Etonogestrel", "drug", "0-11"], "DRUGB": ["antibiotics", "group", "83-93"]}
{"ID": "DDI-MedLine.d76.s5.p5", "TEXT1": "Unmodified NaCMC (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of NaFlu to 1.3 and 1% (m/v) @DRUG$ conjugated with @DRUG$ further enhanced the permeation.", "LBL": "0", "DRUGA": ["NaCMC", "drug_n", "134-138"], "DRUGB": ["cysteine", "drug", "156-163"]}
{"ID": "DDI-MedLine.d109.s7.p5", "TEXT1": "For digoxin AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for (rofecoxib + @DRUG$/placebo + @DRUG$) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively.", "LBL": "0", "DRUGA": ["digoxin", "drug", "119-125"], "DRUGB": ["digoxin", "drug", "137-143"]}
{"ID": "DDI-DrugBank.d140.s1.p3", "TEXT1": "Antacid: When @DRUG$ and @DRUG$ suspension were coadministered, plasma concentrations of atorvastatin decreased approximately 35%.", "LBL": "DDI-mechanism", "DRUGA": ["atorvastatin", "drug", "14-25"], "DRUGB": ["Maalox TC", "brand", "31-39"]}
{"ID": "DDI-DrugBank.d338.s1.p12", "TEXT1": "The action of the benzodiazepines may be potentiated by @DRUG$, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, @DRUG$, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.", "LBL": "0", "DRUGA": ["anticonvulsants", "group", "56-70"], "DRUGB": ["narcotics", "group", "142-150"]}
{"ID": "DDI-DrugBank.d75.s4.p0", "TEXT1": "An in vivo interaction study in humans demonstrated that a single 1mg dose of @DRUG$ administered concomitantly with a single 900 mg dose of @DRUG$ was generally well tolerated.", "LBL": "0", "DRUGA": ["anagrelide", "drug", "78-87"], "DRUGB": ["aspirin", "brand", "145-151"]}
{"ID": "DDI-DrugBank.d81.s7.p1", "TEXT1": "@DRUG$: In a study in healthy volunteers, a one-week course of cimetidine at 400 mg b.i.d. with a single 5 mg dose of @DRUG$ on the sixth day showed an increase in isradipine mean peak plasma concentrations (36%) and significant increase in area under the curve (50%).", "LBL": "0", "DRUGA": ["Cimetidine", "drug", "0-9"], "DRUGB": ["isradipine", "drug", "122-131"]}
{"ID": "DDI-DrugBank.d263.s13.p1", "TEXT1": "Drugs that have been associated with peripheral neuropathy include @DRUG$, chloramphenicol, @DRUG$, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.", "LBL": "0", "DRUGA": ["antiretroviral nucleoside analogues", "drug", "67-101"], "DRUGB": ["cisplatin", "drug", "121-129"]}
{"ID": "DDI-DrugBank.d313.s2.p37", "TEXT1": "The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, @DRUG$, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, @DRUG$ (e.g., in oral contraceptives).", "LBL": "0", "DRUGA": ["danazol", "drug", "117-123"], "DRUGB": ["progestogens", "group", "285-296"]}
{"ID": "DDI-DrugBank.d307.s47.p0", "TEXT1": "Other drug interactions @DRUG$, @DRUG$ and dextropropoxyphene had no effect on the pharmacokinetics of MHD.", "LBL": "0", "DRUGA": ["Cimetidine", "drug", "24-33"], "DRUGB": ["erythromycin", "drug", "36-47"]}
{"ID": "DDI-DrugBank.d335.s3.p5", "TEXT1": "The actions of the benzodiazepines may be potentiated by @DRUG$, @DRUG$, phenothiazines, monoamine oxidase inhibitors or other antidepressants.", "LBL": "0", "DRUGA": ["barbiturates", "group", "57-68"], "DRUGB": ["narcotics", "group", "71-79"]}
{"ID": "DDI-DrugBank.d297.s2.p31", "TEXT1": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, @DRUG$, TNF blocking agents, @DRUG$, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.", "LBL": "0", "DRUGA": ["corticosteroids", "group", "137-151"], "DRUGB": ["azathioprine", "drug", "175-186"]}
{"ID": "DDI-DrugBank.d313.s13.p2", "TEXT1": "When used in external subcutaneous infusion pumps for insulin, @DRUG$ should not be mixed with any other @DRUG$ or diluent.", "LBL": "0", "DRUGA": ["NovoLog", "brand", "63-69"], "DRUGB": ["insulins", "group", "106-113"]}
{"ID": "DDI-DrugBank.d219.s6.p2", "TEXT1": "however, as with other NSAIDs, concomitant administration of @DRUG$ and @DRUG$ is not generally recommended because of the potential of increased adverse effects.", "LBL": "DDI-advise", "DRUGA": ["Lodine", "brand", "61-66"], "DRUGB": ["aspirin", "brand", "72-78"]}
{"ID": "DDI-DrugBank.d277.s10.p7", "TEXT1": "Effects of other Antiepilepsy Drugs (AEDs) on @DRUG$ : Carbamazepine: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking @DRUG$ with or without other enzyme- inducing AEDs.", "LBL": "0", "DRUGA": ["GABITRIL", "brand", "46-53"], "DRUGB": ["carbamazepine", "drug", "176-188"]}
{"ID": "DDI-MedLine.d135.s4.p0", "TEXT1": "@DRUG$ produced distinctive effects in each task: it substituted for the training dose in @DRUG$ discrimination and it increased the number of responses with short (<3 s) interresponse times as well as increasing overall response rates in the DRL schedule.", "LBL": "0", "DRUGA": ["PCP", "drug_n", "0-2"], "DRUGB": ["PCP", "drug_n", "87-89"]}
{"ID": "DDI-DrugBank.d64.s87.p302", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;@DRUG$;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;@DRUG$;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["anabolic steroids", "group", "167-183"], "DRUGB": ["sulindac", "drug", "858-865"]}
{"ID": "DDI-DrugBank.d63.s0.p45", "TEXT1": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), @DRUG$ (e.g., @DRUG$), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.", "LBL": "0", "DRUGA": ["procarbazine", "drug", "101-112"], "DRUGB": ["Matulane", "brand", "121-128"]}
{"ID": "DDI-MedLine.d54.s3.p1", "TEXT1": "In the present study, evoked potentials were recorded at 5, 20, and 40 min following IP injections of saline, @DRUG$ (2.0 g/kg), physostigmine (0.6 mg/kg) or @DRUG$ (15.0 mg/kg) on separate days.", "LBL": "0", "DRUGA": ["ethanol", "drug", "110-116"], "DRUGB": ["atropine", "drug", "159-166"]}
{"ID": "DDI-DrugBank.d472.s0.p24", "TEXT1": "Central nervous system depressant (CNS) drugs including alcohol, @DRUG$, antihistamines, antipsychotics, blood pressure medications (reserpine, @DRUG$, beta-blockers), motion sickness medications, muscle relaxants, narcotics, sedatives, sleeping pills and tranquilizers", "LBL": "0", "DRUGA": ["antidepressants", "group", "65-79"], "DRUGB": ["methyldopa", "drug", "153-162"]}
{"ID": "DDI-DrugBank.d454.s0.p2", "TEXT1": "- @DRUG$ may enhance the CNS depressive effects of alcohol, barbiturates and other @DRUG$", "LBL": "DDI-effect", "DRUGA": ["Lofexidine", "drug", "2-11"], "DRUGB": ["sedatives", "group", "87-95"]}
{"ID": "DDI-MedLine.d51.s4.p2", "TEXT1": "However, the antagonism of the @DRUG$-induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by @DRUG$ nor by CPA.", "LBL": "0", "DRUGA": ["theophylline", "drug", "31-42"], "DRUGB": ["CGS 21680", "drug", "200-208"]}
{"ID": "DDI-DrugBank.d423.s4.p7", "TEXT1": "A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as @DRUG$ (@DRUG$) and dihydroergotamine.", "LBL": "0", "DRUGA": ["Imitrex", "brand", "210-216"], "DRUGB": ["sumatriptan succinate", "drug", "219-239"]}
{"ID": "DDI-DrugBank.d480.s26.p1", "TEXT1": "Such individuals are referred to as poor metabolizers of drugs such as @DRUG$, dextromethorphan, the @DRUG$, and clozapine.", "LBL": "0", "DRUGA": ["debrisoquin", "drug", "71-81"], "DRUGB": ["tricyclic antidepressants", "group", "106-130"]}
{"ID": "DDI-DrugBank.d260.s0.p62", "TEXT1": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, @DRUG$, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, @DRUG$ agents, theophylline, and zidovudine).", "LBL": "0", "DRUGA": ["angiotensin-converting enzyme inhibitors", "group", "139-178"], "DRUGB": ["nonsteroidal anti-inflammatory", "group", "295-324"]}
{"ID": "DDI-DrugBank.d5.s8.p0", "TEXT1": "While not systematically studied, certain drugs may induce the metabolism of @DRUG$ (e.g., @DRUG$, phenobarbital, phenytoin).", "LBL": "DDI-mechanism", "DRUGA": ["bupropion", "drug", "77-85"], "DRUGB": ["carbamazepine", "drug", "94-106"]}
{"ID": "DDI-DrugBank.d94.s11.p216", "TEXT1": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "LBL": "0", "DRUGA": ["buspirone", "drug", "210-218"], "DRUGB": ["clobazam", "drug", "233-240"]}
{"ID": "DDI-DrugBank.d94.s11.p58", "TEXT1": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "LBL": "0", "DRUGA": ["Acetaminophen", "drug", "157-169"], "DRUGB": ["doxycycline", "drug", "326-336"]}
{"ID": "DDI-DrugBank.d249.s16.p22", "TEXT1": "Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, D-penicillamine, @DRUG$, @DRUG$, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.", "LBL": "0", "DRUGA": ["prednisolone", "drug", "151-162"], "DRUGB": ["doxycycline", "drug", "165-175"]}
{"ID": "DDI-DrugBank.d448.s1.p1", "TEXT1": "Concomitant use of @DRUG$ with alcohol, @DRUG$, barbiturates, or other central nervous system depressants may have an additive effect.", "LBL": "DDI-effect", "DRUGA": ["antihistamines", "group", "19-32"], "DRUGB": ["tricyclic antidepressants", "group", "48-72"]}
{"ID": "DDI-DrugBank.d527.s2.p62", "TEXT1": "The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids, danazol, diuretics, sympathomimetic agents (e.g., @DRUG$, albuterol, terbutaline), @DRUG$, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).", "LBL": "0", "DRUGA": ["epinephrine", "drug", "170-180"], "DRUGB": ["isoniazid", "drug", "208-216"]}
{"ID": "DDI-DrugBank.d123.s11.p2", "TEXT1": "Non-steroidal anti-inflammatory drugs (but not @DRUG$): These drugs in combination with very high doses of @DRUG$ have been shown to provoke convulsions in pre-clinical studies.", "LBL": "0", "DRUGA": ["aspirin", "brand", "47-53"], "DRUGB": ["quinolones", "group", "108-117"]}
{"ID": "DDI-DrugBank.d76.s12.p7", "TEXT1": "Other Potentially Important Drug Interactions: Benzodiazepines: @DRUG$ metabolized by hepatic oxidation (e.g., alprazolam, midazolam, @DRUG$ elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.", "LBL": "0", "DRUGA": ["Benzodiazepines", "group", "64-78"], "DRUGB": ["triazolam", "drug", "143-151"]}
{"ID": "DDI-DrugBank.d78.s3.p8", "TEXT1": "Caffeine @DRUG$ Grepafloxacin, like other quinolones, may inhibit the metabolism of caffeine and @DRUG$.", "LBL": "0", "DRUGA": ["Theobromine", "drug", "9-19"], "DRUGB": ["theobromine", "drug", "102-112"]}
{"ID": "DDI-DrugBank.d64.s87.p1161", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;@DRUG$;miconazole;@DRUG$;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["metronidazole", "drug", "560-572"], "DRUGB": ["monoamine oxidase inhibitors", "group", "585-612"]}
{"ID": "DDI-DrugBank.d63.s0.p54", "TEXT1": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., @DRUG$), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., @DRUG$): Using these medicines with L-tryptophan may increase the chance of side effects.", "LBL": "0", "DRUGA": ["Matulane", "brand", "121-128"], "DRUGB": ["Parnate", "brand", "188-194"]}
{"ID": "DDI-DrugBank.d357.s3.p16", "TEXT1": "Dopamine Antagonists: Since @DRUG$ is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of @DRUG$.", "LBL": "0", "DRUGA": ["apomorphine", "drug", "28-38"], "DRUGB": ["APOKYN", "brand", "231-236"]}
{"ID": "DDI-DrugBank.d316.s1.p6", "TEXT1": "Co-administration of CYP3A4 inhibitors (eg, ketoconazole, @DRUG$, erythromycin, grapefruit juice, @DRUG$) with felodipine may lead to several- fold increases in the plasma levels of felodipine, either due to an increase in bioavailability or due to a decrease in metabolism.", "LBL": "0", "DRUGA": ["itraconazole", "drug", "58-69"], "DRUGB": ["cimetidine", "drug", "104-113"]}
{"ID": "DDI-DrugBank.d179.s3.p18", "TEXT1": "- Anabolic steroids (nandrolone [e.g., @DRUG$], oxandrolone [e.g., Anavar], oxymetholone [e.g., @DRUG$], stanozolol [e.g., Winstrol]) or", "LBL": "0", "DRUGA": ["Anabolin", "brand", "39-46"], "DRUGB": ["Anadrol", "brand", "98-104"]}
{"ID": "DDI-DrugBank.d212.s11.p0", "TEXT1": "Potential drug interactions between @DRUG$  and other @DRUG$ (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.", "LBL": "0", "DRUGA": ["Keppra", "brand", "36-41"], "DRUGB": ["AEDs", "group", "54-57"]}
{"ID": "DDI-DrugBank.d30.s9.p2", "TEXT1": "As with other @DRUG$, the antihypertensive effect of losartan may be blunted by the non-steroidal anti-inflammatory drug @DRUG$", "LBL": "0", "DRUGA": ["antihypertensive agents", "group", "14-36"], "DRUGB": ["indomethacin", "drug", "138-149"]}
{"ID": "DDI-DrugBank.d448.s3.p2", "TEXT1": "The antihypertensive effects of @DRUG$, mecamylamine, reserpine, and @DRUG$ may be reduced by sympathomimetics.", "LBL": "0", "DRUGA": ["methyldopa", "drug", "32-41"], "DRUGB": ["veratrum alkaloids", "drug", "73-90"]}
{"ID": "DDI-DrugBank.d64.s29.p273", "TEXT1": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;@DRUG$;unreliable prothrombin time determinations;@DRUG$;warfarin sodium under-dosage.", "LBL": "0", "DRUGA": ["rifampin", "drug", "428-435"], "DRUGB": ["vitamin C", "drug", "480-488"]}
{"ID": "DDI-DrugBank.d86.s1.p42", "TEXT1": "Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., @DRUG$), sparfloxacin, grepafloxacin, guanethidine, @DRUG$, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.", "LBL": "0", "DRUGA": ["propranolol", "drug", "149-159"], "DRUGB": ["guanadrel", "drug", "206-214"]}
{"ID": "DDI-DrugBank.d191.s1.p2", "TEXT1": "@DRUG$ enhance the renal toxicity of edetate calcium disodium in animals. 7 Edetate calcium disodium interferes with the action of @DRUG$ preparations by chelating the zinc. 7", "LBL": "0", "DRUGA": ["Steroids", "group", "0-7"], "DRUGB": ["zinc insulin", "drug", "133-144"]}
{"ID": "DDI-DrugBank.d387.s2.p0", "TEXT1": "@DRUG$ may enhance the effects of @DRUG$.", "LBL": "DDI-effect", "DRUGA": ["Doxylamine", "drug", "0-9"], "DRUGB": ["epinephrine", "drug", "38-48"]}
{"ID": "DDI-DrugBank.d43.s12.p9", "TEXT1": "Plasma concentrations of quinolone antibiotics are decreased when administered with antacids containing magnesium, @DRUG$, or @DRUG$.", "LBL": "0", "DRUGA": ["calcium", "drug", "115-121"], "DRUGB": ["aluminum", "drug", "127-134"]}
{"ID": "DDI-DrugBank.d484.s0.p614", "TEXT1": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), @DRUG$ (Lipitor), clofibrate (@DRUG$), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "LBL": "0", "DRUGA": ["atorvastatin", "drug", "258-269"], "DRUGB": ["Atromid-S", "brand", "294-302"]}
{"ID": "DDI-DrugBank.d454.s0.p4", "TEXT1": "- Lofexidine may enhance the CNS depressive effects of @DRUG$, barbiturates and other @DRUG$", "LBL": "0", "DRUGA": ["alcohol", "drug", "55-61"], "DRUGB": ["sedatives", "group", "87-95"]}
{"ID": "DDI-DrugBank.d485.s12.p1", "TEXT1": "@DRUG$ (carbamazepine, @DRUG$, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.", "LBL": "0", "DRUGA": ["Anticonvulsants", "group", "0-14"], "DRUGB": ["felbamate", "drug", "32-40"]}
{"ID": "DDI-DrugBank.d316.s1.p8", "TEXT1": "Co-administration of CYP3A4 inhibitors (eg, ketoconazole, @DRUG$, erythromycin, grapefruit juice, cimetidine) with felodipine may lead to several- fold increases in the plasma levels of @DRUG$, either due to an increase in bioavailability or due to a decrease in metabolism.", "LBL": "0", "DRUGA": ["itraconazole", "drug", "58-69"], "DRUGB": ["felodipine", "drug", "192-201"]}
{"ID": "DDI-DrugBank.d527.s1.p17", "TEXT1": "The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetes products, ACE inhibitors, disopyramide, @DRUG$, @DRUG$, MAO inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.", "LBL": "0", "DRUGA": ["fibrates", "group", "187-194"], "DRUGB": ["fluoxetine", "drug", "197-206"]}
{"ID": "DDI-DrugBank.d64.s87.p1123", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;@DRUG$;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;@DRUG$*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["methyldopa", "drug", "533-542"], "DRUGB": ["ranitidine", "drug", "793-802"]}
{"ID": "DDI-DrugBank.d347.s1.p3", "TEXT1": "Concomitant administration of @DRUG$ and calcium carbonate, cimetidine, omeprazole, or an @DRUG$/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.", "LBL": "DDI-mechanism", "DRUGA": ["FACTIVE", "brand", "30-36"], "DRUGB": ["estrogen", "group", "91-98"]}
{"ID": "DDI-DrugBank.d246.s0.p14", "TEXT1": "Concurrent use of butorphanol with central nervous system depressants (e.g., @DRUG$, barbiturates, tranquilizers, and antihistamines) may result in increased @DRUG$ effects.", "LBL": "0", "DRUGA": ["alcohol", "drug", "77-83"], "DRUGB": ["central nervous system depressant", "group", "159-191"]}
{"ID": "DDI-DrugBank.d306.s0.p18", "TEXT1": "The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and @DRUG$, and the @DRUG$ rifampin.", "LBL": "0", "DRUGA": ["barbiturates", "group", "144-155"], "DRUGB": ["antituberculosis drug", "group", "166-186"]}
{"ID": "DDI-DrugBank.d5.s0.p0", "TEXT1": "Few systemic data have been collected on the metabolism of @DRUG$ following concomitant administration with other drugs or, alternatively, the effect of concomitant administration of @DRUG$ on the metabolism of other drugs.", "LBL": "0", "DRUGA": ["WELLBUTRIN", "brand", "59-68"], "DRUGB": ["WELLBUTRIN", "brand", "187-196"]}
{"ID": "DDI-DrugBank.d398.s2.p5", "TEXT1": "The use of dextromethorphan hydrobromide may result in additive CNS depressant effects when coadministered with alcohol, @DRUG$, @DRUG$ or other drugs that produce CNS depression.", "LBL": "0", "DRUGA": ["antihistamines", "group", "121-134"], "DRUGB": ["psychotropics", "group", "137-149"]}
{"ID": "DDI-DrugBank.d410.s7.p0", "TEXT1": "@DRUG$: Weakness hyperreflexia, and incoordination have been reported rarely when @DRUG$ have been co-administered with SSRIs (e. g.", "LBL": "0", "DRUGA": ["SSRIs", "group", "0-4"], "DRUGB": ["5-HT1 agonists", "group", "81-94"]}
{"ID": "DDI-DrugBank.d484.s0.p908", "TEXT1": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, @DRUG$), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, @DRUG$, theophylline (Theo-Dur), and vitamin C.", "LBL": "0", "DRUGA": ["Viracept", "brand", "445-452"], "DRUGB": ["temazepam", "drug", "574-582"]}
{"ID": "DDI-DrugBank.d178.s13.p0", "TEXT1": "Coadministration of gly-buride and @DRUG$ did not result in any changes in either @DRUG$ pharmacokinetics or pharmaco-dynamics.", "LBL": "0", "DRUGA": ["metformin", "drug", "35-43"], "DRUGB": ["metformin", "drug", "85-93"]}
{"ID": "DDI-DrugBank.d94.s11.p409", "TEXT1": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "LBL": "0", "DRUGA": ["cyclosporin", "drug", "266-276"], "DRUGB": ["doxycycline", "drug", "326-336"]}
{"ID": "DDI-DrugBank.d415.s8.p3", "TEXT1": "H-2 Antagonists: In studies with human volunteers, co-administration of cimetidine or @DRUG$ with @DRUG$ had no substantive effect on ibuprofen serum concentrations.", "LBL": "0", "DRUGA": ["ranitidine", "drug", "86-95"], "DRUGB": ["ibuprofen", "drug", "102-110"]}
{"ID": "DDI-DrugBank.d566.s2.p0", "TEXT1": "@DRUG$ @DRUG$ may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine resin.", "LBL": "0", "DRUGA": ["Cholestyramine", "drug", "0-13"], "DRUGB": ["resin", "group", "15-19"]}
{"ID": "DDI-DrugBank.d395.s0.p6", "TEXT1": "Bismuth: @DRUG$, given concomitantly with enoxacin or 60 minutes following enoxacin administration, decreased @DRUG$ bioavailability by approximately 25%.", "LBL": "0", "DRUGA": ["Bismuth subsalicylate", "drug", "9-29"], "DRUGB": ["enoxacin", "drug", "125-132"]}
{"ID": "DDI-DrugBank.d468.s10.p7", "TEXT1": "When therapeutic concentrations of furosemide, @DRUG$, dipyridamole, @DRUG$, quinidine, or naproxen were added to human plasma (in vitro), the plasma protein binding of nicardipine HCl was not altered.", "LBL": "0", "DRUGA": ["propranolol", "drug", "47-57"], "DRUGB": ["warfarin", "drug", "74-81"]}
{"ID": "DDI-DrugBank.d176.s12.p24", "TEXT1": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, @DRUG$, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and @DRUG$, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.", "LBL": "0", "DRUGA": ["propanolol", "drug", "105-114"], "DRUGB": ["warfarin", "drug", "194-201"]}
{"ID": "DDI-DrugBank.d284.s3.p1", "TEXT1": "Concomitant treatment with @DRUG$ (aminophylline, @DRUG$), steroids, or diuretics may potentiate any hypokalemic effect of adrenergic agonists.", "LBL": "0", "DRUGA": ["methylxanthines", "group", "27-41"], "DRUGB": ["theophylline", "drug", "59-70"]}
{"ID": "DDI-DrugBank.d64.s87.p798", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;@DRUG$;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;@DRUG$;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["diflunisal", "drug", "341-350"], "DRUGB": ["oxolinic acid", "drug", "638-650"]}
{"ID": "DDI-DrugBank.d143.s13.p1", "TEXT1": "Monitoring for @DRUG$ toxicity and serial measurement of amiodarone serum concentration during concomitant @DRUG$ therapy should be considered.", "LBL": "0", "DRUGA": ["amiodarone", "drug", "15-24"], "DRUGB": ["protease inhibitor", "group", "111-128"]}
{"ID": "DDI-DrugBank.d107.s10.p19", "TEXT1": "Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with @DRUG$, methyldopa, nitrates, calcium-blocking agents, hydralazine, @DRUG$ and digoxin without evidence of clinically significant adverse interactions.", "LBL": "0", "DRUGA": ["beta adrenergic-blocking agents", "group", "90-120"], "DRUGB": ["prazosin", "drug", "183-190"]}
{"ID": "DDI-DrugBank.d558.s32.p61", "TEXT1": "Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (@DRUG$s) and @DRUG$ did not affect the pharmacokinetics of TIKOSYN.", "LBL": "0", "DRUGA": ["aluminum hydroxide", "drug", "196-203;219-227"], "DRUGB": ["theophylline", "drug", "235-246"]}
{"ID": "DDI-DrugBank.d295.s0.p2", "TEXT1": "Since entecavir is primarily eliminated by the kidneys, coadministration of @DRUG$ with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either @DRUG$ or the coadministered drug.", "LBL": "0", "DRUGA": ["BARACLUDE", "brand", "76-84"], "DRUGB": ["entecavir", "drug", "208-216"]}
{"ID": "DDI-DrugBank.d10.s2.p1", "TEXT1": "@DRUG$ administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of antipyrine elimination.14 The effect of alternate-day administration of 0.25 mg of @DRUG$ on drug metabolism in MS patients is unknown.", "LBL": "0", "DRUGA": ["Betaseron", "brand", "0-8"], "DRUGB": ["Betaseron", "brand", "211-219"]}
{"ID": "DDI-DrugBank.d94.s11.p887", "TEXT1": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "LBL": "0", "DRUGA": ["nortriptyline", "drug", "494-506"], "DRUGB": ["protease inhibitors", "group", "588-606"]}
{"ID": "DDI-DrugBank.d77.s14.p9", "TEXT1": "cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, @DRUG$, and the @DRUG$ propafenone and flecainide).", "LBL": "0", "DRUGA": ["phenothiazines", "group", "83-96"], "DRUGB": ["Type 1C antiarrhythmics", "group", "107-129"]}
{"ID": "DDI-DrugBank.d283.s17.p0", "TEXT1": "The pharmacokinetics of @DRUG$ were not significantly affected by @DRUG$", "LBL": "0", "DRUGA": ["fenofibric acid", "drug_n", "24-38"], "DRUGB": ["atorvastatin", "drug", "75-86"]}
{"ID": "DDI-DrugBank.d489.s7.p9", "TEXT1": "Hypotension was more likely to occur if the calcium antagonist were a dihydropyridine derivative, e.g., nifedipine, while left ventricular failure and AV conduction disturbances, including complete heart block, were more likely to occur with either @DRUG$ or @DRUG$.", "LBL": "0", "DRUGA": ["verapamil", "drug", "249-257"], "DRUGB": ["diltiazem", "drug", "262-270"]}
{"ID": "DDI-DrugBank.d179.s21.p11", "TEXT1": "- @DRUG$ (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., @DRUG$], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or", "LBL": "0", "DRUGA": ["Phenothiazines", "group", "2-15"], "DRUGB": ["Compazine", "brand", "200-208"]}
{"ID": "DDI-DrugBank.d260.s0.p98", "TEXT1": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, @DRUG$, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and @DRUG$).", "LBL": "0", "DRUGA": ["bumetanide", "drug", "233-242"], "DRUGB": ["zidovudine", "drug", "352-361"]}
{"ID": "DDI-DrugBank.d413.s19.p1", "TEXT1": "However, in a well-controlled study of patients with lymphoma on combination therapy, @DRUG$ did not increase the marrow toxicity of patients treated with cyclophosphamide, @DRUG$, bleomycin, procarbazine and/or mechlorethamine.", "LBL": "0", "DRUGA": ["allopurinol", "drug", "86-96"], "DRUGB": ["doxorubicin", "drug", "178-188"]}
{"ID": "DDI-DrugBank.d84.s1.p8", "TEXT1": "Although deferasirox has a lower affinity for @DRUG$ than for iron, Exjade should not be taken with aluminum-containing @DRUG$.", "LBL": "0", "DRUGA": ["aluminum", "drug", "46-53"], "DRUGB": ["antacid preparations", "group", "122-141"]}
{"ID": "DDI-DrugBank.d64.s87.p149", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;@DRUG$;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;@DRUG$;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["allopurinol", "drug", "124-134"], "DRUGB": ["salicylates", "group", "805-815"]}
{"ID": "DDI-DrugBank.d547.s2.p7", "TEXT1": "Lithium Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of @DRUG$ with @DRUG$, and with some angiotensin II receptor antagonists.", "LBL": "DDI-mechanism", "DRUGA": ["lithium", "drug", "130-136"], "DRUGB": ["ACE inhibitors", "group", "143-156"]}
{"ID": "DDI-DrugBank.d46.s19.p4", "TEXT1": "- Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a @DRUG$ can reduce the diuretic, natriuretic, and antihypertensive effects of @DRUG$.", "LBL": "DDI-effect", "DRUGA": ["non-steroidal anti-inflammatory agent", "group", "83-119"], "DRUGB": ["loop diuretics", "group", "191-194;228-236"]}
{"ID": "DDI-MedLine.d111.s2.p8", "TEXT1": "Acetaminophen, @DRUG$, phenobarbital, quinidine, theophylline, and @DRUG$ were added to pooled human serum at therapeutic concentrations.", "LBL": "0", "DRUGA": ["lidocaine", "drug", "15-23"], "DRUGB": ["valproic acid", "drug", "70-82"]}
{"ID": "DDI-DrugBank.d533.s7.p42", "TEXT1": "Co-administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, @DRUG$, celecoxib, atenolol, @DRUG$, ramipril or hydrochlorothiazide.", "LBL": "0", "DRUGA": ["metformin", "drug", "128-136"], "DRUGB": ["atorvastatin", "drug", "160-171"]}
{"ID": "DDI-DrugBank.d440.s13.p0", "TEXT1": "However, since @DRUG$, @DRUG$, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate.", "LBL": "0", "DRUGA": ["aspirin", "brand", "15-21"], "DRUGB": ["NSAIDs", "group", "24-29"]}
{"ID": "DDI-DrugBank.d328.s10.p5", "TEXT1": "Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of @DRUG$ and @DRUG$ in some patients.", "LBL": "0", "DRUGA": ["furosemide", "drug", "130-139"], "DRUGB": ["thiazides", "group", "145-153"]}
{"ID": "DDI-DrugBank.d3.s13.p3", "TEXT1": "@DRUG$: Concomitant administration of methotrexate and some NSAIDs has been reported to reduce the clearance of methotrexate, enhancing the toxicity of @DRUG$.", "LBL": "0", "DRUGA": ["Methotrexate", "drug", "0-11"], "DRUGB": ["methotrexate", "drug", "158-169"]}
{"ID": "DDI-DrugBank.d189.s0.p40", "TEXT1": "No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin, @DRUG$, carvedilol, @DRUG$ or itraconazole.", "LBL": "0", "DRUGA": ["isosorbide mononitrate", "drug", "173-194"], "DRUGB": ["ethanol", "drug", "209-215"]}
{"ID": "DDI-DrugBank.d64.s87.p920", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;@DRUG$;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;@DRUG$;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["fenoprofen", "drug", "410-419"], "DRUGB": ["triclofos sodium", "drug", "893-908"]}
{"ID": "DDI-DrugBank.d322.s0.p4", "TEXT1": "Amantadine, @DRUG$, and MAOIs may increase anticholinergic effect of @DRUG$.", "LBL": "DDI-effect", "DRUGA": ["tricyclic antidepressants", "group", "12-36"], "DRUGB": ["clidinium", "drug", "88-96"]}
{"ID": "DDI-DrugBank.d64.s87.p714", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;@DRUG$;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation @DRUG$;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["dextrothyroxine", "drug", "294-308"], "DRUGB": ["anesthetics", "group", "506-516"]}
{"ID": "DDI-DrugBank.d94.s11.p166", "TEXT1": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "LBL": "0", "DRUGA": ["amitriptyline", "drug", "184-196"], "DRUGB": ["topiramate", "drug", "648-657"]}
{"ID": "DDI-DrugBank.d267.s5.p21", "TEXT1": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain @DRUG$ (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "LBL": "0", "DRUGA": ["antibiotics", "group", "122-132"], "DRUGB": ["sodium colistimethate", "drug", "237-257"]}
{"ID": "DDI-DrugBank.d209.s3.p100", "TEXT1": "Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac @DRUG$, diuretics, @DRUG$, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.", "LBL": "0", "DRUGA": ["nitrates", "group", "359-366"], "DRUGB": ["H2 antagonists", "group", "380-393"]}
{"ID": "DDI-DrugBank.d484.s0.p978", "TEXT1": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), @DRUG$ (rifampin), St. Johns wort, temazepam, theophylline (@DRUG$), and vitamin C.", "LBL": "0", "DRUGA": ["rifadin", "brand", "538-544"], "DRUGB": ["Theo-Dur", "brand", "599-606"]}
{"ID": "DDI-DrugBank.d484.s0.p801", "TEXT1": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (@DRUG$, Crixivan, @DRUG$, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "LBL": "0", "DRUGA": ["Agenerase", "brand", "386-394"], "DRUGB": ["Fortovase", "brand", "407-415"]}
{"ID": "DDI-DrugBank.d64.s87.p223", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;@DRUG$;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;@DRUG$;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["amiodarone", "drug", "156-165"], "DRUGB": ["disulfiram", "drug", "352-361"]}
{"ID": "DDI-DrugBank.d457.s0.p13", "TEXT1": "Barbiturates may decrease the effectiveness of oral contraceptives, certain @DRUG$, @DRUG$, theophylline, corticosteroids, anticoagulants, and beta blockers.", "LBL": "0", "DRUGA": ["antibiotics", "group", "76-86"], "DRUGB": ["quinidine", "drug", "89-97"]}
{"ID": "DDI-DrugBank.d457.s0.p20", "TEXT1": "Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, @DRUG$, theophylline, corticosteroids, @DRUG$, and beta blockers.", "LBL": "0", "DRUGA": ["quinidine", "drug", "89-97"], "DRUGB": ["anticoagulants", "group", "131-144"]}
{"ID": "DDI-DrugBank.d441.s6.p9", "TEXT1": "Spontaneous reports of serotonin syndrome associated with co-administration of ZYVOX and serotonergic agents, including antidepressants such as @DRUG$ (@DRUG$), have been reported.", "LBL": "0", "DRUGA": ["selective serotonin reuptake inhibitors", "group", "144-182"], "DRUGB": ["SSRIs", "group", "185-189"]}
{"ID": "DDI-MedLine.d5.s3.p0", "TEXT1": "The treatment of ewes with an intravenous (IV) injection of @DRUG$, insufficient to produce significant inhibition of erythrocyte acetylcholinesterase (AChE) activity, appeared to produce additive effects with those produced by subsequent treatment with 4 mg of @DRUG$/kg/day.", "LBL": "DDI-effect", "DRUGA": ["trichlorfon", "drug_n", "60-70"], "DRUGB": ["coumaphos", "drug_n", "267-275"]}
{"ID": "DDI-DrugBank.d558.s5.p7", "TEXT1": "If a patient requires @DRUG$ and anti-ulcer therapy, it is suggested that omeprazole, ranitidine, or antacids (aluminum and magnesium hydroxides) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of @DRUG$.", "LBL": "0", "DRUGA": ["TIKOSYN", "brand", "22-28"], "DRUGB": ["TIKOSYN", "brand", "251-257"]}
{"ID": "DDI-DrugBank.d94.s11.p206", "TEXT1": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "LBL": "0", "DRUGA": ["bupropion", "drug", "199-207"], "DRUGB": ["theophylline", "drug", "634-645"]}
{"ID": "DDI-DrugBank.d64.s87.p559", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;@DRUG$;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;@DRUG$;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["cimetidine", "drug", "253-262"], "DRUGB": ["nalidixic acid", "drug", "614-627"]}
{"ID": "DDI-DrugBank.d78.s1.p58", "TEXT1": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as @DRUG$, or with multivitamins containing @DRUG$ or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.", "LBL": "0", "DRUGA": ["iron", "drug", "131-134"], "DRUGB": ["iron", "drug", "170-173"]}
{"ID": "DDI-DrugBank.d565.s22.p0", "TEXT1": "The depression of cardiac contractility, conductivity, and automaticity as well as the vascular dilation associated with @DRUG$ may be potentiated by @DRUG$.", "LBL": "DDI-effect", "DRUGA": ["anesthetics", "group", "121-131"], "DRUGB": ["calcium channel blockers", "group", "155-178"]}
{"ID": "DDI-DrugBank.d170.s5.p34", "TEXT1": "Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other @DRUG$, including but not limited to other opioids, @DRUG$, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.", "LBL": "0", "DRUGA": ["central nervous system depressants", "group", "111-144"], "DRUGB": ["sedatives", "group", "191-199"]}
{"ID": "DDI-DrugBank.d94.s11.p676", "TEXT1": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "LBL": "0", "DRUGA": ["felodipine", "drug", "364-373"], "DRUGB": ["topiramate", "drug", "648-657"]}
{"ID": "DDI-DrugBank.d521.s2.p115", "TEXT1": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, @DRUG$, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (@DRUG$, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "LBL": "0", "DRUGA": ["Nuprin", "brand", "82-87"], "DRUGB": ["Voltaren", "brand", "152-159"]}
{"ID": "DDI-DrugBank.d64.s29.p132", "TEXT1": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;@DRUG$;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;@DRUG$;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "LBL": "0", "DRUGA": ["carbamazepine", "drug", "213-225"], "DRUGB": ["meprobamate", "drug", "362-372"]}
{"ID": "DDI-DrugBank.d533.s1.p15", "TEXT1": "Co-administration of lovastatin, @DRUG$, warfarin, furosemide, digoxin, celecoxib, @DRUG$, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.", "LBL": "0", "DRUGA": ["atenolol", "drug", "33-40"], "DRUGB": ["hydrochlorothiazide", "drug", "85-103"]}
{"ID": "DDI-MedLine.d44.s6.p0", "TEXT1": "@DRUG$ elicited 62% enhancement of post-@DRUG$ lipolytic activity and 100% increase of 3H-triglyceride fractional clearance rate compared with placebo treatment.", "LBL": "DDI-effect", "DRUGA": ["Etofibrate", "drug", "0-9"], "DRUGB": ["heparin", "drug", "44-50"]}
{"ID": "DDI-DrugBank.d454.s2.p0", "TEXT1": "- @DRUG$ may enhance the effects of @DRUG$ therapy", "LBL": "DDI-effect", "DRUGA": ["Lofexidine", "drug", "2-11"], "DRUGB": ["anti-hypertensive drug", "group", "40-61"]}
{"ID": "DDI-DrugBank.d45.s1.p2", "TEXT1": "Other TNFa-blocking agents (including @DRUG$) used in combination with @DRUG$ may also result in similar toxicities.", "LBL": "DDI-effect", "DRUGA": ["REMICADE", "brand", "38-45"], "DRUGB": ["anakinra", "drug", "73-80"]}
{"ID": "DDI-DrugBank.d437.s15.p0", "TEXT1": "For comprehensive information concerning laboratory test alterations associated with @DRUG$, physicians should refer to the complete prescribing information for @DRUG$ (ritonavir).", "LBL": "0", "DRUGA": ["ritonavir", "drug", "85-93"], "DRUGB": ["NORVIR", "brand", "164-169"]}
{"ID": "DDI-DrugBank.d94.s11.p84", "TEXT1": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.", "LBL": "0", "DRUGA": ["Acetaminophen", "drug", "157-169"], "DRUGB": ["triazolam", "drug", "681-689"]}
{"ID": "DDI-DrugBank.d475.s3.p0", "TEXT1": "In patients given very high doses (3900 mg) of @DRUG$ daily, increases in serum @DRUG$ levels were seen when nizatidine, 150 mg b.i.d., was administered concurrently.", "LBL": "0", "DRUGA": ["aspirin", "brand", "47-53"], "DRUGB": ["salicylate", "group", "81-90"]}
{"ID": "DDI-DrugBank.d94.s11.p1012", "TEXT1": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.", "LBL": "0", "DRUGA": ["topiramate", "drug", "648-657"], "DRUGB": ["ziprasidone", "drug", "717-727"]}
{"ID": "DDI-DrugBank.d178.s0.p34", "TEXT1": "The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, @DRUG$, monoamine oxidase inhibitors, and @DRUG$.", "LBL": "0", "DRUGA": ["coumarins", "group", "228-236"], "DRUGB": ["beta adrenergic blocking agents", "group", "273-303"]}
{"ID": "DDI-DrugBank.d484.s0.p362", "TEXT1": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, @DRUG$, Trileptal, Topamax, @DRUG$), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "LBL": "0", "DRUGA": ["Tegretol", "brand", "174-181"], "DRUGB": ["Felbatol", "brand", "204-211"]}
{"ID": "DDI-MedLine.d133.s1.p12", "TEXT1": "BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a @DRUG$, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by @DRUG$ (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats.", "LBL": "0", "DRUGA": ["calcium channel blocker", "group", "106-128"], "DRUGB": ["azoxymethane", "drug_n", "214-225"]}
{"ID": "DDI-DrugBank.d131.s8.p0", "TEXT1": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving @DRUG$ metabolized similarly to @DRUG$ or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "LBL": "0", "DRUGA": ["benzodiazepines", "group", "107-121"], "DRUGB": ["alprazolam", "drug", "148-157"]}
{"ID": "DDI-DrugBank.d382.s22.p1", "TEXT1": "@DRUG$: Aprepitant increased the AUC of @DRUG$, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 through 5.", "LBL": "0", "DRUGA": ["Midazolam", "drug", "0-8"], "DRUGB": ["midazolam", "drug", "43-51"]}
{"ID": "DDI-DrugBank.d64.s87.p778", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;@DRUG$;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;@DRUG$;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["diazoxide", "drug", "310-318"], "DRUGB": ["triclofos sodium", "drug", "893-908"]}
{"ID": "DDI-DrugBank.d170.s2.p0", "TEXT1": "The concomitant use of transdermal @DRUG$ with @DRUG$ or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.", "LBL": "DDI-mechanism", "DRUGA": ["fentanyl", "drug", "35-42"], "DRUGB": ["ritonavir", "drug", "49-57"]}
{"ID": "DDI-DrugBank.d318.s8.p0", "TEXT1": "@DRUG$ (e. g., @DRUG$, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.", "LBL": "0", "DRUGA": ["Imidazoles", "group", "0-9"], "DRUGB": ["ketoconazole", "drug", "19-30"]}
{"ID": "DDI-DrugBank.d521.s2.p69", "TEXT1": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (@DRUG$, @DRUG$, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "LBL": "0", "DRUGA": ["Motrin", "brand", "67-72"], "DRUGB": ["Advil", "brand", "75-79"]}
{"ID": "DDI-DrugBank.d328.s43.p5", "TEXT1": "Oral Contraceptives: @DRUG$ (40 mg BID) did not induce the metabolism of the combination oral @DRUG$ norethindrone/ethinyl estradiol (1 mg /35 mcg combination, Ortho-Novum 1/35 ).", "LBL": "0", "DRUGA": ["Valdecoxib", "drug", "21-30"], "DRUGB": ["contraceptive", "group", "98-110"]}
{"ID": "DDI-DrugBank.d124.s26.p127", "TEXT1": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;", "LBL": "0", "DRUGA": ["fentanyl", "drug", "283-290"], "DRUGB": ["alprazolam", "drug", "305-314"]}
{"ID": "DDI-DrugBank.d64.s87.p1456", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;@DRUG$;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;@DRUG$ overdosage.", "LBL": "0", "DRUGA": ["sulfinpyrazone", "drug", "817-830"], "DRUGB": ["warfarin sodium", "drug", "983-997"]}
{"ID": "DDI-DrugBank.d78.s6.p0", "TEXT1": "@DRUG$: @DRUG$ is a competitive inhibitor of the metabolism of theophylline.", "LBL": "0", "DRUGA": ["Theophylline", "drug", "0-11"], "DRUGB": ["Grepafloxacin", "drug", "14-26"]}
{"ID": "DDI-DrugBank.d484.s0.p223", "TEXT1": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and @DRUG$, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), @DRUG$ (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "LBL": "0", "DRUGA": ["tetracycline", "drug", "118-129"], "DRUGB": ["clofibrate", "drug", "282-291"]}
{"ID": "DDI-DrugBank.d522.s5.p0", "TEXT1": "in one man, the C max of @DRUG$ was 8.1 ng/mL with @DRUG$ alone and 7.2 ng/mL with terfenadine plus dirithromycin.", "LBL": "0", "DRUGA": ["terfenadine", "drug", "25-35"], "DRUGB": ["terfenadine", "drug", "56-66"]}
{"ID": "DDI-DrugBank.d199.s2.p3", "TEXT1": "Cimetidine: @DRUG$ does not affect the pharmacokinetics of @DRUG$ when coadministered with MONUROL.", "LBL": "0", "DRUGA": ["Cimetidine", "drug", "12-21"], "DRUGB": ["fosfomycin", "drug", "63-72"]}
{"ID": "DDI-DrugBank.d64.s87.p864", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;@DRUG$;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;@DRUG$;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["ethacrynic acid", "drug", "394-408"], "DRUGB": ["metronidazole", "drug", "560-572"]}
{"ID": "DDI-DrugBank.d94.s11.p945", "TEXT1": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "LBL": "0", "DRUGA": ["Phenytoin", "drug", "560-568"], "DRUGB": ["protease inhibitors", "group", "588-606"]}
{"ID": "DDI-DrugBank.d94.s11.p487", "TEXT1": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "LBL": "0", "DRUGA": ["desipramine", "drug", "292-302"], "DRUGB": ["midazolam", "drug", "470-478"]}
{"ID": "DDI-DrugBank.d521.s2.p144", "TEXT1": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), @DRUG$ (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (@DRUG$, Naprosyn, Aleve);", "LBL": "0", "DRUGA": ["ketoprofen", "drug", "99-108"], "DRUGB": ["Anaprox", "brand", "272-278"]}
{"ID": "DDI-DrugBank.d179.s40.p1", "TEXT1": "- @DRUG$ (e.g., Dilantin) Use of @DRUG$ with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of phenytoin", "LBL": "0", "DRUGA": ["Phenytoin", "drug", "2-10"], "DRUGB": ["phenytoin", "drug", "36-44"]}
{"ID": "DDI-DrugBank.d533.s1.p30", "TEXT1": "Co-administration of lovastatin, atenolol, warfarin, @DRUG$, @DRUG$, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.", "LBL": "0", "DRUGA": ["furosemide", "drug", "53-62"], "DRUGB": ["digoxin", "drug", "65-71"]}
{"ID": "DDI-DrugBank.d521.s2.p146", "TEXT1": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), @DRUG$ (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, @DRUG$);", "LBL": "0", "DRUGA": ["ketoprofen", "drug", "99-108"], "DRUGB": ["Aleve", "brand", "291-295"]}
{"ID": "DDI-MedLine.d30.s8.p5", "TEXT1": "In monkeys, the effects of (-)-NANM, but not (+)-NANM or @DRUG$, were antagonized by @DRUG$;", "LBL": "0", "DRUGA": ["PCP", "drug_n", "57-59"], "DRUGB": ["naloxone", "drug", "82-89"]}
{"ID": "DDI-DrugBank.d321.s1.p0", "TEXT1": "@DRUG$: In the fed state, @DRUG$ (40 mg/kg) increased mean maximum plasma concentration and area under the curve of albendazole sulfoxide by about 50% in healthy subjects (n=10) compared with a separate group of subjects (n=6) given albendazole alone.", "LBL": "0", "DRUGA": ["Praziquantel", "drug", "0-11"], "DRUGB": ["praziquantel", "drug", "32-43"]}
{"ID": "DDI-DrugBank.d43.s2.p3", "TEXT1": "Allopurinol: The AUC of @DRUG$ was increased about 4-fold when @DRUG$ at 300 mg/day was coadministered with a single 200-mg dose of VIDEX to two patients with renal impairment (CLcr=15 and 18 mL/min).", "LBL": "0", "DRUGA": ["didanosine", "drug", "24-33"], "DRUGB": ["allopurinol", "drug", "67-77"]}
{"ID": "DDI-DrugBank.d338.s8.p15", "TEXT1": "The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, fluvoxamine, @DRUG$, @DRUG$, isoniazide, and some macrolide antibiotics.", "LBL": "0", "DRUGA": ["cimetidine", "drug", "167-176"], "DRUGB": ["diltiazem", "drug", "179-187"]}
{"ID": "DDI-DrugBank.d482.s14.p120", "TEXT1": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) @DRUG$ fluoxetine (Prozac) intraconazole (Sporanox) @DRUG$ (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "LBL": "0", "DRUGA": ["estrogens", "group", "183-191"], "DRUGB": ["ketoconazole", "drug", "238-249"]}
{"ID": "DDI-DrugBank.d212.s16.p0", "TEXT1": "Coadministration of this oral @DRUG$ did not influence the pharmacokinetics of @DRUG$.", "LBL": "0", "DRUGA": ["contraceptive", "group", "30-42"], "DRUGB": ["levetiracetam", "drug", "86-98"]}
{"ID": "DDI-DrugBank.d484.s0.p929", "TEXT1": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (@DRUG$, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), @DRUG$ (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "LBL": "0", "DRUGA": ["Astramorph", "brand", "466-475"], "DRUGB": ["rifadin", "brand", "538-544"]}
{"ID": "DDI-DrugBank.d467.s2.p8", "TEXT1": "On the basis of the metabolism of bexarotene by cytochrome P450 3A4, @DRUG$, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma @DRUG$ concentrations.", "LBL": "DDI-mechanism", "DRUGA": ["ketoconazole", "drug", "69-80"], "DRUGB": ["bexarotene", "drug", "237-246"]}
{"ID": "DDI-DrugBank.d566.s5.p4", "TEXT1": "SINCE CHOLESTYRAMINE @DRUG$ MAY BIND OTHER DRUGS GIVEN CONCURRENTLY, IT IS RECOMMENDED THAT PATIENTS TAKE OTHER DRUGS AT LEAST 1 HOUR BEFORE OR 4 TO 6 HOURS AFTER CHOLESTYRAMINE @DRUG$ (OR AT AS GREAT AN INTERVAL AS POSSIBLE) TO AVOID IMPEDING THEIR ABSORPTION.", "LBL": "0", "DRUGA": ["RESIN", "group", "21-25"], "DRUGB": ["RESIN", "group", "177-181"]}
{"ID": "DDI-DrugBank.d382.s19.p4", "TEXT1": "Oral @DRUG$: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of @DRUG$ by 43%, and decreased the AUC of norethindrone by 8%;", "LBL": "0", "DRUGA": ["contraceptives", "group", "5-18"], "DRUGB": ["ethinyl estradiol", "drug", "201-217"]}
{"ID": "DDI-DrugBank.d424.s2.p4", "TEXT1": "The extent of plasma protein binding of atovaquone in human plasma is not affected by the presence of therapeutic concentrations of @DRUG$ (15 mcg/ mL), nor is the binding of phenytoin affected by the presence of @DRUG$.", "LBL": "0", "DRUGA": ["phenytoin", "drug", "132-140"], "DRUGB": ["atovaquone", "drug", "216-225"]}
{"ID": "DDI-DrugBank.d198.s10.p2", "TEXT1": "@DRUG$: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in @DRUG$ AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.", "LBL": "0", "DRUGA": ["HIV Protease Inhibitors", "group", "0-22"], "DRUGB": ["vardenafil", "drug", "123-132"]}
{"ID": "DDI-DrugBank.d537.s0.p86", "TEXT1": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), @DRUG$ (PABA)-containing preparations (e.g., sunscreens and some multivitamins), @DRUG$ (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "LBL": "0", "DRUGA": ["para-aminobenzoic acid", "drug_n", "152-173"], "DRUGB": ["procainamide", "drug", "249-260"]}
{"ID": "DDI-DrugBank.d404.s0.p7", "TEXT1": "Interactions for vitamin D analogues (@DRUG$, @DRUG$, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;", "LBL": "0", "DRUGA": ["Vitamin D2", "drug", "38-47"], "DRUGB": ["Vitamin D3", "drug", "50-59"]}
{"ID": "DDI-DrugBank.d482.s14.p11", "TEXT1": "Tell your doctor if you are taking any of the following drugs: @DRUG$s (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (@DRUG$) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "LBL": "0", "DRUGA": ["blood thinner", "group", "63-75"], "DRUGB": ["Sporanox", "brand", "228-235"]}
{"ID": "DDI-DrugBank.d480.s18.p1", "TEXT1": "Although concomitant use of @DRUG$ and carbamazepine is not recommended, it should be noted that discontinuation of concomitant @DRUG$ administration may result in an increase in Clozapine plasma levels.", "LBL": "0", "DRUGA": ["Clozapine", "drug", "28-36"], "DRUGB": ["carbamazepine", "drug", "131-143"]}
{"ID": "DDI-DrugBank.d60.s5.p2", "TEXT1": "Although not studied systematically in clinical trials, no drug interactions were observed when @DRUG$, pancuronium, or atracurium were administered following varying degrees of recovery from single doses or infusions of @DRUG$.", "LBL": "0", "DRUGA": ["vecuronium", "drug", "96-105"], "DRUGB": ["NIMBEX", "brand", "225-230"]}
{"ID": "DDI-DrugBank.d78.s1.p54", "TEXT1": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with @DRUG$, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as @DRUG$ (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.", "LBL": "0", "DRUGA": ["sucralfate", "drug", "92-101"], "DRUGB": ["VIDEX", "brand", "255-259"]}
{"ID": "DDI-DrugBank.d179.s40.p3", "TEXT1": "- @DRUG$ (e.g., Dilantin) Use of phenytoin with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of @DRUG$", "LBL": "0", "DRUGA": ["Phenytoin", "drug", "2-10"], "DRUGB": ["phenytoin", "drug", "152-160"]}
{"ID": "DDI-DrugBank.d359.s1.p2", "TEXT1": "Considerable caution should be exercised if PEGANONE is administered concurrently with @DRUG$ (@DRUG$) since paranoid symptoms have been reported during therapy with this combination.", "LBL": "0", "DRUGA": ["Phenurone", "brand", "87-95"], "DRUGB": ["phenacemide", "drug", "98-108"]}
{"ID": "DDI-DrugBank.d45.s4.p3", "TEXT1": "In rheumatoid arthritis, concomitant medications besides @DRUG$ were nonsteroidal anti-inflammatory agents, folic acid, corticosteroids and/or @DRUG$.", "LBL": "0", "DRUGA": ["MTX", "drug", "57-59"], "DRUGB": ["narcotics", "group", "140-148"]}
{"ID": "DDI-MedLine.d80.s1.p2", "TEXT1": "In order to provide information for the appropriate package insert labeling of @DRUG$ (POC) in the US, a comprehensive review was made of norgestrel (0.075 mg) and @DRUG$ (0.35 mg), with the clinical differences indicated where applicable.", "LBL": "0", "DRUGA": ["progestin-only oral contraceptives", "group", "79-112"], "DRUGB": ["norethindrone", "drug", "192-204"]}
{"ID": "DDI-DrugBank.d15.s0.p12", "TEXT1": "In clinical studies performed with Fondaparinux, the concomitant use of oral @DRUG$ (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (@DRUG$), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.", "LBL": "0", "DRUGA": ["anticoagulants", "group", "77-90"], "DRUGB": ["piroxicam", "drug", "156-164"]}
{"ID": "DDI-DrugBank.d384.s0.p18", "TEXT1": "Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, @DRUG$, and @DRUG$): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;", "LBL": "0", "DRUGA": ["Calcitriol", "drug", "62-71"], "DRUGB": ["Calcidiol", "drug", "78-86"]}
{"ID": "DDI-DrugBank.d431.s1.p15", "TEXT1": "Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as @DRUG$, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, @DRUG$, diazepam, clarithromycin, or terfenadine in healthy subjects.", "LBL": "0", "DRUGA": ["warfarin", "drug", "155-162"], "DRUGB": ["prednisone", "drug", "226-235"]}
{"ID": "DDI-DrugBank.d297.s2.p11", "TEXT1": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: @DRUG$, @DRUG$, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.", "LBL": "0", "DRUGA": ["MTX", "drug", "124-126"], "DRUGB": ["NSAIDs", "group", "129-134"]}
{"ID": "DDI-DrugBank.d284.s4.p4", "TEXT1": "The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as @DRUG$@DRUG$) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded.", "LBL": "0", "DRUGA": ["loop diuretics", "group", "119-122;136-144"], "DRUGB": ["thiazide diuretics", "group", "127-144"]}
{"ID": "DDI-DrugBank.d97.s73.p1", "TEXT1": "@DRUG$: cyclosporine, @DRUG$, sirolimus", "LBL": "0", "DRUGA": ["Immunosuppressants", "group", "0-17"], "DRUGB": ["tacrolimus", "drug", "34-43"]}
{"ID": "DDI-DrugBank.d388.s5.p14", "TEXT1": "No significant interactions with digoxin, hydrochlorothiazide, @DRUG$, sulfinpyrazone, oral contraceptives, tolbutamide, or @DRUG$ have been observed.", "LBL": "0", "DRUGA": ["hydralazine", "drug", "63-73"], "DRUGB": ["warfarin", "drug", "129-136"]}
{"ID": "DDI-DrugBank.d267.s6.p0", "TEXT1": "As with some other @DRUG$, the time of onset of neuromuscular block induced by @DRUG$ is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.", "LBL": "0", "DRUGA": ["nondepolarizing neuromuscular blocking agents", "group", "19-63"], "DRUGB": ["NUROMAX", "brand", "118-124"]}
{"ID": "DDI-DrugBank.d94.s4.p59", "TEXT1": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, @DRUG$, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, @DRUG$, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "LBL": "0", "DRUGA": ["azole antifungals", "group", "146-162"], "DRUGB": ["fluvoxamine", "drug", "272-282"]}
{"ID": "DDI-DrugBank.d94.s4.p93", "TEXT1": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, @DRUG$, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, @DRUG$, troleandomycin, valproate(1), verapamil, zileuton.", "LBL": "0", "DRUGA": ["cimetidine", "drug", "165-174"], "DRUGB": ["quinupristin", "drug", "437-448"]}
{"ID": "DDI-DrugBank.d389.s3.p1", "TEXT1": "Effects of @DRUG$ are increased with MAO inhibitors and @DRUG$.", "LBL": "DDI-effect", "DRUGA": ["sympathomimetics", "group", "11-26"], "DRUGB": ["beta adrenergic blockers", "group", "66-89"]}
{"ID": "DDI-DrugBank.d558.s33.p6", "TEXT1": "In addition, studies in healthy volunteers have shown that TIKOSYN does not affect the pharmacokinetics or pharmacodynamics of @DRUG$, or the pharmacokinetics of propranolol (40 mg twice daily), @DRUG$, theophylline, or oral contraceptives.", "LBL": "0", "DRUGA": ["warfarin", "drug", "127-134"], "DRUGB": ["phenytoin", "drug", "197-205"]}
{"ID": "DDI-DrugBank.d241.s3.p9", "TEXT1": "In clinical trials, @DRUG$ was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and @DRUG$ (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.", "LBL": "0", "DRUGA": ["FLOLAN", "brand", "20-25"], "DRUGB": ["digoxin", "drug", "326-332"]}
{"ID": "DDI-DrugBank.d60.s12.p117", "TEXT1": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local @DRUG$, @DRUG$, and quinidine.", "LBL": "0", "DRUGA": ["anesthetics", "group", "292-302"], "DRUGB": ["procainamide", "drug", "305-316"]}
{"ID": "DDI-DrugBank.d167.s2.p27", "TEXT1": "In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like lidocaine, procaine, beta-blockers, metaclopramide, @DRUG$, and @DRUG$.", "LBL": "0", "DRUGA": ["lithium carbonate", "drug", "154-170"], "DRUGB": ["terbutaline", "drug", "177-187"]}
{"ID": "DDI-MedLine.d126.s0.p1", "TEXT1": "@DRUG$-induced oxidative stress in rat brain and liver is prevented by vitamin E or @DRUG$.", "LBL": "DDI-effect", "DRUGA": ["Cypermethrin", "drug", "0-11"], "DRUGB": ["allopurinol", "drug", "90-100"]}
{"ID": "DDI-DrugBank.d328.s24.p3", "TEXT1": "Valdecoxib caused a statistically significant increase in plasma exposures of @DRUG$ and @DRUG$ (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of warfarin.", "LBL": "0", "DRUGA": ["R-warfarin", "drug", "78-87"], "DRUGB": ["S-warfarin", "drug", "93-102"]}
{"ID": "DDI-DrugBank.d476.s2.p2", "TEXT1": "In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that @DRUG$ be discontinued for several days before the withdrawal of @DRUG$.", "LBL": "DDI-advise", "DRUGA": ["ZEBETA", "brand", "112-117"], "DRUGB": ["clonidine", "drug", "177-185"]}
{"ID": "DDI-DrugBank.d124.s17.p7", "TEXT1": "Antimycobacterial Agents: rifampin CONTRAINDICATED since the coadministration of this product with @DRUG$ in an @DRUG$ regimen reduces the plasma concentrations of saquinavir.", "LBL": "0", "DRUGA": ["saquinavir", "drug", "99-108"], "DRUGB": ["antiretroviral", "group", "116-129"]}
{"ID": "DDI-DrugBank.d558.s25.p58", "TEXT1": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, @DRUG$, grapefruit juice, nefazadone, @DRUG$, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.", "LBL": "0", "DRUGA": ["diltiazem", "drug", "162-170"], "DRUGB": ["norfloxacin", "drug", "203-213"]}
{"ID": "DDI-DrugBank.d170.s2.p11", "TEXT1": "The concomitant use of transdermal fentanyl with @DRUG$ or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, @DRUG$, and nefazadone may result in an increase in fentanyl plasma concentrations.", "LBL": "0", "DRUGA": ["ritonavir", "drug", "49-57"], "DRUGB": ["nelfinavir", "drug", "158-167"]}
{"ID": "DDI-DrugBank.d94.s11.p312", "TEXT1": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "LBL": "0", "DRUGA": ["clobazam", "drug", "233-240"], "DRUGB": ["midazolam", "drug", "470-478"]}
{"ID": "DDI-DrugBank.d484.s0.p610", "TEXT1": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, @DRUG$), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (@DRUG$), and vitamin C.", "LBL": "0", "DRUGA": ["Sporanox", "brand", "247-254"], "DRUGB": ["Theo-Dur", "brand", "599-606"]}
{"ID": "DDI-DrugBank.d0.s4.p2", "TEXT1": "The pharmacokinetics of naltrexone and its major metabolite @DRUG$ were unaffected following co-administration with @DRUG$.", "LBL": "0", "DRUGA": ["6-beta-naltrexol", "drug_n", "60-75"], "DRUGB": ["Acamprosate", "drug", "126-136"]}
{"ID": "DDI-DrugBank.d171.s4.p2", "TEXT1": "However, a crossover study in healthy subjects receiving either @DRUG$ 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of theophylline (Theo-Dur , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state @DRUG$ peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.", "LBL": "0", "DRUGA": ["Tagamet", "brand", "64-70"], "DRUGB": ["theophylline", "drug", "243-254"]}
{"ID": "DDI-DrugBank.d27.s4.p11", "TEXT1": "In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or @DRUG$, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of @DRUG$.", "LBL": "0", "DRUGA": ["digoxin", "drug", "97-103"], "DRUGB": ["digoxin", "drug", "235-241"]}
{"ID": "DDI-DrugBank.d313.s2.p39", "TEXT1": "The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, @DRUG$, @DRUG$ (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).", "LBL": "0", "DRUGA": ["diuretics", "group", "126-134"], "DRUGB": ["sympathomimetic agents", "group", "137-158"]}
{"ID": "DDI-DrugBank.d536.s1.p45", "TEXT1": "These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, @DRUG$, oral @DRUG$, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid.", "LBL": "0", "DRUGA": ["estrogens", "group", "106-114"], "DRUGB": ["contraceptives", "group", "122-135"]}
{"ID": "DDI-DrugBank.d517.s0.p0", "TEXT1": "@DRUG$, a @DRUG$, may antagonize the bactercidal effect of penicillin and concurrent use of these drugs should be avoided.", "LBL": "0", "DRUGA": ["Tetracycline", "drug", "0-11"], "DRUGB": ["bacteriostatic antibiotic", "group", "16-40"]}
{"ID": "DDI-DrugBank.d499.s3.p5", "TEXT1": "Antacids: Concomitant administration of @DRUG$ and aluminum hydroxide does not interfere with the rate or extent of the absorption of @DRUG$ administered as Orudis.", "LBL": "0", "DRUGA": ["magnesium hydroxide", "drug", "40-58"], "DRUGB": ["ketoprofen", "drug", "147-156"]}
{"ID": "DDI-MedLine.d5.s0.p5", "TEXT1": "Repeated oral administration of coumaphos in sheep: interactions of @DRUG$ with bishydroxycoumarin, @DRUG$, and phenobarbital sodium.", "LBL": "0", "DRUGA": ["coumaphos", "drug_n", "68-76"], "DRUGB": ["trichlorfon", "drug_n", "103-113"]}
{"ID": "DDI-DrugBank.d413.s20.p9", "TEXT1": "Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since @DRUG$ and @DRUG$ may compete for excretion in the renal tubule.", "LBL": "DDI-mechanism", "DRUGA": ["allopurinol", "drug", "88-98"], "DRUGB": ["chlorpropamide", "drug", "104-117"]}
{"ID": "DDI-DrugBank.d458.s3.p2", "TEXT1": "The following drug interactions have been identified involving @DRUG$ Tablets and other drugs metabolized by the cytochrome P450 3A4 enzyme system: Ketoconazole tablets inhibit the metabolism of terfenadine, resulting in an increased plasma concentration of @DRUG$ and a delay in the elimination of its acid metabolite.", "LBL": "0", "DRUGA": ["NIZORAL", "brand", "63-69"], "DRUGB": ["terfenadine", "drug", "259-269"]}
{"ID": "DDI-DrugBank.d522.s5.p1", "TEXT1": "in one man, the C max of @DRUG$ was 8.1 ng/mL with terfenadine alone and 7.2 ng/mL with @DRUG$ plus dirithromycin.", "LBL": "0", "DRUGA": ["terfenadine", "drug", "25-35"], "DRUGB": ["terfenadine", "drug", "93-103"]}
{"ID": "DDI-DrugBank.d64.s87.p1474", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;@DRUG$;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;@DRUG$ overdosage.", "LBL": "0", "DRUGA": ["thyroid drugs", "group", "867-879"], "DRUGB": ["warfarin sodium", "drug", "983-997"]}
{"ID": "DDI-DrugBank.d561.s10.p25", "TEXT1": "Other No clinically important pharmacokinetic interactions occurred when Lotensin was administered concomitantly with hydrochlorothiazide, chlorthalidone, @DRUG$, digoxin, propranolol, atenolol, naproxen, or @DRUG$.", "LBL": "0", "DRUGA": ["furosemide", "drug", "155-164"], "DRUGB": ["cimetidine", "drug", "212-221"]}
{"ID": "DDI-DrugBank.d475.s0.p7", "TEXT1": "No interactions have been observed between nizatidine and @DRUG$, chlordiazepoxide, @DRUG$, lidocaine, phenytoin, and warfarin.", "LBL": "0", "DRUGA": ["theophylline", "drug", "58-69"], "DRUGB": ["lorazepam", "drug", "90-98"]}
{"ID": "DDI-MedLine.d29.s4.p0", "TEXT1": "No significant difference was found between the mean values of the volume of distribution of @DRUG$ with and without @DRUG$ (13.0 and 12.6 liters, respectively).", "LBL": "0", "DRUGA": ["cloxacillin", "drug", "93-103"], "DRUGB": ["probenecid", "drug", "122-131"]}
{"ID": "DDI-DrugBank.d395.s21.p2", "TEXT1": "Enoxacin interferes with the metabolism of @DRUG$ resulting in a 42% to 74% dose-related decrease in @DRUG$ clearance and a subsequent 260% to 350% increase in serum theophylline levels.", "LBL": "0", "DRUGA": ["theophylline", "drug", "43-54"], "DRUGB": ["theophylline", "drug", "107-118"]}
{"ID": "DDI-DrugBank.d107.s10.p8", "TEXT1": "Other Cardiovascular Agents: Enalapril and @DRUG$ IV have been used concomitantly with @DRUG$, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.", "LBL": "0", "DRUGA": ["enalapril", "drug", "43-51"], "DRUGB": ["beta adrenergic-blocking agents", "group", "90-120"]}
{"ID": "DDI-DrugBank.d64.s87.p978", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;@DRUG$;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;@DRUG$*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["ibuprofen", "drug", "448-456"], "DRUGB": ["ranitidine", "drug", "793-802"]}
{"ID": "DDI-DrugBank.d285.s1.p8", "TEXT1": "A similar association, though less marked, has been suggested with barbiturates, phenyl-butazone, @DRUG$, carbamazepine and possibly with griseofulvin, ampicillin, and @DRUG$ (72)", "LBL": "0", "DRUGA": ["phenytoin sodium", "drug", "98-113"], "DRUGB": ["tetracyclines", "group", "178-190"]}
{"ID": "DDI-DrugBank.d94.s11.p816", "TEXT1": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "LBL": "0", "DRUGA": ["lorazepam", "drug", "448-456"], "DRUGB": ["theophylline", "drug", "634-645"]}
{"ID": "DDI-DrugBank.d94.s4.p56", "TEXT1": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, @DRUG$, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, @DRUG$, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "LBL": "0", "DRUGA": ["azole antifungals", "group", "146-162"], "DRUGB": ["diltiazem", "drug", "232-240"]}
{"ID": "DDI-DrugBank.d365.s1.p7", "TEXT1": "H1 and H2 Blockers - Although not reported, @DRUG$, via its metabolism to histamine, might decrease the efficacy of @DRUG$.", "LBL": "DDI-effect", "DRUGA": ["L-histidine", "drug", "44-54"], "DRUGB": ["H1 blockers", "group", "121-122;131-138"]}
{"ID": "DDI-DrugBank.d202.s16.p25", "TEXT1": "Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, @DRUG$, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, @DRUG$), should be approached with caution.", "LBL": "0", "DRUGA": ["carbamazepine", "drug", "164-176"], "DRUGB": ["quinidine", "drug", "286-294"]}
{"ID": "DDI-DrugBank.d21.s1.p0", "TEXT1": "These results would seem to dictate against the clinical use of @DRUG$ with @DRUG$, or during the period following ELSPAR therapy when plasma asparagine levels are below normal.", "LBL": "DDI-advise", "DRUGA": ["methotrexate", "drug", "64-75"], "DRUGB": ["ELSPAR", "brand", "82-87"]}
{"ID": "DDI-DrugBank.d446.s0.p11", "TEXT1": "@DRUG$ may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, @DRUG$, and warfarin.", "LBL": "DDI-int", "DRUGA": ["Chlorotrianisene", "drug", "0-15"], "DRUGB": ["tamoxifen", "drug", "191-199"]}
{"ID": "DDI-DrugBank.d485.s12.p22", "TEXT1": "Anticonvulsants (carbamazepine, felbamate, phenobarbital, @DRUG$, @DRUG$): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.", "LBL": "0", "DRUGA": ["phenytoin", "drug", "58-66"], "DRUGB": ["topiramate", "drug", "69-78"]}
{"ID": "DDI-DrugBank.d94.s11.p586", "TEXT1": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "LBL": "0", "DRUGA": ["doxycycline", "drug", "326-336"], "DRUGB": ["Phenytoin", "drug", "560-568"]}
{"ID": "DDI-DrugBank.d468.s10.p3", "TEXT1": "When therapeutic concentrations of @DRUG$, propranolol, dipyridamole, warfarin, @DRUG$, or naproxen were added to human plasma (in vitro), the plasma protein binding of nicardipine HCl was not altered.", "LBL": "0", "DRUGA": ["furosemide", "drug", "35-44"], "DRUGB": ["quinidine", "drug", "84-92"]}
{"ID": "DDI-DrugBank.d107.s10.p26", "TEXT1": "Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, @DRUG$, @DRUG$, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.", "LBL": "0", "DRUGA": ["nitrates", "group", "135-142"], "DRUGB": ["calcium-blocking agents", "group", "145-167"]}
{"ID": "DDI-DrugBank.d5.s17.p45", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, @DRUG$, @DRUG$, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["imipramine", "drug", "150-159"], "DRUGB": ["desipramine", "drug", "162-172"]}
{"ID": "DDI-DrugBank.d81.s13.p3", "TEXT1": "@DRUG$: The concomitant administration of DynaCirc  (isradipine) and digoxin in a single-dose pharmacokinetic study did not affect renal, nonrenal and total body clearance of @DRUG$.", "LBL": "0", "DRUGA": ["Digoxin", "drug", "0-6"], "DRUGB": ["digoxin", "drug", "176-182"]}
{"ID": "DDI-DrugBank.d131.s8.p57", "TEXT1": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction with @DRUG$ for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "LBL": "0", "DRUGA": ["alprazolam", "drug", "369-378"], "DRUGB": ["alprazolam", "drug", "421-430"]}
{"ID": "DDI-DrugBank.d47.s2.p11", "TEXT1": "Dopamine D2 receptor antagonists (e.g., phenothiazines, @DRUG$, risperidone) and isoniazid may reduce the therapeutic effects of @DRUG$.", "LBL": "DDI-effect", "DRUGA": ["butyrophenones", "group", "56-69"], "DRUGB": ["levodopa", "drug", "137-144"]}
{"ID": "DDI-DrugBank.d434.s28.p5", "TEXT1": "Phenobarbital: Coadministration of @DRUG$ with @DRUG$ causes an increase in phenobarbital plasma concentrations, In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL.", "LBL": "DDI-mechanism", "DRUGA": ["felbamate", "drug", "35-43"], "DRUGB": ["phenobarbital", "drug", "50-62"]}
{"ID": "DDI-DrugBank.d179.s21.p226", "TEXT1": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., @DRUG$], promazine [e.g., Sparine], promethazine [e.g., Phenergan], @DRUG$ [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or", "LBL": "0", "DRUGA": ["Compazine", "brand", "200-208"], "DRUGB": ["thioridazine", "drug", "271-282"]}
{"ID": "DDI-DrugBank.d277.s19.p0", "TEXT1": "@DRUG$: Concomitant administration of @DRUG$ did not affect the steady-state pharmacokinetics of digoxin or the mean daily trough serum level of digoxin.", "LBL": "0", "DRUGA": ["Digoxin", "drug", "0-6"], "DRUGB": ["tiagabine", "drug", "39-47"]}
{"ID": "DDI-DrugBank.d536.s10.p2", "TEXT1": "However, the peak plasma level of metformin was reduced by approximately 20% when taking @DRUG$ due to a slight delay in the absorption of @DRUG$.", "LBL": "DDI-mechanism", "DRUGA": ["Acarbose", "drug", "89-96"], "DRUGB": ["metformin", "drug", "141-149"]}
{"ID": "DDI-DrugBank.d316.s14.p3", "TEXT1": "@DRUG$: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, @DRUG$, or phenobarbital) than in healthy volunteers.", "LBL": "0", "DRUGA": ["Anticonvulsants", "group", "0-14"], "DRUGB": ["carbamazepine", "drug", "187-199"]}
{"ID": "DDI-DrugBank.d239.s2.p3", "TEXT1": "The co-administration of @DRUG$ with IV vasodilators such as nitroglycerin, nitroprusside, @DRUG$, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).", "LBL": "0", "DRUGA": ["Natrecor", "brand", "25-32"], "DRUGB": ["milrinone", "drug", "93-101"]}
{"ID": "DDI-DrugBank.d26.s0.p2", "TEXT1": "Patients receiving other @DRUG$s, general anesthetics, phenothiazines, @DRUG$, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.", "LBL": "0", "DRUGA": ["narcotic analgesic", "group", "25-42"], "DRUGB": ["tranquilizers", "group", "83-95"]}
{"ID": "DDI-DrugBank.d64.s87.p296", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;@DRUG$;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;@DRUG$;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["anabolic steroids", "group", "167-183"], "DRUGB": ["quinidine", "drug", "775-783"]}
{"ID": "DDI-DrugBank.d382.s34.p4", "TEXT1": "therefore, coadministration of @DRUG$ with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of @DRUG$.", "LBL": "0", "DRUGA": ["Aprepitant", "drug", "31-40"], "DRUGB": ["Aprepitant", "drug", "232-241"]}
{"ID": "DDI-MedLine.d83.s5.p0", "TEXT1": "In the first double-blind comparative study (28-week) of @DRUG$ and @DRUG$, olanzapine 10 to 20 mg/day proved to be significantly more effective than risperidone 4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms.", "LBL": "0", "DRUGA": ["olanzapine", "drug", "57-66"], "DRUGB": ["risperidone", "drug", "72-82"]}
{"ID": "DDI-MedLine.d111.s5.p16", "TEXT1": "acetaminophen/@DRUG$, lidocaine/quinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.", "LBL": "0", "DRUGA": ["theophylline", "drug", "14-25"], "DRUGB": ["acetaminophen", "drug", "63-75"]}
{"ID": "DDI-DrugBank.d521.s2.p171", "TEXT1": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, @DRUG$, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (@DRUG$), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "LBL": "0", "DRUGA": ["Orudis KT", "brand", "119-127"], "DRUGB": ["Indocin", "brand", "206-212"]}
{"ID": "DDI-DrugBank.d85.s11.p0", "TEXT1": "Caution should be used if @DRUG$ is administered concomitantly with @DRUG$.", "LBL": "DDI-advise", "DRUGA": ["naproxen", "drug", "26-33"], "DRUGB": ["methotrexate", "drug", "70-81"]}
{"ID": "DDI-DrugBank.d48.s11.p9", "TEXT1": "H2 Blockers/@DRUG$: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and @DRUG$) is likely to reduce dasatinib exposure.", "LBL": "0", "DRUGA": ["Proton Pump Inhibitors", "group", "12-33"], "DRUGB": ["omeprazole", "drug", "145-154"]}
{"ID": "DDI-MedLine.d30.s9.p0", "TEXT1": "the doses of @DRUG$ required to antagonize the effects of @DRUG$ were more than 100 times higher than those required to antagonize the effects of morphine.", "LBL": "DDI-effect", "DRUGA": ["naloxone", "drug", "13-20"], "DRUGB": ["(-)-NANM", "drug_n", "60-67"]}
{"ID": "DDI-DrugBank.d509.s27.p4", "TEXT1": "Alcohol: There was no significant difference between @DRUG$ coadministered with ethanol and placebo coadministered with @DRUG$ on performance of gross motor skills or stimulus response in healthy subjects.", "LBL": "0", "DRUGA": ["aripiprazole", "drug", "53-64"], "DRUGB": ["ethanol", "drug", "126-132"]}
{"ID": "DDI-DrugBank.d411.s4.p435", "TEXT1": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "LBL": "0", "DRUGA": ["insulin", "drug", "568-574"], "DRUGB": ["resorcinol", "drug", "756-765"]}
{"ID": "DDI-DrugBank.d124.s26.p122", "TEXT1": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;", "LBL": "0", "DRUGA": ["carbamazepine", "drug", "268-280"], "DRUGB": ["alfentanyl", "drug", "293-302"]}
{"ID": "DDI-DrugBank.d289.s15.p0", "TEXT1": "Co-administration of @DRUG$ and @DRUG$ resulted in markedly increased plasma concentrations of bosentan in animals.", "LBL": "DDI-mechanism", "DRUGA": ["tacrolimus", "drug", "21-30"], "DRUGB": ["bosentan", "drug", "36-43"]}
{"ID": "DDI-DrugBank.d416.s0.p1", "TEXT1": "Renal clearance measurements of @DRUG$ cannot be made with any significant accuracy in patients receiving sulfonamides, @DRUG$, or thiazolesulfone.", "LBL": "DDI-effect", "DRUGA": ["PAH", "drug", "32-34"], "DRUGB": ["procaine", "drug", "117-124"]}
{"ID": "DDI-DrugBank.d30.s9.p0", "TEXT1": "As with other @DRUG$, the antihypertensive effect of @DRUG$ may be blunted by the non-steroidal anti-inflammatory drug indomethacin", "LBL": "0", "DRUGA": ["antihypertensive agents", "group", "14-36"], "DRUGB": ["losartan", "drug", "70-77"]}
{"ID": "DDI-DrugBank.d484.s0.p72", "TEXT1": "Etonogestrel may interact with the following medications: @DRUG$ (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, @DRUG$, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "LBL": "0", "DRUGA": ["acetaminophen", "drug", "58-70"], "DRUGB": ["Norvir", "brand", "437-442"]}
{"ID": "DDI-DrugBank.d536.s1.p58", "TEXT1": "These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimetics, @DRUG$, and isoniazid.", "LBL": "0", "DRUGA": ["phenytoin", "drug", "138-146"], "DRUGB": ["calcium channel-blocking drugs", "group", "183-212"]}
{"ID": "DDI-MedLine.d1.s6.p2", "TEXT1": "No interactions have been observed with @DRUG$, calcium antagonists, thiazide and @DRUG$ and ACE inhibitors.", "LBL": "0", "DRUGA": ["beta-receptor blockers", "group", "40-61"], "DRUGB": ["loop diuretics", "group", "98-111"]}
{"ID": "DDI-DrugBank.d382.s4.p0", "TEXT1": "@DRUG$ has been shown to induce the metabolism of @DRUG$ and tolbutamide, which are metabolized through CYP2C9.", "LBL": "DDI-mechanism", "DRUGA": ["Aprepitant", "drug", "0-9"], "DRUGB": ["S(-) warfarin", "drug", "54-66"]}
{"ID": "DDI-DrugBank.d484.s0.p389", "TEXT1": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, @DRUG$, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), @DRUG$ (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "LBL": "0", "DRUGA": ["Tegretol", "brand", "174-181"], "DRUGB": ["rifadin", "brand", "538-544"]}
{"ID": "DDI-DrugBank.d76.s10.p2", "TEXT1": "Although it has not been definitively demonstrated that fluvoxamine is a potent IIIA4 inhibitor, it is likely to be, given the substantial interaction of @DRUG$ with @DRUG$.", "LBL": "DDI-int", "DRUGA": ["fluvoxamine", "drug", "154-164"], "DRUGB": ["alprazolam", "drug", "171-180"]}
{"ID": "DDI-DrugBank.d484.s0.p396", "TEXT1": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, @DRUG$, Topamax, @DRUG$), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "LBL": "0", "DRUGA": ["Trileptal", "brand", "184-192"], "DRUGB": ["Felbatol", "brand", "204-211"]}
{"ID": "DDI-DrugBank.d187.s7.p8", "TEXT1": "Carbamazepine: @DRUG$ is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with @DRUG$, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.", "LBL": "0", "DRUGA": ["Isoniazid", "drug", "15-23"], "DRUGB": ["isoniazid", "drug", "186-194"]}
{"ID": "DDI-DrugBank.d537.s0.p26", "TEXT1": "Bentiromide may interact with @DRUG$ (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), @DRUG$ (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "LBL": "0", "DRUGA": ["acetaminophen", "drug", "30-42"], "DRUGB": ["thiazide diuretics", "group", "313-330"]}
{"ID": "DDI-DrugBank.d216.s0.p1", "TEXT1": "CNS-Active Drugs @DRUG$ An additive effect on psychomotor performance was seen with coadministration of eszopiclone and @DRUG$ 0.70 g/kg for up to 4 hours after ethanol administration.", "LBL": "0", "DRUGA": ["Ethanol", "drug", "17-23"], "DRUGB": ["ethanol", "drug", "121-127"]}
{"ID": "DDI-DrugBank.d527.s1.p7", "TEXT1": "The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetes products, @DRUG$, disopyramide, fibrates, fluoxetine, MAO inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., @DRUG$), sulfonamide antibiotics.", "LBL": "0", "DRUGA": ["ACE inhibitors", "group", "157-170"], "DRUGB": ["octreotide", "drug", "279-288"]}
{"ID": "DDI-MedLine.d130.s6.p4", "TEXT1": "Comparison of cisplatin pharmacokinetics in patients treated with 202.5 mg/m2 plus @DRUG$ to those in patients treated with 100 mg/m2 without thiosulfate indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of @DRUG$.", "LBL": "0", "DRUGA": ["thiosulfate", "drug", "83-93"], "DRUGB": ["cisplatin", "drug", "281-289"]}
{"ID": "DDI-MedLine.d103.s1.p6", "TEXT1": "Two different types of therapy with magnesium are used: physiological oral @DRUG$ supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the @DRUG$ intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload.", "LBL": "0", "DRUGA": ["magnesium", "drug", "75-83"], "DRUGB": ["magnesium", "drug", "193-201"]}
{"ID": "DDI-DrugBank.d411.s4.p82", "TEXT1": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "LBL": "0", "DRUGA": ["amiodarone", "drug", "270-279"], "DRUGB": ["lovastatin", "drug", "650-659"]}
{"ID": "DDI-DrugBank.d64.s87.p1427", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;@DRUG$;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;@DRUG$/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["quinine", "drug", "785-791"], "DRUGB": ["trimethoprim", "drug", "910-921"]}
{"ID": "DDI-MedLine.d76.s1.p13", "TEXT1": "The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and @DRUG$ (@DRUG$) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin.", "LBL": "0", "DRUGA": ["carboxymethylcellulose-cysteine", "drug_n", "98-128"], "DRUGB": ["CMC-Cys", "drug_n", "131-137"]}
{"ID": "DDI-DrugBank.d379.s1.p19", "TEXT1": "It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, @DRUG$, phenothiazines, @DRUG$ and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.", "LBL": "0", "DRUGA": ["sulfonylureas", "group", "127-139"], "DRUGB": ["sulfonamides", "group", "158-169"]}
{"ID": "DDI-DrugBank.d170.s7.p6", "TEXT1": "MAO Inhibitors: @DRUG$  is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with @DRUG$", "LBL": "0", "DRUGA": ["DURAGESIC", "brand", "16-24"], "DRUGB": ["opioid analgesics", "group", "191-207"]}
{"ID": "DDI-DrugBank.d223.s7.p11", "TEXT1": "cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, @DRUG$, and the Type 1C antiarrhythmics propafenone and @DRUG$).", "LBL": "0", "DRUGA": ["phenothiazines", "group", "83-96"], "DRUGB": ["flecainide", "drug", "147-156"]}
{"ID": "DDI-DrugBank.d543.s6.p0", "TEXT1": "@DRUG$ may antagonize the effects of the drugs that alter gastrointestinal motility, such as @DRUG$.", "LBL": "DDI-mechanism", "DRUGA": ["Anticholinergic drugs", "group", "0-20"], "DRUGB": ["metoclopramide", "drug", "108-121"]}
{"ID": "DDI-DrugBank.d400.s0.p1", "TEXT1": "@DRUG$: As with other NSAIDs, concomitant administration of @DRUG$ and aspirin is not generally recommended because of the potential of increased adverse effects.", "LBL": "0", "DRUGA": ["Aspirin", "brand", "0-6"], "DRUGB": ["Ponstel", "brand", "61-67"]}
{"ID": "DDI-DrugBank.d461.s0.p8", "TEXT1": "Additive depressant effect when used with general anesthetics, @DRUG$, antianxiety drugs, hypnotics, alcohol, and other @DRUG$.", "LBL": "0", "DRUGA": ["sedatives", "group", "63-71"], "DRUGB": ["opiate analgesics", "group", "123-139"]}
{"ID": "DDI-DrugBank.d449.s2.p0", "TEXT1": "@DRUG$, @DRUG$, sertraline, diltiazem, macrolide antibiotics (exercise caution).", "LBL": "0", "DRUGA": ["Fluoxetine", "drug", "0-9"], "DRUGB": ["OCs", "group", "12-14"]}
{"ID": "DDI-DrugBank.d131.s8.p32", "TEXT1": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with @DRUG$ or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and @DRUG$, and grapefruit juice.", "LBL": "0", "DRUGA": ["alprazolam", "drug", "200-209"], "DRUGB": ["clarithromycin", "drug", "520-533"]}
{"ID": "DDI-DrugBank.d260.s0.p27", "TEXT1": "Probenecid : @DRUG$ is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, @DRUG$, and zidovudine).", "LBL": "DDI-mechanism", "DRUGA": ["Probenecid", "drug", "13-22"], "DRUGB": ["theophylline", "drug", "334-345"]}
{"ID": "DDI-DrugBank.d171.s0.p24", "TEXT1": "Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, @DRUG$, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, @DRUG$, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.", "LBL": "0", "DRUGA": ["phenytoin", "drug", "160-168"], "DRUGB": ["lidocaine", "drug", "259-267"]}
{"ID": "DDI-DrugBank.d64.s29.p257", "TEXT1": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral @DRUG$;paraldehyde;primidone;@DRUG$*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "LBL": "0", "DRUGA": ["contraceptives", "group", "379-392"], "DRUGB": ["ranitidine", "drug", "416-425"]}
{"ID": "DDI-DrugBank.d224.s1.p6", "TEXT1": "Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with @DRUG$ (@DRUG$, barbiturates, opiates, sedatives, anesthetics) should be considered.", "LBL": "0", "DRUGA": ["CNS depressants", "group", "224-238"], "DRUGB": ["alcohol", "drug", "241-247"]}
{"ID": "DDI-DrugBank.d33.s0.p0", "TEXT1": "Although the occurrence has not been reported with @DRUG$, nephrotoxicity has been reported following concomitant administration of other @DRUG$ and aminoglycosides.", "LBL": "0", "DRUGA": ["Cefizox", "brand", "51-57"], "DRUGB": ["cephalosporins", "group", "139-152"]}
{"ID": "DDI-MedLine.d115.s2.p11", "TEXT1": "To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, @DRUG$, vincristine, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.", "LBL": "0", "DRUGA": ["doxorubicin", "drug", "262-272"], "DRUGB": ["prednisone", "drug", "292-301"]}
{"ID": "DDI-DrugBank.d460.s15.p10", "TEXT1": "Certain drugs including thiazides, corticosteroids, @DRUG$, and sympathomimetics may reduce the hypoglycemic action of @DRUG$ and other oral antidiabetic drugs.", "LBL": "DDI-effect", "DRUGA": ["thyroid products", "group", "52-67"], "DRUGB": ["Starlix", "brand", "129-135"]}
{"ID": "DDI-DrugBank.d484.s0.p165", "TEXT1": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), @DRUG$ such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (@DRUG$), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "LBL": "0", "DRUGA": ["antibiotics", "group", "83-93"], "DRUGB": ["rifampin", "drug", "547-554"]}
{"ID": "DDI-DrugBank.d459.s1.p2", "TEXT1": "Caution should be taken when @DRUG$ is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine and @DRUG$ (see CLINICAL PHARMACOLOGY).", "LBL": "DDI-advise", "DRUGA": ["ENABLEX", "brand", "29-35"], "DRUGB": ["tricyclic antidepressants", "group", "202-226"]}
{"ID": "DDI-DrugBank.d525.s5.p0", "TEXT1": "@DRUG$ doses of up to 300 mg b.i.d. have been safely used concomitantly with sustained-release @DRUG$ (sustained-release nifedipine) with no clinically significant adverse interactions.", "LBL": "0", "DRUGA": ["Eprosartan", "drug", "0-9"], "DRUGB": ["calcium channel blockers", "group", "99-122"]}
{"ID": "DDI-DrugBank.d568.s17.p24", "TEXT1": "If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, @DRUG$, sertraline, citalopram, @DRUG$) is clinically warranted, appropriate observation of the patient is advised.", "LBL": "0", "DRUGA": ["paroxetine", "drug", "86-95"], "DRUGB": ["escitalopram", "drug", "122-133"]}
{"ID": "DDI-DrugBank.d484.s0.p880", "TEXT1": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, @DRUG$, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (@DRUG$), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "LBL": "0", "DRUGA": ["Kaletra", "brand", "428-434"], "DRUGB": ["rifampin", "drug", "547-554"]}
{"ID": "DDI-DrugBank.d60.s12.p110", "TEXT1": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), @DRUG$ salts, @DRUG$, local anesthetics, procainamide, and quinidine.", "LBL": "0", "DRUGA": ["magnesium", "group", "260-268"], "DRUGB": ["lithium", "drug", "277-283"]}
{"ID": "DDI-DrugBank.d5.s19.p5", "TEXT1": "MAO Inhibitors: Studies in animals demonstrate that the acute toxicity of bupropion is enhanced by the @DRUG$ @DRUG$ .", "LBL": "0", "DRUGA": ["MAO inhibitor", "group", "103-115"], "DRUGB": ["phenelzine", "drug", "117-126"]}
{"ID": "DDI-DrugBank.d466.s1.p4", "TEXT1": "However, co  administration of fexofenadine hydrochloride with either @DRUG$ or erythromycin led to increased plasma concentrations of @DRUG$.", "LBL": "0", "DRUGA": ["ketoconazole", "drug", "70-81"], "DRUGB": ["fexofenadine", "drug", "141-152"]}
{"ID": "DDI-DrugBank.d345.s14.p5", "TEXT1": "Particular caution should be observed with digitalis preparations since there are conflicting results for the effect of colestipol hydrochloride on the availability of @DRUG$ and @DRUG$.", "LBL": "0", "DRUGA": ["digoxin", "drug", "168-174"], "DRUGB": ["digitoxin", "drug", "180-188"]}
{"ID": "DDI-DrugBank.d94.s4.p69", "TEXT1": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, @DRUG$, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, @DRUG$, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "LBL": "0", "DRUGA": ["azole antifungals", "group", "146-162"], "DRUGB": ["quinine", "drug", "428-434"]}
{"ID": "DDI-DrugBank.d76.s14.p2", "TEXT1": "@DRUG$: When fluvoxamine maleate (100 mg qd) and alprazolam (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of @DRUG$ were approximately twice those observed when alprazolam was administered alone;", "LBL": "0", "DRUGA": ["Alprazolam", "drug", "0-9"], "DRUGB": ["alprazolam", "drug", "194-203"]}
{"ID": "DDI-DrugBank.d78.s1.p32", "TEXT1": "Administration of quinolones with antacids containing @DRUG$, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of @DRUG$, resulting in systemic concentrations considerably lower than desired.", "LBL": "0", "DRUGA": ["aluminum", "drug", "54-61"], "DRUGB": ["quinolones", "group", "394-403"]}
{"ID": "DDI-DrugBank.d245.s4.p25", "TEXT1": "These drugs include the thiazides and other diuretics, @DRUG$, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, @DRUG$, and isoniazid.", "LBL": "0", "DRUGA": ["corticosteroids", "group", "55-69"], "DRUGB": ["calcium channel blocking drugs", "group", "183-212"]}
{"ID": "DDI-DrugBank.d172.s21.p3", "TEXT1": "Methotrexate: In an interaction study of rheumatoid arthritis patients taking @DRUG$, @DRUG$ did not have a significant effect on the pharmacokinetics of methotrexate.", "LBL": "0", "DRUGA": ["methotrexate", "drug", "78-89"], "DRUGB": ["CELEBREX", "brand", "92-99"]}
{"ID": "DDI-DrugBank.d64.s87.p585", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;@DRUG$;clofibrate;dextran;dextrothyroxine;@DRUG$;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["cinchophen", "drug", "264-273"], "DRUGB": ["diazoxide", "drug", "310-318"]}
{"ID": "DDI-DrugBank.d564.s1.p0", "TEXT1": "@DRUG$ and @DRUG$ may reduce or reverse the pressor effect of epinephrine.", "LBL": "0", "DRUGA": ["Phenothiazines", "group", "0-13"], "DRUGB": ["butyrophenones", "group", "19-32"]}
{"ID": "DDI-DrugBank.d395.s6.p1", "TEXT1": "@DRUG$: Elevated serum levels of cyclosporine have been reported with concomitant use of @DRUG$ with other members of the quinolone class.", "LBL": "0", "DRUGA": ["Cyclosporine", "drug", "0-11"], "DRUGB": ["cyclosporine", "drug", "95-106"]}
{"ID": "DDI-DrugBank.d286.s0.p4", "TEXT1": "Ethoxzolamide may increase the action of @DRUG$, @DRUG$, procainamide, and quinidine.", "LBL": "0", "DRUGA": ["tricyclics", "group", "41-50"], "DRUGB": ["amphetamines", "group", "53-64"]}
{"ID": "DDI-DrugBank.d94.s11.p85", "TEXT1": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.", "LBL": "0", "DRUGA": ["Acetaminophen", "drug", "157-169"], "DRUGB": ["valproate", "drug", "692-700"]}
{"ID": "DDI-DrugBank.d103.s3.p9", "TEXT1": "Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: @DRUG$ should be administered with extreme caution in patients being treated with @DRUG$ or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.", "LBL": "DDI-advise", "DRUGA": ["FORADIL", "brand", "60-66"], "DRUGB": ["monoamine oxidase inhibitors", "group", "143-170"]}
{"ID": "DDI-DrugBank.d288.s1.p1", "TEXT1": "Pharmacokinetic data from these patients demonstrated a decrease in @DRUG$ clearance of approximately 33% when TAXOL was administered following @DRUG$.", "LBL": "0", "DRUGA": ["paclitaxel", "drug", "68-77"], "DRUGB": ["cisplatin", "drug", "148-156"]}
{"ID": "DDI-DrugBank.d484.s0.p380", "TEXT1": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, @DRUG$, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, @DRUG$, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "LBL": "0", "DRUGA": ["Tegretol", "brand", "174-181"], "DRUGB": ["Norvir", "brand", "437-442"]}
{"ID": "DDI-DrugBank.d347.s7.p28", "TEXT1": "Magnesium- and/or aluminum-containing antacids, products containing @DRUG$ (iron), multivitamin preparations containing zinc or other metal cations, or Videx (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.", "LBL": "0", "DRUGA": ["ferrous sulfate", "drug", "68-82"], "DRUGB": ["didanosine", "drug", "168-177"]}
{"ID": "DDI-DrugBank.d525.s0.p5", "TEXT1": "Eprosartan has been shown to have no effect on the pharmacokinetics of digoxin and the pharmacodynamics of @DRUG$ and @DRUG$.", "LBL": "0", "DRUGA": ["warfarin", "drug", "107-114"], "DRUGB": ["glyburide", "drug", "120-128"]}
{"ID": "DDI-DrugBank.d64.s29.p159", "TEXT1": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;@DRUG$;cholestyramine;diet high in vitamin K;diuretics*;@DRUG$;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "LBL": "0", "DRUGA": ["chlordiazepoxide", "drug", "244-259"], "DRUGB": ["ethchlorvynol", "drug", "310-322"]}
{"ID": "DDI-DrugBank.d64.s87.p919", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;@DRUG$;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;@DRUG$;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["fenoprofen", "drug", "410-419"], "DRUGB": ["tolbutamide", "drug", "881-891"]}
{"ID": "DDI-DrugBank.d484.s0.p925", "TEXT1": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (@DRUG$, Kadian, @DRUG$), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "LBL": "0", "DRUGA": ["Astramorph", "brand", "466-475"], "DRUGB": ["MS Contin", "brand", "486-494"]}
{"ID": "DDI-DrugBank.d76.s6.p1", "TEXT1": "Potential @DRUG$, Astemizole, and @DRUG$ Interactions", "LBL": "0", "DRUGA": ["Terfenadine", "drug", "10-20"], "DRUGB": ["Cisapride", "drug", "39-47"]}
{"ID": "DDI-DrugBank.d175.s1.p1", "TEXT1": "The possibility of hypotensive effects with @DRUG$ can be minimized by either discontinuing the diuretic or increasing the salt intake approximately one week prior to initiation of treatment with @DRUG$ (captopril tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg).", "LBL": "0", "DRUGA": ["captopril", "drug", "44-52"], "DRUGB": ["captopril", "drug", "199-207"]}
{"ID": "DDI-DrugBank.d345.s13.p13", "TEXT1": "No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: @DRUG$, clindamycin, clofibrate, methyldopa, nicotinic acid (@DRUG$), tolbutamide, phenytoin or warfarin.", "LBL": "0", "DRUGA": ["aspirin", "brand", "137-143"], "DRUGB": ["niacin", "drug", "199-204"]}
{"ID": "DDI-DrugBank.d225.s0.p18", "TEXT1": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some @DRUG$ and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.", "LBL": "0", "DRUGA": ["azoles", "group", "170-175"], "DRUGB": ["sulfonamides", "group", "237-248"]}
{"ID": "DDI-DrugBank.d94.s11.p305", "TEXT1": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "LBL": "0", "DRUGA": ["clobazam", "drug", "233-240"], "DRUGB": ["glucocorticoids", "group", "376-390"]}
{"ID": "DDI-DrugBank.d446.s0.p68", "TEXT1": "Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, @DRUG$, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, @DRUG$, and warfarin.", "LBL": "0", "DRUGA": ["corticosteroids", "group", "111-125"], "DRUGB": ["tamoxifen", "drug", "191-199"]}
{"ID": "DDI-DrugBank.d64.s87.p707", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;@DRUG$;diazoxide;dietary deficiencies;diflunisal;@DRUG$;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["dextrothyroxine", "drug", "294-308"], "DRUGB": ["disulfiram", "drug", "352-361"]}
{"ID": "DDI-DrugBank.d466.s19.p10", "TEXT1": "Drug Interactions with Antacids Administration of 120 mg of @DRUG$ (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased @DRUG$ AUC by 41% and cmax by 43%.", "LBL": "0", "DRUGA": ["fexofenadine hydrochloride", "drug", "60-85"], "DRUGB": ["fexofenadine", "drug", "193-204"]}
{"ID": "DDI-DrugBank.d353.s10.p5", "TEXT1": "Phenytoin: If acitretin is given concurrently with @DRUG$, the protein binding of @DRUG$ may be reduced.", "LBL": "0", "DRUGA": ["phenytoin", "drug", "51-59"], "DRUGB": ["phenytoin", "drug", "85-93"]}
{"ID": "DDI-DrugBank.d184.s0.p59", "TEXT1": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), @DRUG$ (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral @DRUG$ containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "LBL": "0", "DRUGA": ["central nervous system (CNS) depressants", "group", "209-248"], "DRUGB": ["contraceptives", "group", "488-501"]}
{"ID": "DDI-DrugBank.d143.s23.p1", "TEXT1": "@DRUG$ taken concomitantly with digoxin increases the serum @DRUG$ concentration by 70% after one day.", "LBL": "0", "DRUGA": ["Amiodarone", "drug", "0-9"], "DRUGB": ["digoxin", "drug", "64-70"]}
{"ID": "DDI-DrugBank.d320.s3.p4", "TEXT1": "Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as @DRUG$, @DRUG$, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;", "LBL": "0", "DRUGA": ["phenytoin", "drug", "156-164"], "DRUGB": ["phenobarbital", "drug", "167-179"]}
{"ID": "DDI-DrugBank.d64.s87.p995", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;@DRUG$;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;@DRUG$;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["indomethacin", "drug", "458-469"], "DRUGB": ["miconazole", "drug", "574-583"]}
{"ID": "DDI-DrugBank.d94.s11.p983", "TEXT1": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "LBL": "0", "DRUGA": ["quetiapine", "drug", "609-618"], "DRUGB": ["tiagabine", "drug", "660-668"]}
{"ID": "DDI-DrugBank.d395.s12.p0", "TEXT1": "@DRUG$ and @DRUG$: Quinolones form chelates with metal cations.", "LBL": "0", "DRUGA": ["Sucralfate", "drug", "0-9"], "DRUGB": ["antacids", "group", "15-22"]}
{"ID": "DDI-DrugBank.d333.s5.p8", "TEXT1": "Cytochrome P-450 inducers, such as phenytoin, carbamazepine and @DRUG$, induce clonazepam metabolism, causing an approximately 30% decrease in plasma @DRUG$ levels.", "LBL": "0", "DRUGA": ["phenobarbital", "drug", "64-76"], "DRUGB": ["clonazepam", "drug", "157-166"]}
{"ID": "DDI-DrugBank.d20.s4.p2", "TEXT1": "@DRUG$ and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received @DRUG$ or angiotensin II receptor antagonists (ACEI/ARB).", "LBL": "0", "DRUGA": ["ACE Inhibitors", "group", "0-13"], "DRUGB": ["ACE inhibitors", "group", "185-198"]}
{"ID": "DDI-DrugBank.d140.s7.p2", "TEXT1": "@DRUG$: When multiple doses of atorvastatin and digoxin were coadministered, steady-state plasma @DRUG$ concentrations increased by approximately 20%.", "LBL": "0", "DRUGA": ["Digoxin", "drug", "0-6"], "DRUGB": ["digoxin", "drug", "98-104"]}
{"ID": "DDI-DrugBank.d263.s21.p0", "TEXT1": "Patients receiving these drugs in combination with @DRUG$ should be monitored for signs of toxicity and the dose of @DRUG$ reduced if warranted.", "LBL": "0", "DRUGA": ["zalcitabine", "drug", "51-61"], "DRUGB": ["zalcitabine", "drug", "121-131"]}
{"ID": "DDI-MedLine.d139.s0.p0", "TEXT1": "[Quantitative approach to treatment with incisive @DRUG$ by therapeutic monitoring]; The problems encountered during the longterm treatment of psychotic patients with @DRUG$ are illustrated by six typical case reports.", "LBL": "0", "DRUGA": ["neuroleptics", "group", "50-61"], "DRUGB": ["neuroleptics", "group", "173-184"]}
{"ID": "DDI-DrugBank.d179.s21.p263", "TEXT1": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], @DRUG$ [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., @DRUG$]) or", "LBL": "0", "DRUGA": ["promethazine", "drug", "239-250"], "DRUGB": ["Temaril", "brand", "390-396"]}
{"ID": "DDI-DrugBank.d64.s87.p534", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;@DRUG$;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;@DRUG$;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["chymotrypsin", "drug", "240-251"], "DRUGB": ["tolbutamide", "drug", "881-891"]}
{"ID": "DDI-DrugBank.d244.s0.p10", "TEXT1": "Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., @DRUG$, amikacin), amphotericin B, @DRUG$, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin.", "LBL": "0", "DRUGA": ["gentamicin", "drug", "161-170"], "DRUGB": ["cyclosporine", "drug", "200-211"]}
{"ID": "DDI-DrugBank.d521.s6.p1", "TEXT1": "- a @DRUG$ (water pill) such as hydrochlorothiazide (@DRUG$, Hydrodiuril), chlorothiazide (Diuril), and others;", "LBL": "0", "DRUGA": ["diuretic", "group", "4-11"], "DRUGB": ["HCTZ", "drug", "55-58"]}
{"ID": "DDI-DrugBank.d277.s10.p0", "TEXT1": "Effects of other Antiepilepsy Drugs (@DRUG$) on @DRUG$ : Carbamazepine: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing AEDs.", "LBL": "0", "DRUGA": ["AEDs", "group", "37-40"], "DRUGB": ["GABITRIL", "brand", "46-53"]}
{"ID": "DDI-DrugBank.d297.s2.p5", "TEXT1": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, @DRUG$, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.", "LBL": "0", "DRUGA": ["ORENCIA", "brand", "115-121"], "DRUGB": ["chloroquine", "drug", "189-199"]}
{"ID": "DDI-DrugBank.d462.s5.p0", "TEXT1": "@DRUG$: The oral combination of @DRUG$ before intramuscular injection of PIPRACIL produces an increase in piperacillin peak serum level of about 30%.", "LBL": "0", "DRUGA": ["Probenecid", "drug", "0-9"], "DRUGB": ["probenecid", "drug", "36-45"]}
{"ID": "DDI-DrugBank.d397.s8.p88", "TEXT1": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, @DRUG$, @DRUG$, and astemizole.", "LBL": "0", "DRUGA": ["valproate", "drug", "191-199"], "DRUGB": ["terfenadine", "drug", "202-212"]}
{"ID": "DDI-DrugBank.d411.s4.p188", "TEXT1": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "LBL": "0", "DRUGA": ["pertechnetate", "drug", "365-377"], "DRUGB": ["dopamine", "drug", "472-479"]}
{"ID": "DDI-DrugBank.d283.s5.p0", "TEXT1": "@DRUG$: Because @DRUG$ can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including TRICOR, there is a risk that an interaction will lead to deterioration.", "LBL": "0", "DRUGA": ["Cyclosporine", "drug", "0-11"], "DRUGB": ["cyclosporine", "drug", "22-33"]}
{"ID": "DDI-DrugBank.d521.s2.p106", "TEXT1": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, @DRUG$, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and @DRUG$ (Anaprox, Naprosyn, Aleve);", "LBL": "0", "DRUGA": ["Advil", "brand", "75-79"], "DRUGB": ["naproxen", "drug", "262-269"]}
{"ID": "DDI-DrugBank.d64.s87.p1237", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;@DRUG$;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;@DRUG$;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["nalidixic acid", "drug", "614-627"], "DRUGB": ["phenyramidol", "drug_n", "698-709"]}
{"ID": "DDI-DrugBank.d446.s0.p42", "TEXT1": "Chlorotrianisene may interact with antidepressants, aspirin, @DRUG$, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, @DRUG$, somatropin, tamoxifen, and warfarin.", "LBL": "0", "DRUGA": ["barbiturates", "group", "61-72"], "DRUGB": ["nicotine", "drug", "169-176"]}
{"ID": "DDI-DrugBank.d313.s1.p45", "TEXT1": "The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, @DRUG$, @DRUG$, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.", "LBL": "0", "DRUGA": ["propoxyphene", "drug", "245-256"], "DRUGB": ["salicylates", "group", "259-269"]}
{"ID": "DDI-DrugBank.d64.s87.p201", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;@DRUG$;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;@DRUG$;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["aminosalicylic acid", "drug", "136-154"], "DRUGB": ["sulfinpyrazone", "drug", "817-830"]}
{"ID": "DDI-DrugBank.d51.s2.p1", "TEXT1": "@DRUG$: Although ipratropium bromide is minimally absorbed into the systemic circulation, there is some potential for an additive interaction with concomitantly used @DRUG$.", "LBL": "0", "DRUGA": ["Anticholinergic agents", "group", "0-21"], "DRUGB": ["anticholinergic medications", "group", "182-208"]}
{"ID": "DDI-DrugBank.d328.s24.p5", "TEXT1": "Valdecoxib caused a statistically significant increase in plasma exposures of R-warfarin and @DRUG$ (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of @DRUG$.", "LBL": "0", "DRUGA": ["S-warfarin", "drug", "93-102"], "DRUGB": ["warfarin", "drug", "207-214"]}
{"ID": "DDI-DrugBank.d324.s4.p0", "TEXT1": "@DRUG$: Coadministration of single doses of @DRUG$ 20 mg and imipramine 75 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.", "LBL": "0", "DRUGA": ["Imipramine", "drug", "0-9"], "DRUGB": ["Sonata", "brand", "48-53"]}
{"ID": "DDI-DrugBank.d484.s0.p52", "TEXT1": "Etonogestrel may interact with the following medications: @DRUG$ (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, @DRUG$, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "LBL": "0", "DRUGA": ["acetaminophen", "drug", "58-70"], "DRUGB": ["Trileptal", "brand", "184-192"]}
{"ID": "DDI-DrugBank.d237.s10.p2", "TEXT1": "@DRUG$: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on @DRUG$ absorption when it is coadministered with ranitidine.", "LBL": "0", "DRUGA": ["H2 Receptor Antagonists", "group", "0-22"], "DRUGB": ["cisapride", "drug", "145-153"]}
{"ID": "DDI-DrugBank.d501.s10.p31", "TEXT1": "In vitro studies evaluating the minimum inhibitory concentration (MIC) of vancomycin, cefazolin, ampicillin, ampicillin/flucoxacillin, ceftazidime, @DRUG$, and amphotericin demonstrated no evidence of incompatibility of these @DRUG$ with EXTRANEAL.", "LBL": "0", "DRUGA": ["gentamicin", "drug", "148-157"], "DRUGB": ["antibiotics", "group", "230-240"]}
{"ID": "DDI-DrugBank.d225.s6.p3", "TEXT1": "These drugs include the @DRUG$ and other diuretics, corticosteroids, phenothiazines, @DRUG$, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.", "LBL": "0", "DRUGA": ["thiazides", "group", "24-32"], "DRUGB": ["thyroid products", "group", "88-103"]}
{"ID": "DDI-DrugBank.d411.s4.p32", "TEXT1": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.", "LBL": "0", "DRUGA": ["aminoglutethimide", "drug", "228-244"], "DRUGB": ["thiazide diuretics", "group", "829-846"]}
{"ID": "DDI-MedLine.d111.s14.p5", "TEXT1": "Coingestion of acetaminophen with @DRUG$, @DRUG$ with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug.", "LBL": "0", "DRUGA": ["theophylline", "drug", "34-45"], "DRUGB": ["phenobarbital", "drug", "48-60"]}
{"ID": "DDI-DrugBank.d364.s17.p0", "TEXT1": "Another study showed that @DRUG$ had no clinically significant effect on plasma concentrations of the oral @DRUG$ ethinyl estradiol and levonorgestrel (CYP3A4 substrates).", "LBL": "0", "DRUGA": ["alosetron", "drug", "26-34"], "DRUGB": ["contraceptive agents", "group", "110-129"]}
{"ID": "DDI-MedLine.d58.s7.p1", "TEXT1": "These data suggest that @DRUG$ are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an @DRUG$-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel.", "LBL": "0", "DRUGA": ["ginsenosides", "drug_n", "24-35"], "DRUGB": ["omega-agatoxin IVA", "drug_n", "187-204"]}
{"ID": "DDI-DrugBank.d64.s29.p90", "TEXT1": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;@DRUG$;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;@DRUG$;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "LBL": "0", "DRUGA": ["antihistamines", "group", "185-198"], "DRUGB": ["cholestyramine", "drug", "261-274"]}
{"ID": "DDI-DrugBank.d5.s17.p68", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, @DRUG$, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., @DRUG$, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["desipramine", "drug", "162-172"], "DRUGB": ["propafenone", "drug", "344-354"]}
{"ID": "DDI-DrugBank.d114.s2.p3", "TEXT1": "Concurrent administration of drugs possessing nephrotoxic (e.g., @DRUG$, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., @DRUG$, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.", "LBL": "0", "DRUGA": ["aminoglycosides", "group", "65-79"], "DRUGB": ["methotrexate", "drug", "194-205"]}
{"ID": "DDI-DrugBank.d283.s12.p0", "TEXT1": "Therefore, @DRUG$ should be taken at least 1 hour before or 4-6 hours after a @DRUG$ to avoid impeding its absorption .", "LBL": "DDI-advise", "DRUGA": ["fenofibrate", "drug", "11-21"], "DRUGB": ["bile acid binding resin", "group", "83-105"]}
{"ID": "DDI-DrugBank.d29.s14.p0", "TEXT1": "Concomitant administration of @DRUG$ with @DRUG$ is contraindicated.", "LBL": "DDI-advise", "DRUGA": ["clarithromycin", "drug", "30-43"], "DRUGB": ["pimozide", "drug", "50-57"]}
{"ID": "DDI-DrugBank.d60.s12.p104", "TEXT1": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.", "LBL": "0", "DRUGA": ["colistin", "drug", "222-229"], "DRUGB": ["quinidine", "drug", "323-331"]}
{"ID": "DDI-DrugBank.d170.s2.p26", "TEXT1": "The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, @DRUG$, nelfinavir, and nefazadone may result in an increase in @DRUG$ plasma concentrations.", "LBL": "0", "DRUGA": ["clarithromycin", "drug", "142-155"], "DRUGB": ["fentanyl", "drug", "214-221"]}
{"ID": "DDI-DrugBank.d558.s25.p43", "TEXT1": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, @DRUG$, cannabinoids, @DRUG$, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.", "LBL": "0", "DRUGA": ["amiodarone", "drug", "136-145"], "DRUGB": ["diltiazem", "drug", "162-170"]}
{"ID": "DDI-DrugBank.d521.s2.p294", "TEXT1": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and @DRUG$ (@DRUG$, Naprosyn, Aleve);", "LBL": "0", "DRUGA": ["naproxen", "drug", "262-269"], "DRUGB": ["Anaprox", "brand", "272-278"]}
{"ID": "DDI-DrugBank.d98.s2.p14", "TEXT1": "Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of @DRUG$, but may reduce endogenous plasma levels of @DRUG$/ergocalcitriol by accelerating metabolism.", "LBL": "0", "DRUGA": ["vitamin D", "group", "117-125"], "DRUGB": ["calcitriol", "drug", "171-180"]}
{"ID": "DDI-DrugBank.d223.s8.p7", "TEXT1": "While all the selective serotonin reuptake inhibitors (@DRUG$), e.g., citalopram, @DRUG$, fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.", "LBL": "0", "DRUGA": ["SSRIs", "group", "55-59"], "DRUGB": ["escitalopram", "drug", "81-92"]}
{"ID": "DDI-DrugBank.d244.s0.p11", "TEXT1": "Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., @DRUG$, amikacin), amphotericin B, cyclosporine, @DRUG$ drugs (e.g., ibuprofen), tacrolimus, vancomycin.", "LBL": "0", "DRUGA": ["gentamicin", "drug", "161-170"], "DRUGB": ["non-steroidal anti-inflammatory", "group", "214-244"]}
{"ID": "DDI-DrugBank.d64.s87.p701", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;@DRUG$;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;@DRUG$;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["dextran", "drug", "286-292"], "DRUGB": ["triclofos sodium", "drug", "893-908"]}
{"ID": "DDI-DrugBank.d225.s6.p10", "TEXT1": "These drugs include the @DRUG$ and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and @DRUG$.", "LBL": "0", "DRUGA": ["thiazides", "group", "24-32"], "DRUGB": ["isoniazid", "drug", "219-227"]}
{"ID": "DDI-DrugBank.d86.s1.p27", "TEXT1": "Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, @DRUG$ (e.g., @DRUG$), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.", "LBL": "0", "DRUGA": ["beta-blockers", "group", "128-140"], "DRUGB": ["propranolol", "drug", "149-159"]}
{"ID": "DDI-DrugBank.d467.s2.p12", "TEXT1": "On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, @DRUG$, @DRUG$, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.", "LBL": "0", "DRUGA": ["erythromycin", "drug", "97-108"], "DRUGB": ["gemfibrozil", "drug", "111-121"]}
{"ID": "DDI-DrugBank.d81.s14.p1", "TEXT1": "@DRUG$ Anesthesia: Severe hypotension has been reported during fentanyl anesthesia with concomitant use of a @DRUG$ and a calcium channel blocker.", "LBL": "0", "DRUGA": ["Fentanyl", "drug", "0-7"], "DRUGB": ["beta blocker", "group", "111-122"]}
{"ID": "DDI-DrugBank.d250.s2.p4", "TEXT1": "@DRUG$ (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and @DRUG$, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.", "LBL": "0", "DRUGA": ["Curariform muscle relaxants", "brand", "0-26"], "DRUGB": ["sodium citrate", "drug", "127-140"]}
{"ID": "DDI-DrugBank.d363.s0.p0", "TEXT1": "No clinically significant adverse interactions with commonly used preanesthetic drugs, or drugs used during anesthesia (@DRUG$, intravenous agents, and local @DRUG$) were reported in clinical trials.", "LBL": "0", "DRUGA": ["muscle relaxants", "group", "120-135"], "DRUGB": ["anesthetic agents", "group", "168-184"]}
{"ID": "DDI-DrugBank.d213.s0.p1", "TEXT1": "@DRUG$ or iodine excess may decrease the effect of @DRUG$, and an iodine deficiency can increase the effect of Carbimazole.", "LBL": "DDI-effect", "DRUGA": ["Iodine", "drug", "0-5"], "DRUGB": ["Carbimazole", "drug", "51-61"]}
{"ID": "DDI-DrugBank.d484.s0.p233", "TEXT1": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and @DRUG$, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, @DRUG$, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "LBL": "0", "DRUGA": ["tetracycline", "drug", "118-129"], "DRUGB": ["Kaletra", "brand", "428-434"]}
{"ID": "DDI-DrugBank.d313.s2.p18", "TEXT1": "The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, @DRUG$, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, @DRUG$, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).", "LBL": "0", "DRUGA": ["niacin", "drug", "109-114"], "DRUGB": ["salbutamol", "drug", "180-189"]}
{"ID": "DDI-DrugBank.d225.s0.p17", "TEXT1": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some @DRUG$ and other drugs that are highly protein bound, @DRUG$, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.", "LBL": "0", "DRUGA": ["azoles", "group", "170-175"], "DRUGB": ["salicylates", "group", "224-234"]}
{"ID": "DDI-MedLine.d113.s3.p2", "TEXT1": "In addition to this pharmacological interaction, this report describes a novel chemical reaction between temazepam (a @DRUG$) and @DRUG$ under acidic conditions similar to those found in vivo, resulting in a 3-ethoxylated product.", "LBL": "0", "DRUGA": ["benzodiazepine", "group", "118-131"], "DRUGB": ["ethanol", "drug", "138-144"]}
{"ID": "DDI-DrugBank.d423.s0.p22", "TEXT1": "In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with @DRUG$ (e.g., fluoxetine, @DRUG$, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.", "LBL": "0", "DRUGA": ["serotoninergic agents", "group", "125-145"], "DRUGB": ["fluvoxamine", "drug", "166-176"]}
{"ID": "DDI-DrugBank.d263.s22.p15", "TEXT1": "Magnesium/Aluminum-containing Antacid Products: Absorption of @DRUG$ is moderately reduced (approximately 25%) when coadministered with @DRUG$/aluminum-containing antacid products.", "LBL": "0", "DRUGA": ["zalcitabine", "drug", "62-72"], "DRUGB": ["magnesium", "drug", "141-149"]}
{"ID": "DDI-DrugBank.d411.s4.p334", "TEXT1": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "LBL": "0", "DRUGA": ["dopamine", "drug", "472-479"], "DRUGB": ["insulin", "drug", "568-574"]}
{"ID": "DDI-DrugBank.d568.s17.p4", "TEXT1": "If concomitant treatment with @DRUG$ and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, @DRUG$, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.", "LBL": "DDI-advise", "DRUGA": ["sumatriptan", "drug", "30-40"], "DRUGB": ["sertraline", "drug", "98-107"]}
{"ID": "DDI-DrugBank.d336.s0.p0", "TEXT1": "Although clinical studies have not established a cause and effect relationship, physicians should be aware that variable effects an blood coagulation have been reported very rarely in patients receiving oral @DRUG$ and @DRUG$.", "LBL": "DDI-effect", "DRUGA": ["anticoagulants", "group", "208-221"], "DRUGB": ["chlordiazepoxide", "drug", "227-242"]}
{"ID": "DDI-DrugBank.d324.s34.p2", "TEXT1": "Drugs with a Narrow Therapeutic Index Digoxin: @DRUG$ (10 mg) did not affect the pharmacokinetic or pharmacodynamic profile of @DRUG$ (0.375 mg q24h for 8 days).", "LBL": "0", "DRUGA": ["Sonata", "brand", "47-52"], "DRUGB": ["digoxin", "drug", "127-133"]}
{"ID": "DDI-DrugBank.d88.s1.p0", "TEXT1": "There was a small increase in plasma concentrations of @DRUG$ and one metabolite (@DRUG$);", "LBL": "0", "DRUGA": ["capecitabine", "drug", "55-66"], "DRUGB": ["5-DFCR", "drug_n", "88-93"]}
{"ID": "DDI-DrugBank.d86.s1.p46", "TEXT1": "Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., @DRUG$), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, @DRUG$ pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.", "LBL": "0", "DRUGA": ["propranolol", "drug", "149-159"], "DRUGB": ["narcotic", "group", "252-259"]}
{"ID": "DDI-DrugBank.d253.s3.p6", "TEXT1": "Antidepressants (@DRUG$), atropine or other @DRUG$, or digitalis glycosides: concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.", "LBL": "0", "DRUGA": ["tricyclic", "group", "17-25"], "DRUGB": ["anticholinergic agents", "group", "47-68"]}
{"ID": "DDI-DrugBank.d60.s12.p31", "TEXT1": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain @DRUG$ (e. g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "LBL": "0", "DRUGA": ["antibiotics", "group", "121-131"], "DRUGB": ["bacitracin", "drug", "173-182"]}
{"ID": "DDI-DrugBank.d210.s4.p0", "TEXT1": "In a 12-week endoscopy study conducted in OA patients there was no difference in the cumulative incidence of endoscopic gastroduodenal ulcers in patients taking low-dose (81 mg) enteric coated @DRUG$ plus @DRUG$ 25 mg daily, as compared to those taking ibuprofen 2400 mg daily alone.", "LBL": "0", "DRUGA": ["aspirin", "brand", "193-199"], "DRUGB": ["VIOXX", "brand", "206-210"]}
{"ID": "DDI-DrugBank.d509.s27.p5", "TEXT1": "Alcohol: There was no significant difference between aripiprazole coadministered with @DRUG$ and placebo coadministered with @DRUG$ on performance of gross motor skills or stimulus response in healthy subjects.", "LBL": "0", "DRUGA": ["ethanol", "drug", "86-92"], "DRUGB": ["ethanol", "drug", "126-132"]}
{"ID": "DDI-DrugBank.d94.s4.p49", "TEXT1": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: @DRUG$, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), @DRUG$, zileuton.", "LBL": "0", "DRUGA": ["Acetazolamide", "drug", "131-143"], "DRUGB": ["verapamil", "drug", "481-489"]}
{"ID": "DDI-DrugBank.d86.s1.p1", "TEXT1": "Interactions may also occur with the following: @DRUG$/anti-anxiety drugs, drugs used to treat an overactive thyroid, @DRUG$ (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.", "LBL": "0", "DRUGA": ["anti-depressants", "group", "48-63"], "DRUGB": ["beta-blockers", "group", "128-140"]}
{"ID": "DDI-DrugBank.d263.s24.p2", "TEXT1": "Metoclopramide: Bioavailability is mildly reduced (approximately 10%) when @DRUG$ and @DRUG$ are coadministered.", "LBL": "DDI-mechanism", "DRUGA": ["zalcitabine", "drug", "75-85"], "DRUGB": ["metoclopramide", "drug", "91-104"]}
{"ID": "DDI-DrugBank.d76.s1.p1", "TEXT1": "In patients receiving another @DRUG$ in combination with monoamine oxidase inhibitors (@DRUG$), there have been reports of serious, sometimes fatal, reactions including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma.", "LBL": "DDI-effect", "DRUGA": ["serotonin reuptake inhibitor drug", "group", "30-62"], "DRUGB": ["MAOI", "group", "114-117"]}
{"ID": "DDI-DrugBank.d124.s26.p19", "TEXT1": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;", "LBL": "0", "DRUGA": ["dapsone", "drug", "148-154"], "DRUGB": ["quinidine", "drug", "192-200"]}
{"ID": "DDI-DrugBank.d413.s4.p6", "TEXT1": "In patients receiving mercaptopurine (@DRUG$) or @DRUG$ (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.", "LBL": "0", "DRUGA": ["Purinethol", "brand", "38-47"], "DRUGB": ["azathioprine", "drug", "53-64"]}
{"ID": "DDI-DrugBank.d247.s9.p0", "TEXT1": "@DRUG$ may antagonize the neuron blockade produced by @DRUG$ resulting in decreased antihypertensive effect and requiring increased dosage of the latter.", "LBL": "DDI-effect", "DRUGA": ["Epinephrine", "drug", "0-10"], "DRUGB": ["guanethidine", "drug", "59-70"]}
{"ID": "DDI-DrugBank.d165.s4.p7", "TEXT1": "Another oral azole antifungal, ketoconazole, inhibits the metabolism of @DRUG$, resulting in elevated plasma concentrations of @DRUG$ and its active metabolite desmethylastermizole which may prolong QT intervals.", "LBL": "0", "DRUGA": ["astemizole", "drug", "72-81"], "DRUGB": ["astemizole", "drug", "131-140"]}
{"ID": "DDI-DrugBank.d413.s18.p0", "TEXT1": "@DRUG$: Enhanced bone marrow suppression by @DRUG$ and other cytotoxic agents has been reported among patients with neoplastic disease, except leukemia, in the presence of allopurinol.", "LBL": "0", "DRUGA": ["Cytotoxic Agents", "group", "0-15"], "DRUGB": ["cyclophosphamide", "drug", "54-69"]}
{"ID": "DDI-DrugBank.d64.s87.p478", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;@DRUG$;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;@DRUG$;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["chlorpropamide", "drug", "225-238"], "DRUGB": ["phenyramidol", "drug_n", "698-709"]}
{"ID": "DDI-DrugBank.d484.s0.p790", "TEXT1": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as @DRUG$ (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, @DRUG$), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "LBL": "0", "DRUGA": ["protease inhibitors", "group", "365-383"], "DRUGB": ["MS Contin", "brand", "486-494"]}
{"ID": "DDI-DrugBank.d411.s13.p0", "TEXT1": "@DRUG$: Marked hypertension and tachycardia have been reported in association with concomitant administration of @DRUG$ and ketamine.", "LBL": "0", "DRUGA": ["Ketamine", "drug", "0-7"], "DRUGB": ["levothyroxine sodium", "drug", "115-134"]}
{"ID": "DDI-DrugBank.d143.s41.p38", "TEXT1": "Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or @DRUG$ antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a @DRUG$ inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;", "LBL": "0", "DRUGA": ["calcium channel", "drug", "150-164"], "DRUGB": ["CYP3A4", "drug", "233-238"]}
{"ID": "DDI-DrugBank.d435.s2.p7", "TEXT1": "Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, @DRUG$, @DRUG$, or St. John s wort) may significantly decrease exposure to exemestane.", "LBL": "0", "DRUGA": ["carbamazepine", "drug", "65-77"], "DRUGB": ["phenobarbital", "drug", "80-92"]}
{"ID": "DDI-DrugBank.d568.s23.p2", "TEXT1": "Although trough @DRUG$ plasma levels were unaffected, given the enzyme-inducing properties of carbamazepine, the possibility that carbamazepine might increase the clearance of @DRUG$ should be considered if the two drugs are coadministered.", "LBL": "0", "DRUGA": ["citalopram", "drug", "16-25"], "DRUGB": ["escitalopram", "drug", "180-191"]}
{"ID": "DDI-DrugBank.d318.s8.p26", "TEXT1": "Imidazoles (e. g., ketoconazole, miconazole, clotrimazole, @DRUG$, etc.): in vitro and animal studies with the combination of @DRUG$ and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.", "LBL": "0", "DRUGA": ["fluconazole", "drug", "59-69"], "DRUGB": ["amphotericin B", "drug", "131-144"]}
{"ID": "DDI-DrugBank.d196.s4.p0", "TEXT1": "Nucleoside Analogues @DRUG$ Co-administration of @DRUG$ and didanosine is not recommended.", "LBL": "0", "DRUGA": ["Didanosine", "drug", "21-30"], "DRUGB": ["COPEGUS", "brand", "53-59"]}
{"ID": "DDI-DrugBank.d521.s2.p219", "TEXT1": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (@DRUG$, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (@DRUG$, Naprosyn, Aleve);", "LBL": "0", "DRUGA": ["Voltaren", "brand", "152-159"], "DRUGB": ["Anaprox", "brand", "272-278"]}
{"ID": "DDI-DrugBank.d533.s3.p0", "TEXT1": "Co-administration of @DRUG$ resulted in about a 50% increase in @DRUG$ Cmax and AUC after multiple dosing.", "LBL": "DDI-mechanism", "DRUGA": ["atorvastatin", "drug", "21-32"], "DRUGB": ["aliskiren", "drug", "70-78"]}
{"ID": "DDI-DrugBank.d114.s5.p5", "TEXT1": "Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and @DRUG$, specifically, @DRUG$, cis-platinum, tamoxifen and interferon-alfa.", "LBL": "0", "DRUGA": ["antineoplastic agents", "group", "135-155"], "DRUGB": ["dacarbazine", "drug", "172-182"]}
{"ID": "DDI-DrugBank.d257.s0.p30", "TEXT1": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, @DRUG$, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, @DRUG$, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.", "LBL": "0", "DRUGA": ["alcohol", "drug", "117-123"], "DRUGB": ["tranquilizers", "group", "241-253"]}
{"ID": "DDI-DrugBank.d448.s3.p7", "TEXT1": "The antihypertensive effects of methyldopa, mecamylamine, @DRUG$, and @DRUG$ may be reduced by sympathomimetics.", "LBL": "0", "DRUGA": ["reserpine", "drug", "58-66"], "DRUGB": ["veratrum alkaloids", "drug", "73-90"]}
{"ID": "DDI-DrugBank.d257.s6.p30", "TEXT1": "Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, @DRUG$ and @DRUG$) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.", "LBL": "0", "DRUGA": ["dezocine", "drug", "135-142"], "DRUGB": ["buprenorphine", "drug", "148-160"]}
{"ID": "DDI-DrugBank.d64.s87.p821", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;@DRUG$;drugs affecting blood elements;ethacrynic acid;fenoprofen;@DRUG$;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["disulfiram", "drug", "352-361"], "DRUGB": ["glucagon", "drug", "421-428"]}
{"ID": "DDI-DrugBank.d249.s4.p3", "TEXT1": "Ingestion of diclofenac may increase serum concentrations of @DRUG$ and @DRUG$ and increase cyclosporine s nephrotoxicity.", "LBL": "0", "DRUGA": ["digoxin", "drug", "61-67"], "DRUGB": ["methotrexate", "drug", "73-84"]}
{"ID": "DDI-DrugBank.d64.s87.p335", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;@DRUG$;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;@DRUG$;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["antibiotics", "group", "185-195"], "DRUGB": ["naproxen", "drug", "629-636"]}
{"ID": "DDI-DrugBank.d485.s27.p3", "TEXT1": "Non-nucleoside reverse transcriptase inhibitors (@DRUG$): @DRUG$ may decrease plasma levels of combination hormonal contraceptives;", "LBL": "0", "DRUGA": ["NNRTIs", "group", "49-54"], "DRUGB": ["Nevirapine", "drug", "58-67"]}
{"ID": "DDI-DrugBank.d64.s87.p727", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;@DRUG$;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;@DRUG$;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["dextrothyroxine", "drug", "294-308"], "DRUGB": ["phenyramidol", "drug_n", "698-709"]}
{"ID": "DDI-DrugBank.d441.s2.p5", "TEXT1": "Adrenergic Agents:Some individuals receiving @DRUG$ may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, @DRUG$ or dopaminergic agents.", "LBL": "DDI-effect", "DRUGA": ["ZYVOX", "brand", "45-49"], "DRUGB": ["vasopressor", "group", "158-168"]}
{"ID": "DDI-DrugBank.d318.s8.p12", "TEXT1": "Imidazoles (e. g., @DRUG$, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and @DRUG$ suggest that imidazoles may induce fungal resistance to amphotericin B.", "LBL": "0", "DRUGA": ["ketoconazole", "drug", "19-30"], "DRUGB": ["imidazoles", "group", "150-159"]}
{"ID": "DDI-DrugBank.d114.s2.p10", "TEXT1": "Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, @DRUG$), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with @DRUG$ may increase toxicity in these organ systems.", "LBL": "DDI-effect", "DRUGA": ["indomethacin", "drug", "82-93"], "DRUGB": ["PROLEUKIN", "brand", "235-243"]}
{"ID": "DDI-DrugBank.d208.s0.p4", "TEXT1": "@DRUG$ may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, @DRUG$, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.", "LBL": "DDI-int", "DRUGA": ["Benzthiazide", "drug", "0-11"], "DRUGB": ["norepinephrine", "drug", "138-151"]}
{"ID": "DDI-DrugBank.d235.s4.p2", "TEXT1": "Example inhibitors include @DRUG$, ciprofloxacin, clarithromycin, @DRUG$, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.", "LBL": "0", "DRUGA": ["azole antifungals", "group", "27-43"], "DRUGB": ["diclofenac", "drug", "77-86"]}
{"ID": "DDI-DrugBank.d501.s10.p6", "TEXT1": "In vitro studies evaluating the minimum inhibitory concentration (MIC) of @DRUG$, cefazolin, ampicillin, ampicillin/flucoxacillin, ceftazidime, gentamicin, and amphotericin demonstrated no evidence of incompatibility of these @DRUG$ with EXTRANEAL.", "LBL": "0", "DRUGA": ["vancomycin", "drug", "74-83"], "DRUGB": ["antibiotics", "group", "230-240"]}
{"ID": "DDI-DrugBank.d333.s3.p5", "TEXT1": "In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without @DRUG$ (an @DRUG$ with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.", "LBL": "0", "DRUGA": ["propantheline", "drug", "103-115"], "DRUGB": ["anticholinergic agent", "group", "121-141"]}
{"ID": "DDI-DrugBank.d64.s87.p1398", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;@DRUG$;quinidine;quinine;ranitidine*;salicylates;@DRUG$;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["pyrazolones", "group", "763-773"], "DRUGB": ["sulfinpyrazone", "drug", "817-830"]}
{"ID": "DDI-DrugBank.d163.s4.p4", "TEXT1": "Micro-dosed Progesterone Preparations: Micro-dosed @DRUG$ preparations (minipills that do not contain an estrogen) may be an inadequate method of contraception during @DRUG$ therapy.", "LBL": "DDI-effect", "DRUGA": ["progesterone", "drug", "51-62"], "DRUGB": ["Accutane", "brand", "173-180"]}
{"ID": "DDI-DrugBank.d297.s2.p13", "TEXT1": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: @DRUG$, NSAIDs, corticosteroids, @DRUG$, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.", "LBL": "0", "DRUGA": ["MTX", "drug", "124-126"], "DRUGB": ["TNF blocking agents", "group", "154-172"]}
{"ID": "DDI-DrugBank.d103.s3.p14", "TEXT1": "Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or @DRUG$ because the action of @DRUG$ on the cardiovascular system may be potentiated by these agents.", "LBL": "0", "DRUGA": ["tricyclic antidepressants", "group", "175-199"], "DRUGB": ["formoterol", "drug", "223-232"]}
{"ID": "DDI-DrugBank.d140.s4.p1", "TEXT1": "@DRUG$: Plasma concentrations of atorvastatin decreased approximately 25% when @DRUG$ and atorvastatin were coadministered.", "LBL": "0", "DRUGA": ["Colestipol", "drug", "0-9"], "DRUGB": ["colestipol", "drug", "83-92"]}
{"ID": "DDI-DrugBank.d410.s7.p2", "TEXT1": "SSRIs: Weakness hyperreflexia, and incoordination have been reported rarely when @DRUG$ have been co-administered with @DRUG$ (e. g.", "LBL": "DDI-effect", "DRUGA": ["5-HT1 agonists", "group", "81-94"], "DRUGB": ["SSRIs", "group", "127-131"]}
{"ID": "DDI-DrugBank.d382.s41.p8", "TEXT1": "Diltiazem: In patients with mild to moderate hypertension, administration of aprepitant once daily, as a tablet formulation comparable to 230 mg of the capsule formulation, with @DRUG$ 120 mg 3 times daily for 5 days, resulted in a 2-fold increase of aprepitant AUC and a simultaneous 1.7-fold increase of @DRUG$ AUC.", "LBL": "0", "DRUGA": ["diltiazem", "drug", "178-186"], "DRUGB": ["diltiazem", "drug", "309-317"]}
{"ID": "DDI-DrugBank.d531.s90.p61", "TEXT1": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, @DRUG$, nelfinavir, @DRUG$, and zidovudine.", "LBL": "0", "DRUGA": ["lorazepam", "drug", "255-263"], "DRUGB": ["paroxetine", "drug", "278-287"]}
{"ID": "DDI-DrugBank.d64.s29.p229", "TEXT1": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;@DRUG$;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;@DRUG$;warfarin sodium under-dosage.", "LBL": "0", "DRUGA": ["glutethimide", "drug", "324-335"], "DRUGB": ["vitamin C", "drug", "480-488"]}
{"ID": "DDI-DrugBank.d219.s11.p1", "TEXT1": "Nevertheless, clinical studies, as well as postmarketing observations have shown that @DRUG$ can reduce the natriuretic effect of furosemide and @DRUG$ in some patients.", "LBL": "DDI-effect", "DRUGA": ["Lodine", "brand", "86-91"], "DRUGB": ["thiazides", "group", "145-153"]}
{"ID": "DDI-DrugBank.d3.s6.p0", "TEXT1": "In another study, TORADOLIV/IM was given with two doses of 5000 U of @DRUG$ to 11 healthy volunteers, resulting in a mean template bleeding time of 6.4 minutes (3.2 to 11.4 min) compared to a mean of 6.0 minutes (3.4 to 7.5 min) for @DRUG$ alone and 5.1 minutes (3.5 to 8.5 min) for placebo.", "LBL": "0", "DRUGA": ["heparin", "drug", "69-75"], "DRUGB": ["heparin", "drug", "234-240"]}
{"ID": "DDI-DrugBank.d208.s0.p15", "TEXT1": "Benzthiazide may interact with alcohol, @DRUG$s, @DRUG$ (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.", "LBL": "0", "DRUGA": ["blood thinner", "group", "40-52"], "DRUGB": ["decongestant drugs", "group", "56-73"]}
{"ID": "DDI-DrugBank.d64.s87.p253", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;@DRUG$;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;@DRUG$;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["amiodarone", "drug", "156-165"], "DRUGB": ["sulindac", "drug", "858-865"]}
{"ID": "DDI-DrugBank.d105.s0.p3", "TEXT1": "@DRUG$ including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs), and @DRUG$ may increase the risk of bleeding when administered concomitantly with ardeparin.", "LBL": "0", "DRUGA": ["Anticoagulants", "group", "0-13"], "DRUGB": ["aspirin", "brand", "166-172"]}
{"ID": "DDI-DrugBank.d94.s11.p620", "TEXT1": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "LBL": "0", "DRUGA": ["ethosuximide", "drug", "339-350"], "DRUGB": ["theophylline", "drug", "634-645"]}
{"ID": "DDI-DrugBank.d124.s30.p2", "TEXT1": "Coadministration with compounds that are potent inducers of CYP3A4 (eg, @DRUG$, phenytoin, dexamethasone, @DRUG$) may result in decreased plasma levels of saquinavir.", "LBL": "0", "DRUGA": ["phenobarbital", "drug", "72-84"], "DRUGB": ["carbamazepine", "drug", "113-125"]}
{"ID": "DDI-DrugBank.d521.s2.p3", "TEXT1": "- a @DRUG$ (NSAID) such as ibuprofen (Motrin, @DRUG$, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "LBL": "0", "DRUGA": ["nonsteroidal anti-inflammatory drug", "group", "4-38"], "DRUGB": ["Advil", "brand", "75-79"]}
{"ID": "DDI-DrugBank.d412.s7.p0", "TEXT1": "During controlled hypotensive anesthesia using @DRUG$ in association with @DRUG$, high concentrations (3% or above) of halothane should not be used because the degree of hypotension will be increased and because of the possibility of a large reduction in cardiac output and an increase in central venous pressure.", "LBL": "DDI-effect", "DRUGA": ["labetalol HCl", "drug", "47-59"], "DRUGB": ["halothane", "drug", "81-89"]}
{"ID": "DDI-DrugBank.d531.s90.p11", "TEXT1": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (@DRUG$) is given with the following: @DRUG$, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.", "LBL": "0", "DRUGA": ["efavirenz", "drug", "113-121"], "DRUGB": ["aluminum/magnesium hydroxide antacids", "group", "153-189"]}
{"ID": "DDI-MedLine.d7.s1.p0", "TEXT1": "This report describes two cases in which @DRUG$ clearance accelerated markedly with concomitant @DRUG$ administration.", "LBL": "DDI-mechanism", "DRUGA": ["theophylline", "drug", "41-52"], "DRUGB": ["phenytoin", "drug", "102-110"]}
{"ID": "DDI-DrugBank.d434.s30.p29", "TEXT1": "Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of @DRUG$  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of @DRUG$  given as monotherapy.", "LBL": "0", "DRUGA": ["Felbatol", "brand", "122-129"], "DRUGB": ["Felbatol", "brand", "324-331"]}
{"ID": "DDI-DrugBank.d470.s1.p9", "TEXT1": "Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as @DRUG$ or @DRUG$).", "LBL": "0", "DRUGA": ["diuretics", "group", "200-208"], "DRUGB": ["amphotericin B", "drug", "213-226"]}
{"ID": "DDI-DrugBank.d395.s3.p3", "TEXT1": "In a multiple-dose study, enoxacin caused a dose-related increase in the mean elimination half-life of @DRUG$, thereby decreasing the clearance of @DRUG$ by up to 80% and leading to a five-fold increase in the AUC and the half-life of caffeine.", "LBL": "0", "DRUGA": ["caffeine", "drug", "103-110"], "DRUGB": ["caffeine", "drug", "149-156"]}
{"ID": "DDI-DrugBank.d64.s87.p759", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;@DRUG$;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;@DRUG$;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["diazoxide", "drug", "310-318"], "DRUGB": ["nalidixic acid", "drug", "614-627"]}
{"ID": "DDI-MedLine.d27.s0.p14", "TEXT1": "[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and @DRUG$ and reduces the action of @DRUG$.", "LBL": "0", "DRUGA": ["amizyl", "drug_n", "208-213"], "DRUGB": ["phentolamine", "drug", "241-252"]}
{"ID": "DDI-DrugBank.d107.s10.p2", "TEXT1": "Other Cardiovascular Agents: @DRUG$ and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, @DRUG$, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.", "LBL": "0", "DRUGA": ["Enalapril", "drug", "29-37"], "DRUGB": ["methyldopa", "drug", "123-132"]}
{"ID": "DDI-DrugBank.d131.s10.p12", "TEXT1": "Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: @DRUG$, cyclosporine, @DRUG$, nicardipine, and nifedipine.", "LBL": "0", "DRUGA": ["ergotamine", "drug", "123-132"], "DRUGB": ["amiodarone", "drug", "149-158"]}
{"ID": "DDI-DrugBank.d75.s2.p25", "TEXT1": "Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with anagrelide in clinical trials were aspirin, acetaminophen, furosemide, iron, @DRUG$, @DRUG$, and allopurinol.", "LBL": "0", "DRUGA": ["ranitidine", "drug", "199-208"], "DRUGB": ["hydroxyurea", "drug", "211-221"]}
{"ID": "DDI-DrugBank.d484.s0.p190", "TEXT1": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as @DRUG$ and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (@DRUG$, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "LBL": "0", "DRUGA": ["ampicillin", "drug", "103-112"], "DRUGB": ["Agenerase", "brand", "386-394"]}
{"ID": "DDI-DrugBank.d5.s19.p0", "TEXT1": "@DRUG$: Studies in animals demonstrate that the acute toxicity of @DRUG$ is enhanced by the MAO inhibitor phenelzine .", "LBL": "0", "DRUGA": ["MAO Inhibitors", "group", "0-13"], "DRUGB": ["bupropion", "drug", "74-82"]}
{"ID": "DDI-DrugBank.d64.s29.p67", "TEXT1": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;@DRUG$;antihistamines;@DRUG$;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "LBL": "0", "DRUGA": ["antacids", "group", "176-183"], "DRUGB": ["barbiturates", "group", "200-211"]}
{"ID": "DDI-MedLine.d111.s7.p4", "TEXT1": "Similarly dialyzed were phenobarbital, @DRUG$, and theophylline, both alone at therapeutic concentrations in serum and with @DRUG$ at three different concentrations in serum.", "LBL": "0", "DRUGA": ["quinidine", "drug", "39-47"], "DRUGB": ["ethanol", "drug", "127-133"]}
{"ID": "DDI-DrugBank.d113.s2.p0", "TEXT1": "@DRUG$: Concurrent administration of @DRUG$ may lower meclofenamate sodium plasma levels, possibly by competing for protein-binding sites.", "LBL": "0", "DRUGA": ["Aspirin", "brand", "0-6"], "DRUGB": ["aspirin", "brand", "38-44"]}
{"ID": "DDI-DrugBank.d78.s1.p39", "TEXT1": "Administration of quinolones with antacids containing aluminum, @DRUG$, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as @DRUG$ (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.", "LBL": "0", "DRUGA": ["magnesium", "drug", "64-72"], "DRUGB": ["VIDEX", "brand", "255-259"]}
{"ID": "DDI-DrugBank.d411.s4.p350", "TEXT1": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.", "LBL": "0", "DRUGA": ["dopamine", "drug", "472-479"], "DRUGB": ["thiazide diuretics", "group", "829-846"]}
{"ID": "DDI-DrugBank.d522.s21.p0", "TEXT1": "@DRUG$: There have been reports of increased anticoagulant effects when @DRUG$ and oral anticoagulants were used concomitantly.", "LBL": "0", "DRUGA": ["Anticoagulants", "group", "0-13"], "DRUGB": ["erythromycin", "drug", "80-91"]}
{"ID": "DDI-DrugBank.d60.s12.p21", "TEXT1": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "LBL": "DDI-effect", "DRUGA": ["NIMBEX", "brand", "98-103"], "DRUGB": ["clindamycin", "drug", "209-219"]}
{"ID": "DDI-DrugBank.d313.s2.p2", "TEXT1": "The following are examples of substances that may reduce the blood-glucose-lowering effect: @DRUG$, niacin, danazol, @DRUG$, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).", "LBL": "0", "DRUGA": ["corticosteroids", "group", "92-106"], "DRUGB": ["diuretics", "group", "126-134"]}
{"ID": "DDI-DrugBank.d64.s87.p1032", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;@DRUG$;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;@DRUG$;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["influenza virus vaccine", "group", "471-493"], "DRUGB": ["phenylbutazone", "drug", "683-696"]}
{"ID": "DDI-DrugBank.d64.s87.p725", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;@DRUG$;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;@DRUG$;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["dextrothyroxine", "drug", "294-308"], "DRUGB": ["pentoxifylline", "drug", "668-681"]}
{"ID": "DDI-DrugBank.d94.s11.p633", "TEXT1": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "LBL": "0", "DRUGA": ["felbamate", "drug", "353-361"], "DRUGB": ["lamotrigine", "drug", "420-430"]}
{"ID": "DDI-DrugBank.d335.s3.p2", "TEXT1": "The actions of the @DRUG$ may be potentiated by barbiturates, narcotics, @DRUG$, monoamine oxidase inhibitors or other antidepressants.", "LBL": "DDI-effect", "DRUGA": ["benzodiazepines", "group", "19-33"], "DRUGB": ["phenothiazines", "group", "82-95"]}
{"ID": "DDI-DrugBank.d179.s21.p229", "TEXT1": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., @DRUG$], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., @DRUG$], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or", "LBL": "0", "DRUGA": ["Compazine", "brand", "200-208"], "DRUGB": ["Stelazine", "brand", "325-333"]}
{"ID": "DDI-DrugBank.d488.s7.p10", "TEXT1": "Heparin Sodium Injection should not be mixed with doxorubicin, @DRUG$, ciprofloxacin, or @DRUG$, since it has been reported that these drugs are incompatible with heparin and a precipitate may form.", "LBL": "0", "DRUGA": ["droperidol", "drug", "63-72"], "DRUGB": ["mitoxantrone", "drug", "93-104"]}
{"ID": "DDI-DrugBank.d531.s90.p35", "TEXT1": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, @DRUG$, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, @DRUG$, paroxetine, and zidovudine.", "LBL": "0", "DRUGA": ["azithromycin", "drug", "192-203"], "DRUGB": ["nelfinavir", "drug", "266-275"]}
{"ID": "DDI-DrugBank.d382.s19.p2", "TEXT1": "Oral @DRUG$: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of @DRUG$ and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;", "LBL": "0", "DRUGA": ["contraceptives", "group", "5-18"], "DRUGB": ["ethinyl estradiol", "drug", "135-151"]}
{"ID": "DDI-DrugBank.d263.s13.p72", "TEXT1": "Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, @DRUG$, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, @DRUG$, ribavirin, and vincristine.", "LBL": "0", "DRUGA": ["ethionamide", "drug", "153-163"], "DRUGB": ["phenytoin", "drug", "253-261"]}
{"ID": "DDI-DrugBank.d179.s3.p7", "TEXT1": "- @DRUG$ (nandrolone [e.g., Anabolin], oxandrolone [e.g., Anavar], oxymetholone [e.g., Anadrol], stanozolol [e.g., @DRUG$]) or", "LBL": "0", "DRUGA": ["Anabolic steroids", "group", "2-18"], "DRUGB": ["Winstrol", "brand", "126-133"]}
{"ID": "DDI-DrugBank.d176.s12.p22", "TEXT1": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, @DRUG$, hydrochlorothiazide, cimetidine, metoclopramide, @DRUG$, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.", "LBL": "0", "DRUGA": ["propanolol", "drug", "105-114"], "DRUGB": ["propantheline", "drug", "166-178"]}
{"ID": "DDI-DrugBank.d140.s10.p2", "TEXT1": "Oral @DRUG$: Coadministration of atorvastatin and an oral contraceptive increased AUC values for @DRUG$ and ethinyl estradiol by approximately 30% and 20%.", "LBL": "0", "DRUGA": ["Contraceptives", "group", "5-18"], "DRUGB": ["norethindrone", "drug", "105-117"]}
{"ID": "DDI-DrugBank.d460.s14.p16", "TEXT1": "Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, @DRUG$, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of @DRUG$ and other oral antidiabetic drugs.", "LBL": "DDI-effect", "DRUGA": ["monoamine oxidase inhibitors", "group", "86-113"], "DRUGB": ["Starlix", "brand", "208-214"]}
{"ID": "DDI-DrugBank.d297.s2.p57", "TEXT1": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, @DRUG$, hydroxychloroquine, @DRUG$, sulfasalazine, and anakinra.", "LBL": "0", "DRUGA": ["gold", "drug", "202-205"], "DRUGB": ["leflunomide", "drug", "228-238"]}
{"ID": "DDI-DrugBank.d123.s8.p32", "TEXT1": "Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or @DRUG$ antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or @DRUG$ may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.", "LBL": "0", "DRUGA": ["aluminum", "drug", "172-179"], "DRUGB": ["zinc", "drug", "297-300"]}
{"ID": "DDI-DrugBank.d192.s0.p26", "TEXT1": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "LBL": "0", "DRUGA": ["anticholinergics", "group", "161-176"], "DRUGB": ["antihistamines", "group", "323-336"]}
{"ID": "DDI-DrugBank.d558.s7.p1", "TEXT1": "Co-administration of @DRUG$ with verapamil resulted in increases in @DRUG$ peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.", "LBL": "0", "DRUGA": ["TIKOSYN", "brand", "21-27"], "DRUGB": ["dofetilide", "drug", "69-78"]}
{"ID": "DDI-DrugBank.d431.s1.p16", "TEXT1": "Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as @DRUG$, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, @DRUG$, clarithromycin, or terfenadine in healthy subjects.", "LBL": "0", "DRUGA": ["warfarin", "drug", "155-162"], "DRUGB": ["diazepam", "drug", "238-245"]}
{"ID": "DDI-DrugBank.d139.s8.p0", "TEXT1": "@DRUG$-@DRUG$ can antagonize the effect of warfarin", "LBL": "0", "DRUGA": ["Warfarin", "drug", "0-7"], "DRUGB": ["Vitamin K", "group", "9-17"]}
{"ID": "DDI-MedLine.d111.s2.p11", "TEXT1": "Acetaminophen, lidocaine, @DRUG$, quinidine, theophylline, and @DRUG$ were added to pooled human serum at therapeutic concentrations.", "LBL": "0", "DRUGA": ["phenobarbital", "drug", "26-38"], "DRUGB": ["valproic acid", "drug", "70-82"]}
{"ID": "DDI-DrugBank.d235.s4.p88", "TEXT1": "Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, @DRUG$, @DRUG$, and verapamil.", "LBL": "0", "DRUGA": ["protease inhibitors", "group", "172-190"], "DRUGB": ["quinidine", "drug", "193-201"]}
{"ID": "DDI-DrugBank.d64.s87.p353", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;@DRUG$;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;@DRUG$;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["antibiotics", "group", "185-195"], "DRUGB": ["triclofos sodium", "drug", "893-908"]}
{"ID": "DDI-DrugBank.d411.s4.p413", "TEXT1": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "LBL": "0", "DRUGA": ["heparin", "drug", "534-540"], "DRUGB": ["6-mercaptopurine", "drug", "671-686"]}
{"ID": "DDI-DrugBank.d484.s0.p472", "TEXT1": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, @DRUG$), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, @DRUG$), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "LBL": "0", "DRUGA": ["Felbatol", "brand", "204-211"], "DRUGB": ["Sandimmune", "brand", "328-337"]}
{"ID": "DDI-DrugBank.d382.s9.p18", "TEXT1": "Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and @DRUG$ when given as 80 mg/day with @DRUG$ coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.", "LBL": "DDI-mechanism", "DRUGA": ["Aprepitant", "drug", "141-150"], "DRUGB": ["dexamethasone", "drug", "181-193"]}
{"ID": "DDI-DrugBank.d254.s0.p13", "TEXT1": "Other CNS depressant drugs (e.g. barbiturates, tranquilizers, @DRUG$ and general anesthetics) have additive or potentiating effects with @DRUG$.", "LBL": "DDI-effect", "DRUGA": ["opioids", "group", "62-68"], "DRUGB": ["INAPSINE", "brand", "138-145"]}
{"ID": "DDI-DrugBank.d209.s3.p70", "TEXT1": "Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, @DRUG$, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, @DRUG$, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.", "LBL": "0", "DRUGA": ["anticonvulsants", "group", "276-290"], "DRUGB": ["H2 antagonists", "group", "380-393"]}
{"ID": "DDI-DrugBank.d384.s0.p13", "TEXT1": "Interactions for vitamin D analogues (Vitamin D2, @DRUG$, @DRUG$, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;", "LBL": "0", "DRUGA": ["Vitamin D3", "drug", "50-59"], "DRUGB": ["Calcitriol", "drug", "62-71"]}
{"ID": "DDI-DrugBank.d571.s4.p1", "TEXT1": "Patients on oral @DRUG$ receiving VELCADE treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their @DRUG$.", "LBL": "0", "DRUGA": ["antidiabetic agents", "group", "17-35"], "DRUGB": ["antidiabetic medication", "group", "160-182"]}
{"ID": "DDI-DrugBank.d202.s14.p1", "TEXT1": "In addition, certain drugs that are metabolized by this isoenzyme, including many @DRUG$ (tricyclic antidepressants, @DRUG$, and others), may inhibit the activity of this isoenzyme, and thus may make normal metab-olizers resemble poor metabolizers with regard to concomitant therapy with other drugs metabolized by this enzyme system, leading to drug interactions.", "LBL": "0", "DRUGA": ["antidepressants", "group", "82-96"], "DRUGB": ["selective serotonin reuptake inhibitors", "group", "126-164"]}
{"ID": "DDI-DrugBank.d426.s3.p3", "TEXT1": "@DRUG$ (SSRIs) (e.g., fluoxetine, fluvoxamine, @DRUG$, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.", "LBL": "0", "DRUGA": ["Selective serotonin reuptake inhibitors", "group", "0-38"], "DRUGB": ["paroxetine", "drug", "80-89"]}
{"ID": "DDI-MedLine.d100.s5.p3", "TEXT1": "Slow-channel calcium blockers, such as @DRUG$, @DRUG$ and nifedipine, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly.", "LBL": "0", "DRUGA": ["verapamil", "drug", "39-47"], "DRUGB": ["diltiazem", "drug", "50-58"]}
{"ID": "DDI-DrugBank.d260.s0.p17", "TEXT1": "Probenecid : @DRUG$ is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, @DRUG$, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).", "LBL": "DDI-mechanism", "DRUGA": ["Probenecid", "drug", "13-22"], "DRUGB": ["angiotensin-converting enzyme inhibitors", "group", "139-178"]}
{"ID": "DDI-DrugBank.d171.s0.p38", "TEXT1": "Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, @DRUG$, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, @DRUG$ and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.", "LBL": "0", "DRUGA": ["nifedipine", "drug", "184-193"], "DRUGB": ["theophylline", "drug", "270-281"]}
{"ID": "DDI-DrugBank.d63.s0.p31", "TEXT1": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), @DRUG$ (e.g., Nardil), @DRUG$ (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.", "LBL": "0", "DRUGA": ["phenelzine", "drug", "74-83"], "DRUGB": ["procarbazine", "drug", "101-112"]}
{"ID": "DDI-DrugBank.d274.s3.p45", "TEXT1": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, @DRUG$, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and @DRUG$.", "LBL": "0", "DRUGA": ["spironolactone", "drug", "177-190"], "DRUGB": ["acetaminophen", "drug", "323-335"]}
{"ID": "DDI-DrugBank.d115.s0.p20", "TEXT1": "Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, @DRUG$).", "LBL": "0", "DRUGA": ["erythromycin", "drug", "230-241"], "DRUGB": ["clarithromycin", "drug", "244-257"]}
{"ID": "DDI-DrugBank.d558.s25.p21", "TEXT1": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, @DRUG$, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with @DRUG$ as they can potentially increase dofetilide levels.", "LBL": "DDI-advise", "DRUGA": ["azole antifungal agents", "group", "59-81"], "DRUGB": ["TIKOSYN", "brand", "279-285"]}
{"ID": "DDI-MedLine.d112.s2.p0", "TEXT1": "Five days of @DRUG$ treatment did not significantly affect steady-state pharmacokinetic variables of @DRUG$ compared with placebo;", "LBL": "0", "DRUGA": ["dofetilide", "drug", "13-22"], "DRUGB": ["digoxin", "drug", "105-111"]}
{"ID": "DDI-DrugBank.d94.s4.p254", "TEXT1": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, @DRUG$, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, @DRUG$, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "LBL": "0", "DRUGA": ["isoniazid", "drug", "303-311"], "DRUGB": ["quinine", "drug", "428-434"]}
{"ID": "DDI-DrugBank.d350.s3.p4", "TEXT1": "Clinical studies in healthy volunteers show that the pharmacokinetics of @DRUG$ are not altered by itraconazole, amphotericin B, mycophenolate, nelfinavir, or @DRUG$.", "LBL": "0", "DRUGA": ["CANCIDAS", "brand", "73-80"], "DRUGB": ["tacrolimus", "drug", "161-170"]}
{"ID": "DDI-DrugBank.d53.s7.p17", "TEXT1": "When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of @DRUG$, carbamazepine, cetirizine, @DRUG$, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.", "LBL": "0", "DRUGA": ["atorvastatin", "drug", "92-103"], "DRUGB": ["didanosine", "drug", "133-142"]}
{"ID": "DDI-MedLine.d39.s2.p0", "TEXT1": "Injection of @DRUG$ 5 min before a nonlethal dose of @DRUG$ changed the serum sex steroid hormone response of male rats to endotoxin.", "LBL": "DDI-effect", "DRUGA": ["estradiol", "drug", "13-21"], "DRUGB": ["endotoxin", "drug_n", "56-64"]}
{"ID": "DDI-DrugBank.d277.s10.p9", "TEXT1": "Effects of other Antiepilepsy Drugs (AEDs) on GABITRIL : @DRUG$: Population pharmacokinetic analyses indicate that @DRUG$ clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing AEDs.", "LBL": "0", "DRUGA": ["Carbamazepine", "drug", "57-69"], "DRUGB": ["tiagabine", "drug", "122-130"]}
{"ID": "DDI-DrugBank.d521.s2.p128", "TEXT1": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, @DRUG$, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, @DRUG$);", "LBL": "0", "DRUGA": ["Nuprin", "brand", "82-87"], "DRUGB": ["Aleve", "brand", "291-295"]}
{"ID": "DDI-DrugBank.d411.s4.p333", "TEXT1": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "LBL": "0", "DRUGA": ["dopamine", "drug", "472-479"], "DRUGB": ["heparin", "drug", "534-540"]}
{"ID": "DDI-DrugBank.d3.s1.p4", "TEXT1": "@DRUG$, Digoxin, Salicylate, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by @DRUG$ (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.", "LBL": "0", "DRUGA": ["Warfarin", "drug", "0-7"], "DRUGB": ["ketorolac tromethamine", "drug", "123-144"]}
{"ID": "DDI-DrugBank.d558.s32.p26", "TEXT1": "Other Drugs: In healthy volunteers, amlodipine, phenytoin, @DRUG$, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (@DRUG$s) and theophylline did not affect the pharmacokinetics of TIKOSYN.", "LBL": "0", "DRUGA": ["glyburide", "drug", "59-67"], "DRUGB": ["aluminum hydroxide", "drug", "196-203;219-227"]}
{"ID": "DDI-DrugBank.d566.s2.p14", "TEXT1": "Cholestyramine resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of @DRUG$ resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine @DRUG$.", "LBL": "0", "DRUGA": ["cholestyramine", "drug", "132-145"], "DRUGB": ["resin", "group", "315-319"]}
{"ID": "DDI-DrugBank.d64.s87.p841", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;@DRUG$;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;@DRUG$;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["disulfiram", "drug", "352-361"], "DRUGB": ["pyrazolones", "group", "763-773"]}
{"ID": "DDI-DrugBank.d132.s10.p0", "TEXT1": "This effect is small with occasional doses of @DRUG$, but may be clinically significant when @DRUG$ are used on a continuous schedule.", "LBL": "0", "DRUGA": ["antacids", "group", "46-53"], "DRUGB": ["antacids", "group", "95-102"]}
{"ID": "DDI-DrugBank.d172.s13.p1", "TEXT1": "@DRUG$: CELEBREX can be used with low dose @DRUG$.", "LBL": "0", "DRUGA": ["Aspirin", "brand", "0-6"], "DRUGB": ["aspirin", "brand", "44-50"]}
{"ID": "DDI-DrugBank.d110.s0.p6", "TEXT1": "The administration of local anesthetic solutions containing @DRUG$ or norepinephrine to patients receiving @DRUG$, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.", "LBL": "DDI-effect", "DRUGA": ["epinephrine", "drug", "60-70"], "DRUGB": ["monoamine oxidase inhibitors", "group", "112-139"]}
{"ID": "DDI-DrugBank.d293.s0.p19", "TEXT1": "May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, @DRUG$, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., @DRUG$, omeprazole).", "LBL": "0", "DRUGA": ["antacids", "group", "88-95"], "DRUGB": ["lansoprazole", "drug", "179-190"]}
{"ID": "DDI-DrugBank.d64.s87.p962", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;@DRUG$;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;@DRUG$;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["ibuprofen", "drug", "448-456"], "DRUGB": ["methylphenidate", "drug", "544-558"]}
{"ID": "DDI-DrugBank.d226.s0.p0", "TEXT1": "Intravenous @DRUG$ (@DRUG$) has been effectively administered in the presence of other cardioactive drugs, such as quinidine, beta-adrenergic blocking agents, calcium channel blocking agents, and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile.", "LBL": "0", "DRUGA": ["Adenocard", "brand", "12-20"], "DRUGB": ["adenosine", "drug", "23-31"]}
{"ID": "DDI-DrugBank.d260.s3.p14", "TEXT1": "Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous @DRUG$ (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous @DRUG$, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.", "LBL": "0", "DRUGA": ["aminoglycosides", "group", "116-130"], "DRUGB": ["pentamidine", "drug", "217-227"]}
{"ID": "DDI-DrugBank.d382.s10.p5", "TEXT1": "The oral dexamethasone doses should be reduced by approximately 50% when coadministered with Aprepitant, to achieve exposures of @DRUG$ similar to those obtained when it is given without @DRUG$.", "LBL": "0", "DRUGA": ["dexamethasone", "drug", "129-141"], "DRUGB": ["Aprepitant", "drug", "194-203"]}
{"ID": "DDI-DrugBank.d172.s8.p0", "TEXT1": "The effects @DRUG$ on the pharmacokinetics and/or pharmacodynamics of @DRUG$, ketoconazole, methotrexate, phenytoin, tolbutamide, and warfarin have been studied in vivo and clinically important interactions have not been found.", "LBL": "0", "DRUGA": ["celecoxib", "drug", "12-20"], "DRUGB": ["glyburide", "drug", "73-81"]}
{"ID": "DDI-DrugBank.d335.s5.p0", "TEXT1": "In bioavailability studies with normal subjects, the concurrent administration of @DRUG$ at therapeutic levels did not significantly influence the bioavailability of @DRUG$ tablets.", "LBL": "0", "DRUGA": ["antacids", "group", "82-89"], "DRUGB": ["TRANXENE", "brand", "168-175"]}
{"ID": "DDI-DrugBank.d5.s17.p46", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, @DRUG$, desipramine, @DRUG$, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["imipramine", "drug", "150-159"], "DRUGB": ["paroxetine", "drug", "175-184"]}
{"ID": "DDI-DrugBank.d5.s14.p0", "TEXT1": "In a study of 15 male subjects (ages 19 to 35 years) who were extensive metabolizers of the CYP2D6 isoenzyme, daily doses of @DRUG$ given as 150 mg twice daily followed by a single dose of 50 mg @DRUG$ increased the Cmax, AUC, and t1/2 of desipramine by an average of approximately 2-, 5- and 2-fold, respectively.", "LBL": "DDI-mechanism", "DRUGA": ["bupropion", "drug", "125-133"], "DRUGB": ["desipramine", "drug", "198-208"]}
{"ID": "DDI-MedLine.d20.s4.p2", "TEXT1": "The successive application of glycine (5 or 10 mg/kg egg weight (e.w.) and @DRUG$ (15 mg/kg e.w.) in a 10 min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of @DRUG$ alone.", "LBL": "0", "DRUGA": ["glutamate", "drug", "75-83"], "DRUGB": ["glutamate", "drug", "246-254"]}
{"ID": "DDI-MedLine.d105.s7.p2", "TEXT1": "@DRUG$ had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated @DRUG$ by 110%.", "LBL": "DDI-mechanism", "DRUGA": ["Azithromycin", "drug", "0-11"], "DRUGB": ["zidovudine", "drug", "196-205"]}
{"ID": "DDI-DrugBank.d521.s2.p50", "TEXT1": "- a nonsteroidal anti-inflammatory drug (NSAID) such as @DRUG$ (Motrin, Advil, Nuprin, others), @DRUG$ (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "LBL": "0", "DRUGA": ["ibuprofen", "drug", "56-64"], "DRUGB": ["ketoprofen", "drug", "99-108"]}
{"ID": "DDI-DrugBank.d94.s11.p113", "TEXT1": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "LBL": "0", "DRUGA": ["alprazolam", "drug", "172-181"], "DRUGB": ["mirtazapine", "drug", "481-491"]}
{"ID": "DDI-DrugBank.d351.s0.p9", "TEXT1": "Probenecid: As with other b-lactam antibiotics, renal excretion of loracarbef is inhibited by @DRUG$ and resulted in an approximate 80% increase in the AUC for @DRUG$.", "LBL": "0", "DRUGA": ["probenecid", "drug", "94-103"], "DRUGB": ["loracarbef", "drug", "164-173"]}
{"ID": "DDI-DrugBank.d460.s11.p31", "TEXT1": "In vitro displacement studies with highly protein-bound drugs such as furosemide, propranolol, captopril, @DRUG$, pravastatin, @DRUG$, warfarin, phenytoin, acetylsalicylic acid, tolbutamide, and metformin showed no influence on the extent of nateglinide protein binding.", "LBL": "0", "DRUGA": ["nicardipine", "drug", "106-116"], "DRUGB": ["glyburide", "drug", "132-140"]}
{"ID": "DDI-MedLine.d133.s1.p5", "TEXT1": "BACKGROUND: The effects of combined administration of bombesin and @DRUG$ (@DRUG$), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats.", "LBL": "0", "DRUGA": ["verapamil hydrochloride", "drug", "67-89"], "DRUGB": ["verapamil", "drug", "92-100"]}
{"ID": "DDI-DrugBank.d178.s0.p10", "TEXT1": "The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.", "LBL": "0", "DRUGA": ["nonsteroidal anti-inflammatory agents", "group", "87-123"], "DRUGB": ["chloramphenicol", "drug", "199-213"]}
{"ID": "DDI-DrugBank.d441.s6.p6", "TEXT1": "Spontaneous reports of serotonin syndrome associated with co-administration of ZYVOX and @DRUG$, including antidepressants such as selective serotonin reuptake inhibitors (@DRUG$), have been reported.", "LBL": "0", "DRUGA": ["serotonergic agents", "group", "89-107"], "DRUGB": ["SSRIs", "group", "185-189"]}
{"ID": "DDI-DrugBank.d5.s17.p34", "TEXT1": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., @DRUG$, imipramine, desipramine, paroxetine, @DRUG$, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "LBL": "0", "DRUGA": ["nortriptyline", "drug", "135-147"], "DRUGB": ["fluoxetine", "drug", "187-196"]}
{"ID": "DDI-DrugBank.d48.s1.p52", "TEXT1": "Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, @DRUG$, atazanavir, indinavir, @DRUG$, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.", "LBL": "0", "DRUGA": ["ritonavir", "drug", "120-128"], "DRUGB": ["nefazodone", "drug", "154-163"]}
{"ID": "DDI-DrugBank.d64.s87.p1272", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;@DRUG$;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;@DRUG$/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["naproxen", "drug", "629-636"], "DRUGB": ["trimethoprim", "drug", "910-921"]}
{"ID": "DDI-DrugBank.d484.s0.p519", "TEXT1": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), @DRUG$ (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), @DRUG$ (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "LBL": "0", "DRUGA": ["antifungals", "group", "215-225"], "DRUGB": ["rifadin", "brand", "538-544"]}
{"ID": "DDI-DrugBank.d204.s0.p2", "TEXT1": "When administered concurrently, the following drugs may interact with beta-adrenergic receptor blocking agents: @DRUG$, general: exaggeration of the hypotension induced by general @DRUG$.", "LBL": "0", "DRUGA": ["Anesthetics", "group", "112-122"], "DRUGB": ["anesthetics", "group", "185-195"]}
{"ID": "DDI-DrugBank.d212.s11.p47", "TEXT1": "Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, @DRUG$, primidone and valproate) were also assessed by evaluating the serum concentrations of @DRUG$ and these AEDs during placebo-controlled clinical studies.", "LBL": "0", "DRUGA": ["phenytoin", "drug", "115-123"], "DRUGB": ["levetiracetam", "drug", "212-224"]}
{"ID": "DDI-DrugBank.d456.s1.p19", "TEXT1": "Caution should be used when administering or taking TARCEVA with @DRUG$ and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, @DRUG$, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .", "LBL": "0", "DRUGA": ["ketoconazole", "drug", "65-76"], "DRUGB": ["ritonavir", "drug", "219-227"]}
{"ID": "DDI-DrugBank.d313.s1.p23", "TEXT1": "The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, @DRUG$, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, @DRUG$, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.", "LBL": "0", "DRUGA": ["disopyramide", "drug", "173-184"], "DRUGB": ["salicylates", "group", "259-269"]}
{"ID": "DDI-DrugBank.d353.s1.p4", "TEXT1": "Glibenclamide: In a study of 7 healthy male volunteers, @DRUG$ treatment potentiated the blood glucose lowering effect of @DRUG$ (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects.", "LBL": "DDI-effect", "DRUGA": ["acitretin", "drug", "56-64"], "DRUGB": ["glibenclamide", "drug", "125-137"]}
{"ID": "DDI-DrugBank.d106.s5.p3", "TEXT1": "Pharmacokinetic interactions between nisoldipine and @DRUG$ (@DRUG$, propranolol) were variable and not significant.", "LBL": "0", "DRUGA": ["beta-blockers", "group", "53-65"], "DRUGB": ["atenolol", "drug", "68-75"]}
{"ID": "DDI-DrugBank.d537.s0.p39", "TEXT1": "Bentiromide may interact with acetaminophen (e.g., Tylenol), @DRUG$ (e.g., @DRUG$), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "LBL": "0", "DRUGA": ["chloramphenicol", "drug", "61-75"], "DRUGB": ["Chloromycetin", "brand", "84-96"]}
{"ID": "DDI-DrugBank.d184.s0.p86", "TEXT1": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral @DRUG$ containing estrogens (@DRUG$ may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "LBL": "0", "DRUGA": ["contraceptives", "group", "488-501"], "DRUGB": ["barbiturates", "group", "525-536"]}
{"ID": "DDI-DrugBank.d94.s4.p290", "TEXT1": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, @DRUG$, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, @DRUG$, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "LBL": "0", "DRUGA": ["loratadine", "drug", "342-351"], "DRUGB": ["quinine", "drug", "428-434"]}
{"ID": "DDI-DrugBank.d78.s16.p7", "TEXT1": "include terfenadine, astemizole, @DRUG$, @DRUG$, and triazolam.", "LBL": "0", "DRUGA": ["cisapride", "drug", "33-41"], "DRUGB": ["midazolam", "drug", "44-52"]}
{"ID": "DDI-DrugBank.d64.s87.p988", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;@DRUG$;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;@DRUG$ overdosage.", "LBL": "0", "DRUGA": ["ibuprofen", "drug", "448-456"], "DRUGB": ["warfarin sodium", "drug", "983-997"]}
{"ID": "DDI-DrugBank.d94.s11.p730", "TEXT1": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.", "LBL": "0", "DRUGA": ["haloperidol", "drug", "393-403"], "DRUGB": ["triazolam", "drug", "681-689"]}
{"ID": "DDI-DrugBank.d94.s11.p943", "TEXT1": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.", "LBL": "0", "DRUGA": ["oxcarbazepine", "drug", "545-557"], "DRUGB": ["zonisamide", "drug", "734-743"]}
{"ID": "DDI-DrugBank.d238.s4.p5", "TEXT1": "Several tricyclic antidepressants have been reported to block the pharmacologic effects of @DRUG$, clonidine, or similar agents, and such an effect may be anticipated with @DRUG$ because of its structural similarity to other tricyclic antidepressants.", "LBL": "0", "DRUGA": ["guanethidine", "drug", "91-102"], "DRUGB": ["CMI", "drug", "178-180"]}
{"ID": "DDI-DrugBank.d124.s18.p2", "TEXT1": "Garlic Capsules Garlic capsules should not be used while taking @DRUG$ (FORTOVASE) as the sole protease inhibitor due to the risk of decreased @DRUG$ plasma concentrations.", "LBL": "0", "DRUGA": ["saquinavir", "drug", "64-73"], "DRUGB": ["saquinavir", "drug", "147-156"]}
{"ID": "DDI-DrugBank.d484.s0.p119", "TEXT1": "Etonogestrel may interact with the following medications: acetaminophen (@DRUG$), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, @DRUG$), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "LBL": "0", "DRUGA": ["Tylenol", "brand", "73-79"], "DRUGB": ["MS Contin", "brand", "486-494"]}
{"ID": "DDI-DrugBank.d93.s0.p9", "TEXT1": "Clinical trials have indicated that Pulmozyme can be effectively and safely used in conjunction with standard cystic fibrosis therapies including oral, inhaled and/or parenteral antibiotics, @DRUG$, enzyme supplements, @DRUG$, oral or inhaled corticosteroids, and analgesics.", "LBL": "0", "DRUGA": ["bronchodilators", "group", "191-205"], "DRUGB": ["vitamins", "group", "228-235"]}
{"ID": "DDI-DrugBank.d231.s17.p0", "TEXT1": "Patients receiving both @DRUG$ and @DRUG$ should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.", "LBL": "DDI-advise", "DRUGA": ["indomethacin", "drug", "24-35"], "DRUGB": ["furosemide", "drug", "41-50"]}
{"ID": "DDI-DrugBank.d397.s8.p64", "TEXT1": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, @DRUG$, cisapride, @DRUG$, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.", "LBL": "0", "DRUGA": ["alfentanil", "drug", "127-136"], "DRUGB": ["disopyramide", "drug", "150-161"]}
{"ID": "DDI-DrugBank.d3.s7.p3", "TEXT1": "Although these results do not indicate a significant interaction between @DRUG$ and warfarin or heparin, the administration of TORADOL to patients taking @DRUG$ should be done extremely cautiously, and patients should be closely monitored.", "LBL": "0", "DRUGA": ["TORADOL", "brand", "73-79"], "DRUGB": ["anticoagulants", "group", "155-168"]}
{"ID": "DDI-DrugBank.d150.s1.p4", "TEXT1": "FLEXERIL may enhance the effects of @DRUG$, barbiturates, and other @DRUG$.", "LBL": "0", "DRUGA": ["alcohol", "drug", "36-42"], "DRUGB": ["CNS depressants", "group", "69-83"]}
{"ID": "DDI-DrugBank.d350.s12.p7", "TEXT1": "In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, @DRUG$, phenytoin, @DRUG$, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.", "LBL": "0", "DRUGA": ["nevirapine", "drug", "157-166"], "DRUGB": ["dexamethasone", "drug", "180-192"]}
{"ID": "DDI-DrugBank.d476.s3.p15", "TEXT1": "ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain @DRUG$ (particularly of the @DRUG$ [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.", "LBL": "0", "DRUGA": ["calcium antagonists", "group", "108-126"], "DRUGB": ["phenylalkylamine", "group", "149-164"]}
{"ID": "DDI-DrugBank.d413.s2.p12", "TEXT1": "Mercaptopurine/Azathioprine: Allopurinol inhibits the enzymatic oxidation of @DRUG$ and @DRUG$ to 6-thiouric acid.", "LBL": "0", "DRUGA": ["mercaptopurine", "drug", "77-90"], "DRUGB": ["azathioprine", "drug", "96-107"]}
{"ID": "DDI-DrugBank.d107.s1.p7", "TEXT1": "The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the @DRUG$ or increasing the salt intake prior to initiation of treatment with @DRUG$ or enalaprilat.", "LBL": "0", "DRUGA": ["diuretic", "drug", "114-121"], "DRUGB": ["enalapril", "drug", "191-199"]}
{"ID": "DDI-DrugBank.d415.s1.p6", "TEXT1": "However, because bleeding has been reported when ibuprofen and other @DRUG$ have been administered to patients on coumarin-type anticoagulants, the physician should be cautious when administering ibuprofen to patients on @DRUG$.", "LBL": "0", "DRUGA": ["nonsteroidal anti-inflammatory agents", "group", "69-105"], "DRUGB": ["anticoagulants", "group", "252-265"]}
{"ID": "DDI-DrugBank.d484.s0.p532", "TEXT1": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (@DRUG$, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (@DRUG$, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "LBL": "0", "DRUGA": ["Gris-PEG", "brand", "228-235"], "DRUGB": ["Neoral", "brand", "320-325"]}
{"ID": "DDI-DrugBank.d124.s26.p31", "TEXT1": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;", "LBL": "0", "DRUGA": ["disopyramide", "drug", "157-168"], "DRUGB": ["quinine", "drug", "171-177"]}
{"ID": "DDI-DrugBank.d94.s8.p59", "TEXT1": "Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), @DRUG$, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for @DRUG$ may be necessary.", "LBL": "0", "DRUGA": ["primidone", "drug", "204-212"], "DRUGB": ["EQUETROTM", "brand", "441-449"]}
{"ID": "DDI-DrugBank.d384.s13.p0", "TEXT1": "@DRUG$: The coadministration of any of the @DRUG$ should be avoided as this could create possible additive effects and hypercalcemia.", "LBL": "0", "DRUGA": ["Vitamin D", "group", "0-8"], "DRUGB": ["vitamin D analogues", "group", "46-64"]}
{"ID": "DDI-MedLine.d140.s13.p0", "TEXT1": "@DRUG$ doses, trough concentrations, and AUC exhibited similar temporal patterns during the course of the study regardless of the co-administered @DRUG$ dose level (P = .13, .82, and .76, respectively).", "LBL": "0", "DRUGA": ["Cyclosporine", "drug", "0-11"], "DRUGB": ["everolimus", "drug", "152-161"]}
{"ID": "DDI-DrugBank.d307.s43.p0", "TEXT1": "Therefore, concurrent use of @DRUG$ with @DRUG$ may render these contraceptives less effective.", "LBL": "DDI-effect", "DRUGA": ["Trileptal", "brand", "29-37"], "DRUGB": ["hormonal contraceptives", "group", "44-66"]}
{"ID": "DDI-DrugBank.d269.s18.p1", "TEXT1": "@DRUG$ or Oral Hypoglycemics: @DRUG$ may enhance the blood-sugar-reducing effect of insulin and oral hypoglycemics.", "LBL": "0", "DRUGA": ["Insulin", "drug", "0-6"], "DRUGB": ["Agents with b-blocking properties", "group", "31-63"]}
{"ID": "DDI-DrugBank.d484.s0.p9", "TEXT1": "@DRUG$ may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, @DRUG$, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "LBL": "DDI-int", "DRUGA": ["Etonogestrel", "drug", "0-11"], "DRUGB": ["Trileptal", "brand", "184-192"]}
{"ID": "DDI-DrugBank.d559.s1.p14", "TEXT1": "Butalbital, @DRUG$ and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as @DRUG$, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.", "LBL": "DDI-effect", "DRUGA": ["acetaminophen", "drug", "12-24"], "DRUGB": ["chlordiazepoxide", "drug", "146-161"]}
{"ID": "DDI-DrugBank.d225.s0.p34", "TEXT1": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and @DRUG$.", "LBL": "0", "DRUGA": ["sulfonamides", "group", "237-248"], "DRUGB": ["beta adrenergic blocking agents", "group", "325-355"]}
{"ID": "DDI-MedLine.d111.s5.p2", "TEXT1": "@DRUG$/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.", "LBL": "0", "DRUGA": ["acetaminophen", "drug", "0-12"], "DRUGB": ["quinidine", "drug", "38-46"]}
{"ID": "DDI-DrugBank.d558.s5.p6", "TEXT1": "If a patient requires @DRUG$ and anti-ulcer therapy, it is suggested that omeprazole, ranitidine, or antacids (aluminum and magnesium hydroxides) be used as alternatives to @DRUG$, as these agents have no effect on the pharmacokinetic profile of TIKOSYN.", "LBL": "DDI-advise", "DRUGA": ["TIKOSYN", "brand", "22-28"], "DRUGB": ["cimetidine", "drug", "174-183"]}
{"ID": "DDI-DrugBank.d94.s11.p350", "TEXT1": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "LBL": "0", "DRUGA": ["clonazepam", "drug", "243-252"], "DRUGB": ["mirtazapine", "drug", "481-491"]}
{"ID": "DDI-DrugBank.d172.s13.p0", "TEXT1": "@DRUG$: @DRUG$ can be used with low dose aspirin.", "LBL": "0", "DRUGA": ["Aspirin", "brand", "0-6"], "DRUGB": ["CELEBREX", "brand", "9-16"]}
{"ID": "DDI-DrugBank.d404.s0.p26", "TEXT1": "Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): @DRUG$: Cholestyramine has been reported to reduce intestinal absorption of @DRUG$;", "LBL": "0", "DRUGA": ["Cholestyramine", "drug", "90-103"], "DRUGB": ["fat soluble vitamins", "group", "174-193"]}
{"ID": "DDI-DrugBank.d521.s2.p257", "TEXT1": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), @DRUG$ (Indocin), nabumetone (@DRUG$), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "LBL": "0", "DRUGA": ["indomethacin", "drug", "192-203"], "DRUGB": ["Relafen", "brand", "228-234"]}
{"ID": "DDI-DrugBank.d86.s0.p9", "TEXT1": "The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an @DRUG$ (eg, @DRUG$), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.", "LBL": "0", "DRUGA": ["antiparkinsonian drug", "group", "126-146"], "DRUGB": ["trihexyphenidyl", "drug", "153-167"]}
{"ID": "DDI-DrugBank.d501.s10.p15", "TEXT1": "In vitro studies evaluating the minimum inhibitory concentration (MIC) of vancomycin, cefazolin, @DRUG$, @DRUG$/flucoxacillin, ceftazidime, gentamicin, and amphotericin demonstrated no evidence of incompatibility of these antibiotics with EXTRANEAL.", "LBL": "0", "DRUGA": ["ampicillin", "drug", "97-106"], "DRUGB": ["ampicillin", "drug", "109-118"]}
{"ID": "DDI-DrugBank.d395.s9.p3", "TEXT1": "Non-steroidal anti-inflammatory agents: Seizures have been reported in patients taking @DRUG$ concomitantly with the @DRUG$ fenbufen.", "LBL": "0", "DRUGA": ["enoxacin", "drug", "87-94"], "DRUGB": ["nonsteroidal anti-inflammatory drug", "group", "119-153"]}
{"ID": "DDI-DrugBank.d99.s8.p2", "TEXT1": "While all the selective @DRUG$ (SSRIs), e.g., fluoxetine, @DRUG$, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.", "LBL": "0", "DRUGA": ["serotonin reuptake inhibitors", "group", "24-52"], "DRUGB": ["sertraline", "drug", "81-90"]}
{"ID": "DDI-DrugBank.d94.s11.p753", "TEXT1": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "LBL": "0", "DRUGA": ["itraconazole", "drug", "406-417"], "DRUGB": ["tramadol", "drug", "671-678"]}
{"ID": "DDI-MedLine.d111.s5.p53", "TEXT1": "acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and @DRUG$/phenobarbital.", "LBL": "0", "DRUGA": ["phenobarbital", "drug", "49-61"], "DRUGB": ["valproic acid", "drug", "160-172"]}
{"ID": "DDI-DrugBank.d194.s1.p7", "TEXT1": "High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in @DRUG$ exposure with a 38% decrease in total body clearance of @DRUG$ compared to etoposide alone.", "LBL": "0", "DRUGA": ["etoposide", "drug", "132-140"], "DRUGB": ["etoposide", "drug", "198-206"]}
{"ID": "DDI-DrugBank.d54.s21.p1", "TEXT1": "@DRUG$s: Thyroxine increases the adrenergic effect of catecholamines such as @DRUG$ and norepinephrine.", "LBL": "0", "DRUGA": ["Vasopressor", "group", "0-10"], "DRUGB": ["epinephrine", "drug", "82-92"]}
{"ID": "DDI-DrugBank.d425.s1.p41", "TEXT1": "Medications can interfere with folate utilization, including: anticonvulsant medications (such as phenytoin, and primidone) metformin (sometimes prescribed to control blood sugar in type 2 diabetes) sulfasalazine (used to control inflammation associated with Crohns disease and ulcerative colitis) triamterene (a @DRUG$) Methotrexate There has been concern about the interaction between vitamin B12 and @DRUG$.", "LBL": "0", "DRUGA": ["diuretic", "group", "313-320"], "DRUGB": ["folic acid", "drug", "405-414"]}
{"ID": "DDI-DrugBank.d64.s90.p23", "TEXT1": "Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic agents) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal anti-inflammatory drugs, dipyridamole, @DRUG$, clofibrate, @DRUG$) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations.", "LBL": "0", "DRUGA": ["hydrochloroquine", "drug", "231-246"], "DRUGB": ["dextran", "drug", "261-267"]}
{"ID": "DDI-DrugBank.d64.s87.p421", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;@DRUG$*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;@DRUG$;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["chloral hydrate", "drug", "208-222"], "DRUGB": ["mefenamic acid", "drug", "518-531"]}
{"ID": "DDI-DrugBank.d48.s1.p48", "TEXT1": "Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, @DRUG$, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, @DRUG$) may increase exposure to dasatinib and should be avoided.", "LBL": "0", "DRUGA": ["clarithromycin", "drug", "104-117"], "DRUGB": ["telithromycin", "drug", "190-202"]}
{"ID": "DDI-DrugBank.d189.s0.p33", "TEXT1": "No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, @DRUG$, warfarin, isosorbide mononitrate, carvedilol, @DRUG$ or itraconazole.", "LBL": "0", "DRUGA": ["digoxin", "drug", "154-160"], "DRUGB": ["ethanol", "drug", "209-215"]}
{"ID": "DDI-DrugBank.d94.s4.p271", "TEXT1": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, @DRUG$, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), @DRUG$, zileuton.", "LBL": "0", "DRUGA": ["itraconazole", "drug", "314-325"], "DRUGB": ["verapamil", "drug", "481-489"]}
{"ID": "DDI-MedLine.d83.s13.p2", "TEXT1": "In comparison with @DRUG$, the adverse events reported significantly more frequently with olanzapine in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with risperidone, only bodyweight gain occurred significantly more frequently with @DRUG$.", "LBL": "0", "DRUGA": ["haloperidol", "drug", "19-29"], "DRUGB": ["olanzapine", "drug", "284-293"]}
{"ID": "DDI-DrugBank.d64.s29.p260", "TEXT1": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral @DRUG$;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;@DRUG$ under-dosage.", "LBL": "0", "DRUGA": ["contraceptives", "group", "379-392"], "DRUGB": ["warfarin sodium", "drug", "490-504"]}
{"ID": "DDI-DrugBank.d13.s0.p22", "TEXT1": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "LBL": "0", "DRUGA": ["MAOI", "group", "97-100"], "DRUGB": ["flupenthixol", "drug", "136-147"]}
{"ID": "DDI-DrugBank.d333.s7.p20", "TEXT1": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by @DRUG$, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other @DRUG$.", "LBL": "0", "DRUGA": ["alcohol", "drug", "115-121"], "DRUGB": ["anticonvulsant drugs", "group", "356-375"]}
{"ID": "DDI-DrugBank.d251.s0.p43", "TEXT1": "Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, @DRUG$, Rifampin, Ritanovir, @DRUG$.", "LBL": "0", "DRUGA": ["Rifabutin", "drug", "129-137"], "DRUGB": ["Saquinavir", "drug", "161-170"]}
{"ID": "DDI-DrugBank.d94.s11.p4", "TEXT1": "Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "LBL": "DDI-mechanism", "DRUGA": ["EQUETROTM", "brand", "96-104"], "DRUGB": ["buspirone", "drug", "210-218"]}
{"ID": "DDI-DrugBank.d411.s4.p452", "TEXT1": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.", "LBL": "0", "DRUGA": ["iodine-containing compounds", "group", "611-637"], "DRUGB": ["somatostatin analogs", "group", "778-797"]}
{"ID": "DDI-DrugBank.d64.s87.p768", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;@DRUG$;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;@DRUG$;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["diazoxide", "drug", "310-318"], "DRUGB": ["pyrazolones", "group", "763-773"]}
{"ID": "DDI-DrugBank.d434.s28.p13", "TEXT1": "Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in @DRUG$ plasma concentrations, In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) @DRUG$ concentration was 14.2 micrograms/mL.", "LBL": "0", "DRUGA": ["phenobarbital", "drug", "86-98"], "DRUGB": ["phenobarbital", "drug", "219-231"]}
{"ID": "DDI-DrugBank.d460.s12.p8", "TEXT1": "Similarly, nateglinide had no influence on the serum protein binding of @DRUG$, glyburide, @DRUG$, warfarin, phenytoin, acetylsalicylic acid, and tolbutamide in vitro .", "LBL": "0", "DRUGA": ["propranolol", "drug", "72-82"], "DRUGB": ["nicardipine", "drug", "96-106"]}
{"ID": "DDI-DrugBank.d31.s1.p0", "TEXT1": "When other potent parental @DRUG$, such as @DRUG$, are used in combination with hydralazine, patients should be continuously observed for several hours for any excessive fall in blood pressure.", "LBL": "DDI-effect", "DRUGA": ["antihypertensive drugs", "group", "27-48"], "DRUGB": ["diazoxide", "drug", "59-67"]}
{"ID": "DDI-DrugBank.d434.s30.p11", "TEXT1": "Effects of Other Antiepileptic Drugs on @DRUG$  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (@DRUG$) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "LBL": "0", "DRUGA": ["Felbatol", "brand", "40-47"], "DRUGB": ["felbamate", "drug", "133-141"]}
{"ID": "DDI-DrugBank.d178.s4.p16", "TEXT1": "These drugs include the thiazides and other @DRUG$, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and @DRUG$.", "LBL": "0", "DRUGA": ["diuretics", "group", "44-52"], "DRUGB": ["isoniazid", "drug", "221-229"]}
{"ID": "DDI-DrugBank.d123.s3.p3", "TEXT1": "Glyburide: The concomitant administration of @DRUG$ with the @DRUG$ glyburide has, on rare occasions, resulted in severe hypoglycemia.", "LBL": "DDI-effect", "DRUGA": ["ciprofloxacin", "drug", "45-57"], "DRUGB": ["sulfonylurea", "group", "68-79"]}
{"ID": "DDI-DrugBank.d219.s19.p2", "TEXT1": "Phenylbutazone: @DRUG$ causes increase (by about 80%) in the free fraction of @DRUG$.", "LBL": "DDI-mechanism", "DRUGA": ["Phenylbutazone", "drug", "16-29"], "DRUGB": ["etodolac", "drug", "86-93"]}
{"ID": "DDI-MedLine.d111.s5.p0", "TEXT1": "@DRUG$/@DRUG$, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.", "LBL": "0", "DRUGA": ["acetaminophen", "drug", "0-12"], "DRUGB": ["theophylline", "drug", "14-25"]}
{"ID": "DDI-DrugBank.d225.s6.p58", "TEXT1": "These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimetics, @DRUG$, and isoniazid.", "LBL": "0", "DRUGA": ["phenytoin", "drug", "138-146"], "DRUGB": ["calcium channel blocking drugs", "group", "183-212"]}
{"ID": "DDI-DrugBank.d367.s9.p20", "TEXT1": "Analgesic/anti-inflammatory (e.g., acetaminophen, @DRUG$, codeine and codeine combinations, @DRUG$, indomethacin).", "LBL": "0", "DRUGA": ["aspirin", "brand", "50-56"], "DRUGB": ["ibuprofen", "drug", "93-101"]}
{"ID": "DDI-DrugBank.d411.s4.p219", "TEXT1": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "LBL": "0", "DRUGA": ["antithyroid drugs", "group", "381-397"], "DRUGB": ["insulin", "drug", "568-574"]}
{"ID": "DDI-DrugBank.d558.s33.p3", "TEXT1": "In addition, studies in healthy volunteers have shown that @DRUG$ does not affect the pharmacokinetics or pharmacodynamics of warfarin, or the pharmacokinetics of propranolol (40 mg twice daily), phenytoin, @DRUG$, or oral contraceptives.", "LBL": "0", "DRUGA": ["TIKOSYN", "brand", "59-65"], "DRUGB": ["theophylline", "drug", "208-219"]}
{"ID": "DDI-DrugBank.d484.s0.p212", "TEXT1": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and @DRUG$, anticonvulsants (Dilantin, @DRUG$, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "LBL": "0", "DRUGA": ["tetracycline", "drug", "118-129"], "DRUGB": ["Phenobarbital", "drug", "159-171"]}
{"ID": "DDI-DrugBank.d528.s0.p2", "TEXT1": "@DRUG$ and methotrexate - L-methionine may decrease hepatic toxicity in those with @DRUG$ overdosage or in those taking methotrexate.", "LBL": "0", "DRUGA": ["Acetaminophen", "drug", "0-12"], "DRUGB": ["acetaminophen", "drug", "90-102"]}
{"ID": "DDI-DrugBank.d499.s13.p6", "TEXT1": "Digoxin: In a study in 12 patients with congestive heart failure where @DRUG$ and digoxin were concomitantly administered, ketoprofen did not alter the serum levels of @DRUG$.", "LBL": "0", "DRUGA": ["ketoprofen", "drug", "71-80"], "DRUGB": ["digoxin", "drug", "172-178"]}
{"ID": "DDI-DrugBank.d347.s4.p2", "TEXT1": "However, because some @DRUG$ have been reported to enhance the anticoagulant effects of warfarin or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a quinolone antimicrobial is administered concomitantly with @DRUG$ or its derivatives.", "LBL": "0", "DRUGA": ["quinolones", "group", "22-31"], "DRUGB": ["warfarin", "drug", "281-288"]}
{"ID": "DDI-DrugBank.d64.s87.p869", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;@DRUG$;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;@DRUG$;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["ethacrynic acid", "drug", "394-408"], "DRUGB": ["oxolinic acid", "drug", "638-650"]}
{"ID": "DDI-MedLine.d3.s1.p1", "TEXT1": "The objective of this study was to determine if there is a pharmacokinetic interaction when @DRUG$ is given with rifabutin or @DRUG$ and to determine the effects of these drugs on the erythromycin breath test (ERMBT).", "LBL": "0", "DRUGA": ["amprenavir", "drug", "92-101"], "DRUGB": ["rifampin", "drug", "130-137"]}
{"ID": "DDI-MedLine.d123.s2.p0", "TEXT1": "Here we show that a combination of @DRUG$ or 3,7-dihydroxyflavone with @DRUG$ may be used to sensitize resistant strains of Enterococcus faecalis and Enterococcus faecium to the level of vancomycin-sensitive strains.", "LBL": "0", "DRUGA": ["galangin", "drug", "35-42"], "DRUGB": ["vancomycin", "drug", "73-82"]}
{"ID": "DDI-DrugBank.d482.s14.p142", "TEXT1": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (@DRUG$) ketoconazole (Nizoral) levodopa lithium @DRUG$ birth control pills sleeping pills thyroid medications", "LBL": "0", "DRUGA": ["Sporanox", "brand", "228-235"], "DRUGB": ["muscle relaxants", "group", "278-293"]}
{"ID": "DDI-DrugBank.d54.s14.p0", "TEXT1": "Therefore, patients without a functioning @DRUG$ gland who are on thyroid replacement therapy may need to increase their thyroid dose if @DRUG$ or estrogen-containing oral contraceptives are given.", "LBL": "DDI-advise", "DRUGA": ["thyroid", "group", "42-48"], "DRUGB": ["estrogens", "group", "138-146"]}
{"ID": "DDI-DrugBank.d224.s1.p4", "TEXT1": "Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of @DRUG$ 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, @DRUG$, anesthetics) should be considered.", "LBL": "DDI-advise", "DRUGA": ["IOPIDINE", "brand", "130-137"], "DRUGB": ["sedatives", "group", "273-281"]}
{"ID": "DDI-DrugBank.d94.s4.p34", "TEXT1": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: @DRUG$, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), @DRUG$, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "LBL": "0", "DRUGA": ["Acetazolamide", "drug", "131-143"], "DRUGB": ["fluoxetine", "drug", "260-269"]}
{"ID": "DDI-DrugBank.d457.s0.p3", "TEXT1": "@DRUG$ may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, @DRUG$, corticosteroids, anticoagulants, and beta blockers.", "LBL": "DDI-effect", "DRUGA": ["Barbiturates", "group", "0-11"], "DRUGB": ["theophylline", "drug", "100-111"]}
{"ID": "DDI-DrugBank.d568.s3.p0", "TEXT1": "Drugs That Interfere With Hemostasis (@DRUG$, @DRUG$, Warfarin, etc.)", "LBL": "0", "DRUGA": ["NSAIDs", "group", "38-43"], "DRUGB": ["Aspirin", "brand", "46-52"]}
{"ID": "DDI-DrugBank.d235.s4.p66", "TEXT1": "Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, @DRUG$, isoniazid, nefazodone, nicardipine, @DRUG$, protease inhibitors, quinidine, and verapamil.", "LBL": "0", "DRUGA": ["imatinib", "drug", "116-123"], "DRUGB": ["propofol", "drug", "162-169"]}
{"ID": "DDI-DrugBank.d351.s0.p3", "TEXT1": "@DRUG$: As with other b-lactam antibiotics, renal excretion of loracarbef is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for @DRUG$.", "LBL": "0", "DRUGA": ["Probenecid", "drug", "0-9"], "DRUGB": ["loracarbef", "drug", "164-173"]}
{"ID": "DDI-DrugBank.d94.s4.p185", "TEXT1": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, @DRUG$, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, @DRUG$, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "LBL": "0", "DRUGA": ["diltiazem", "drug", "232-240"], "DRUGB": ["ketoconazole", "drug", "328-339"]}
{"ID": "DDI-DrugBank.d94.s4.p186", "TEXT1": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, @DRUG$, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, @DRUG$, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "LBL": "0", "DRUGA": ["diltiazem", "drug", "232-240"], "DRUGB": ["loratadine", "drug", "342-351"]}
{"ID": "DDI-DrugBank.d64.s29.p259", "TEXT1": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral @DRUG$;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;@DRUG$;warfarin sodium under-dosage.", "LBL": "0", "DRUGA": ["contraceptives", "group", "379-392"], "DRUGB": ["vitamin C", "drug", "480-488"]}
{"ID": "DDI-DrugBank.d484.s0.p341", "TEXT1": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, @DRUG$, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, @DRUG$, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "LBL": "0", "DRUGA": ["Phenobarbital", "drug", "159-171"], "DRUGB": ["Crixivan", "brand", "397-404"]}
{"ID": "DDI-MedLine.d132.s4.p8", "TEXT1": "Both efavirenz and @DRUG$ have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with @DRUG$.", "LBL": "0", "DRUGA": ["nevirapine", "drug", "19-28"], "DRUGB": ["efavirenz", "drug", "216-224"]}
{"ID": "DDI-DrugBank.d184.s0.p43", "TEXT1": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, @DRUG$ (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing @DRUG$ (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "LBL": "0", "DRUGA": ["corticotropin", "drug", "135-147"], "DRUGB": ["estrogens", "group", "514-522"]}
{"ID": "DDI-DrugBank.d411.s3.p59", "TEXT1": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, @DRUG$, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, @DRUG$, salicylates, tamoxifen.", "LBL": "0", "DRUGA": ["asparaginase", "drug", "210-221"], "DRUGB": ["phenytoin", "drug", "402-410"]}
{"ID": "DDI-DrugBank.d568.s12.p4", "TEXT1": "Because lithium may enhance the serotonergic effects of @DRUG$, caution should be exercised when LEXAPRO and @DRUG$ are coadministered.", "LBL": "0", "DRUGA": ["escitalopram", "drug", "56-67"], "DRUGB": ["lithium", "drug", "115-121"]}
{"ID": "DDI-DrugBank.d94.s11.p567", "TEXT1": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.", "LBL": "0", "DRUGA": ["dicumarol", "drug", "315-323"], "DRUGB": ["warfarin", "drug", "703-710"]}
{"ID": "DDI-DrugBank.d566.s0.p45", "TEXT1": "Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, @DRUG$ (acidic) or propranolol (basic), as well as tetracycline penicillin G, @DRUG$, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.", "LBL": "0", "DRUGA": ["thiazide diuretics", "group", "121-138"], "DRUGB": ["phenobarbital", "drug", "211-223"]}
{"ID": "DDI-DrugBank.d410.s3.p2", "TEXT1": "@DRUG$: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45  (dihydroergotamine mesylate) Injection, USP to subjects already receiving @DRUG$, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.", "LBL": "0", "DRUGA": ["Beta Blockers", "group", "0-12"], "DRUGB": ["propranolol", "drug", "211-221"]}
{"ID": "DDI-DrugBank.d3.s13.p8", "TEXT1": "Methotrexate: Concomitant administration of methotrexate and some @DRUG$ has been reported to reduce the clearance of methotrexate, enhancing the toxicity of @DRUG$.", "LBL": "0", "DRUGA": ["NSAIDs", "group", "66-71"], "DRUGB": ["methotrexate", "drug", "158-169"]}
{"ID": "DDI-DrugBank.d397.s8.p86", "TEXT1": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, @DRUG$, valproate, @DRUG$, and astemizole.", "LBL": "0", "DRUGA": ["bromocriptine", "drug", "176-188"], "DRUGB": ["terfenadine", "drug", "202-212"]}
{"ID": "DDI-DrugBank.d382.s20.p0", "TEXT1": "therefore, the efficacy of oral @DRUG$ during administration of @DRUG$ may be reduced.", "LBL": "DDI-effect", "DRUGA": ["contraceptives", "group", "32-45"], "DRUGB": ["Aprepitant", "drug", "72-81"]}
{"ID": "DDI-DrugBank.d484.s0.p732", "TEXT1": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), @DRUG$ (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (@DRUG$), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "LBL": "0", "DRUGA": ["cyclosporine", "drug", "306-317"], "DRUGB": ["rifampin", "drug", "547-554"]}
{"ID": "DDI-DrugBank.d48.s15.p85", "TEXT1": "Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or @DRUG$ (@DRUG$, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.", "LBL": "0", "DRUGA": ["ergot alkaloids", "group", "197-211"], "DRUGB": ["ergotamine", "drug", "214-223"]}
{"ID": "DDI-DrugBank.d328.s48.p4", "TEXT1": "Plasma exposure of diazepam (10 mg BID) was increased by 28% following administration of @DRUG$ (40 mg BID) for 12 days, while plasma exposure of valdecoxib (40 mg BID) was not substantially increased following administration of @DRUG$ (10 mg BID) for 12 days.", "LBL": "0", "DRUGA": ["valdecoxib", "drug", "89-98"], "DRUGB": ["diazepam", "drug", "233-240"]}
{"ID": "DDI-DrugBank.d235.s4.p40", "TEXT1": "Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, @DRUG$, doxycycline, erythromycin, imatinib, isoniazid, @DRUG$, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.", "LBL": "0", "DRUGA": ["diclofenac", "drug", "77-86"], "DRUGB": ["nefazodone", "drug", "137-146"]}
{"ID": "DDI-DrugBank.d382.s16.p2", "TEXT1": "Although there was no effect of @DRUG$ on the plasma AUC of R(+) or S(-) warfarin determined on Day 3, there was a 34% decrease in @DRUG$ (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with Aprepitant.", "LBL": "0", "DRUGA": ["Aprepitant", "drug", "32-41"], "DRUGB": ["S(-)warfarin", "drug", "135-146"]}
{"ID": "DDI-DrugBank.d45.s4.p1", "TEXT1": "In rheumatoid arthritis, concomitant medications besides @DRUG$ were nonsteroidal anti-inflammatory agents, @DRUG$, corticosteroids and/or narcotics.", "LBL": "0", "DRUGA": ["MTX", "drug", "57-59"], "DRUGB": ["folic acid", "drug", "105-114"]}
{"ID": "DDI-DrugBank.d330.s2.p4", "TEXT1": "Oral neomycin inhibits the gastrointestinal absorption of @DRUG$, oral @DRUG$, methotrexate and 5-fluorouracil.", "LBL": "0", "DRUGA": ["penicillin V", "drug", "58-69"], "DRUGB": ["vitamin B-12", "drug", "77-88"]}
{"ID": "DDI-DrugBank.d527.s2.p94", "TEXT1": "The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), isoniazid, @DRUG$, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral @DRUG$).", "LBL": "0", "DRUGA": ["phenothiazine derivatives", "group", "219-243"], "DRUGB": ["contraceptives", "group", "315-328"]}
{"ID": "DDI-DrugBank.d460.s12.p11", "TEXT1": "Similarly, nateglinide had no influence on the serum protein binding of @DRUG$, glyburide, nicardipine, warfarin, phenytoin, @DRUG$, and tolbutamide in vitro .", "LBL": "0", "DRUGA": ["propranolol", "drug", "72-82"], "DRUGB": ["acetylsalicylic acid", "drug", "130-149"]}
{"ID": "DDI-DrugBank.d415.s12.p0", "TEXT1": "@DRUG$: @DRUG$ produced an elevation of plasma lithium levels and a reduction in renal lithium clearance in a study of eleven normal volunteers.", "LBL": "0", "DRUGA": ["Lithium", "drug", "0-6"], "DRUGB": ["Ibuprofen", "drug", "9-17"]}
{"ID": "DDI-DrugBank.d388.s5.p12", "TEXT1": "No significant interactions with digoxin, hydrochlorothiazide, @DRUG$, sulfinpyrazone, oral @DRUG$, tolbutamide, or warfarin have been observed.", "LBL": "0", "DRUGA": ["hydralazine", "drug", "63-73"], "DRUGB": ["contraceptives", "group", "97-110"]}
{"ID": "DDI-DrugBank.d94.s4.p238", "TEXT1": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, @DRUG$, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, @DRUG$, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "LBL": "0", "DRUGA": ["fluvoxamine", "drug", "272-282"], "DRUGB": ["protease inhibitors", "group", "393-411"]}
{"ID": "DDI-DrugBank.d480.s30.p22", "TEXT1": "Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, @DRUG$, and Type 1C antiarrhythmics (e.g., @DRUG$, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.", "LBL": "0", "DRUGA": ["carbamazepine", "drug", "140-152"], "DRUGB": ["propafenone", "drug", "190-200"]}
{"ID": "DDI-MedLine.d29.s3.p3", "TEXT1": "To determine whether probenecid has a direct effect on the distribution of @DRUG$, the elimination and distribution of @DRUG$ was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of probenecid.", "LBL": "0", "DRUGA": ["cloxacillin", "drug", "75-85"], "DRUGB": ["cloxacillin", "drug", "124-134"]}
{"ID": "DDI-DrugBank.d64.s29.p239", "TEXT1": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;@DRUG$;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;@DRUG$ under-dosage.", "LBL": "0", "DRUGA": ["griseofulvin", "drug", "337-348"], "DRUGB": ["warfarin sodium", "drug", "490-504"]}
{"ID": "DDI-DrugBank.d176.s12.p21", "TEXT1": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, @DRUG$, hydrochlorothiazide, cimetidine, @DRUG$, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.", "LBL": "0", "DRUGA": ["propanolol", "drug", "105-114"], "DRUGB": ["metoclopramide", "drug", "150-163"]}
{"ID": "DDI-DrugBank.d244.s0.p20", "TEXT1": "Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, @DRUG$), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, @DRUG$.", "LBL": "0", "DRUGA": ["amikacin", "drug", "173-180"], "DRUGB": ["vancomycin", "drug", "283-292"]}
{"ID": "DDI-DrugBank.d413.s12.p2", "TEXT1": "@DRUG$: The reports that the concomitant use of allopurinol and thiazide diuretics may contribute to the enhancement of @DRUG$ toxicity in some patients have been reviewed in an attempt to establish a cause-and-effect relationship and a mechanism of causation.", "LBL": "0", "DRUGA": ["Thiazide Diuretics", "group", "0-17"], "DRUGB": ["allopurinol", "drug", "132-142"]}
{"ID": "DDI-DrugBank.d525.s2.p3", "TEXT1": "Because eprosartan is not metabolized by the cytochrome P450 system, inhibitors of CYP450 enzyme would not be expected to affect its metabolism, and @DRUG$ and @DRUG$, potent inhibitors of CYP3A and 2C9, respectively, have been shown to have no effect on eprosartan pharmacokinetics.", "LBL": "0", "DRUGA": ["ketoconazole", "drug", "149-160"], "DRUGB": ["fluconazole", "drug", "166-176"]}
{"ID": "DDI-DrugBank.d460.s11.p6", "TEXT1": "In vitro displacement studies with highly protein-bound drugs such as @DRUG$, propranolol, captopril, nicardipine, pravastatin, glyburide, warfarin, @DRUG$, acetylsalicylic acid, tolbutamide, and metformin showed no influence on the extent of nateglinide protein binding.", "LBL": "0", "DRUGA": ["furosemide", "drug", "70-79"], "DRUGB": ["phenytoin", "drug", "153-161"]}
{"ID": "DDI-DrugBank.d485.s17.p9", "TEXT1": "Benzodiazepines: Combination @DRUG$ may decrease the clearance of some benzodiazepines (@DRUG$, chlordiazepoxide, diazepam) and increase the clearance of others (lorazepam, oxazepam, temazepam).", "LBL": "DDI-mechanism", "DRUGA": ["hormonal contraceptives", "group", "29-51"], "DRUGB": ["alprazolam", "drug", "105-114"]}
{"ID": "DDI-DrugBank.d551.s1.p1", "TEXT1": "@DRUG$  was found to have no significant effect on the bioavailability of digoxin, @DRUG$, metoprolol, quinidine, valproic acid, and warfarin.", "LBL": "0", "DRUGA": ["WelChol", "brand", "0-6"], "DRUGB": ["lovastatin", "drug", "84-93"]}
{"ID": "DDI-DrugBank.d558.s7.p3", "TEXT1": "Co-administration of TIKOSYN with @DRUG$ resulted in increases in @DRUG$ peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.", "LBL": "0", "DRUGA": ["verapamil", "drug", "34-42"], "DRUGB": ["dofetilide", "drug", "69-78"]}
{"ID": "DDI-MedLine.d111.s5.p84", "TEXT1": "acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen, and valproic acid/@DRUG$.", "LBL": "0", "DRUGA": ["lidocaine", "drug", "117-125"], "DRUGB": ["phenobarbital", "drug", "174-186"]}
{"ID": "DDI-DrugBank.d411.s3.p55", "TEXT1": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, @DRUG$, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, @DRUG$, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.", "LBL": "0", "DRUGA": ["asparaginase", "drug", "210-221"], "DRUGB": ["mefenamic acid", "drug", "345-358"]}
{"ID": "DDI-DrugBank.d179.s7.p0", "TEXT1": "- @DRUG$ (e.g., @DRUG$) or", "LBL": "0", "DRUGA": ["Carmustine", "drug", "2-11"], "DRUGB": ["BiCNU", "brand", "20-24"]}
{"ID": "DDI-DrugBank.d31.s2.p0", "TEXT1": "Profound hypotensive episodes may occur when @DRUG$ infection and @DRUG$ are used concomitantly.", "LBL": "DDI-effect", "DRUGA": ["diazoxide", "drug", "45-53"], "DRUGB": ["hydralazine", "drug", "69-79"]}
{"ID": "DDI-DrugBank.d562.s10.p0", "TEXT1": "Seizures have been reported in patients taking another @DRUG$ and the @DRUG$ fenbufen concurrently.", "LBL": "DDI-effect", "DRUGA": ["quinolone class antimicrobial", "group", "55-83"], "DRUGB": ["nonsteroidal anti-inflammatory drug", "group", "93-127"]}
{"ID": "DDI-DrugBank.d347.s0.p0", "TEXT1": "Administration of repeat doses of @DRUG$ had no effect on the repeat dose pharmacokinetics of @DRUG$, digoxin or an ethinylestradiol/levonorgestrol oral contraceptive product in healthy subjects.", "LBL": "0", "DRUGA": ["FACTIVE", "brand", "34-40"], "DRUGB": ["theophylline", "drug", "95-106"]}
{"ID": "DDI-DrugBank.d306.s0.p13", "TEXT1": "The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants @DRUG$, carbamazepine, and barbiturates, and the @DRUG$ rifampin.", "LBL": "0", "DRUGA": ["phenytoin", "drug", "114-122"], "DRUGB": ["antituberculosis drug", "group", "166-186"]}
{"ID": "DDI-DrugBank.d78.s1.p57", "TEXT1": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as @DRUG$, or with @DRUG$ containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.", "LBL": "0", "DRUGA": ["iron", "drug", "131-134"], "DRUGB": ["multivitamins", "group", "145-157"]}
{"ID": "DDI-DrugBank.d202.s16.p11", "TEXT1": "Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other @DRUG$, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, @DRUG$, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.", "LBL": "0", "DRUGA": ["antidepressants", "group", "131-145"], "DRUGB": ["propafenone", "drug", "212-222"]}
{"ID": "DDI-DrugBank.d77.s21.p0", "TEXT1": "It is desirable to monitor @DRUG$ plasma levels whenever a @DRUG$ is going to be co-administered with another drug known to be an inhibitor of P450 2D6.", "LBL": "0", "DRUGA": ["TCA", "group", "27-29"], "DRUGB": ["TCA", "group", "56-58"]}
{"ID": "DDI-DrugBank.d138.s0.p14", "TEXT1": "Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (@DRUG$, barbiturates, opiates, sedatives, or @DRUG$) should be considered.", "LBL": "0", "DRUGA": ["alcohol", "drug", "160-166"], "DRUGB": ["anesthetics", "group", "206-216"]}
{"ID": "DDI-DrugBank.d521.s8.p35", "TEXT1": "- a phenothiazine such as chlorpromazine (Thorazine), fluphenazine (Prolixin, @DRUG$), @DRUG$ (Compazine), promethazine (Phenergan), and others;", "LBL": "0", "DRUGA": ["Permitil", "brand", "78-85"], "DRUGB": ["prochlorperazine", "drug", "89-104"]}
{"ID": "DDI-DrugBank.d5.s13.p0", "TEXT1": "Although @DRUG$ is not metabolized by this isoenzyme, @DRUG$ and hydroxybupropion are inhibitors of the CYP2D6 isoenzyme in vitro.", "LBL": "0", "DRUGA": ["bupropion", "drug", "9-17"], "DRUGB": ["bupropion", "drug", "57-65"]}
{"ID": "DDI-MedLine.d111.s5.p15", "TEXT1": "acetaminophen/@DRUG$, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.", "LBL": "0", "DRUGA": ["theophylline", "drug", "14-25"], "DRUGB": ["phenobarbital", "drug", "49-61"]}
{"ID": "DDI-DrugBank.d536.s4.p10", "TEXT1": "Intestinal adsorbents (e. g., charcoal) and @DRUG$ containing carbohydrate-splitting enzymes (e. g., amylase, @DRUG$) may reduce the effect of Acarbose and should not be taken concomitantly.", "LBL": "0", "DRUGA": ["digestive enzyme preparations", "group", "44-72"], "DRUGB": ["pancreatin", "drug", "133-142"]}
{"ID": "DDI-MedLine.d19.s4.p2", "TEXT1": "Numerous drug interactions are possible with some anticonvulsant agents, such as @DRUG$ and @DRUG$, which affect hepatic microsomal enzyme systems.", "LBL": "0", "DRUGA": ["phenobarbitone", "drug", "81-94"], "DRUGB": ["phenytoin", "drug", "100-108"]}
{"ID": "DDI-DrugBank.d521.s2.p153", "TEXT1": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (@DRUG$, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (@DRUG$), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "LBL": "0", "DRUGA": ["Orudis", "brand", "111-116"], "DRUGB": ["Lodine", "brand", "183-188"]}
{"ID": "DDI-DrugBank.d568.s11.p0", "TEXT1": "Nevertheless, plasma @DRUG$ levels should be monitored with appropriate adjustment to the @DRUG$ dose in accordance with standard clinical practice.", "LBL": "0", "DRUGA": ["lithium", "drug", "21-27"], "DRUGB": ["lithium", "drug", "91-97"]}
{"ID": "DDI-DrugBank.d484.s0.p67", "TEXT1": "Etonogestrel may interact with the following medications: @DRUG$ (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (@DRUG$, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "LBL": "0", "DRUGA": ["acetaminophen", "drug", "58-70"], "DRUGB": ["Agenerase", "brand", "386-394"]}
{"ID": "DDI-DrugBank.d411.s4.p251", "TEXT1": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "LBL": "0", "DRUGA": ["b-adrenergic blocking agents", "group", "400-427"], "DRUGB": ["mitotane", "drug", "705-712"]}
{"ID": "DDI-DrugBank.d299.s8.p1", "TEXT1": "@DRUG$: Coadministration of almotriptan and @DRUG$ resulted in a 24% increase in plasma concentrations of almotriptan.", "LBL": "0", "DRUGA": ["Verapamil", "drug", "0-8"], "DRUGB": ["verapamil", "drug", "47-55"]}
{"ID": "DDI-DrugBank.d81.s11.p4", "TEXT1": "Warfarin: In a study in healthy volunteers, no clinically relevant pharmacokinetic or pharmacodynamic interaction between @DRUG$ and racemic @DRUG$ was seen when two single oral doses of warfarin (0.7 mg/kg body weight) were administered during 11 days of multipledose treatment with 5 mg b.i.d. isradipine.", "LBL": "0", "DRUGA": ["isradipine", "drug", "122-131"], "DRUGB": ["warfarin", "drug", "145-152"]}
{"ID": "DDI-DrugBank.d60.s12.p0", "TEXT1": "Other drugs which may enhance the neuromuscular blocking action of @DRUG$ such as @DRUG$ include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "LBL": "DDI-effect", "DRUGA": ["nondepolarizing agents", "group", "67-88"], "DRUGB": ["NIMBEX", "brand", "98-103"]}
{"ID": "DDI-DrugBank.d64.s87.p5", "TEXT1": "Drugs that reportedly may increase oral @DRUG$ response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;@DRUG$;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "DDI-effect", "DRUGA": ["anticoagulant", "group", "40-52"], "DRUGB": ["antibiotics", "group", "185-195"]}
{"ID": "DDI-DrugBank.d110.s0.p5", "TEXT1": "The administration of local anesthetic solutions containing @DRUG$ or @DRUG$ to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.", "LBL": "0", "DRUGA": ["epinephrine", "drug", "60-70"], "DRUGB": ["norepinephrine", "drug", "75-88"]}
{"ID": "DDI-DrugBank.d17.s21.p0", "TEXT1": "(Concurrent use with @DRUG$ is not recommended, as they may provoke @DRUG$ toxicity because of reduced renal clearance.)", "LBL": "0", "DRUGA": ["thiazide diuretics", "group", "21-38"], "DRUGB": ["lithium", "drug", "80-86"]}
{"ID": "DDI-DrugBank.d551.s1.p14", "TEXT1": "WelChol  was found to have no significant effect on the bioavailability of digoxin, @DRUG$, metoprolol, quinidine, valproic acid, and @DRUG$.", "LBL": "0", "DRUGA": ["lovastatin", "drug", "84-93"], "DRUGB": ["warfarin", "drug", "138-145"]}
{"ID": "DDI-DrugBank.d324.s35.p4", "TEXT1": "Warfarin: Multiple oral doses of @DRUG$ (20 mg q24h for 13 days) did not affect the pharmacokinetics of warfarin (R+)- or (S-)-enantiomers or the pharmacodynamics (prothrombin time) following a single 25-mg oral dose of @DRUG$.", "LBL": "0", "DRUGA": ["Sonata", "brand", "33-38"], "DRUGB": ["warfarin", "drug", "220-227"]}
{"ID": "DDI-DrugBank.d64.s87.p1150", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;@DRUG$;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;@DRUG$;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["methylphenidate", "drug", "544-558"], "DRUGB": ["salicylates", "group", "805-815"]}
{"ID": "DDI-MedLine.d114.s1.p1", "TEXT1": "The effects of @DRUG$ (RR) on @DRUG$ (InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry.", "LBL": "0", "DRUGA": ["ruthenium red", "drug_n", "15-27"], "DRUGB": ["inositol 1,4,5-trisphosphate", "drug_n", "37-64"]}
{"ID": "DDI-DrugBank.d546.s0.p2", "TEXT1": "Drug Interactions with Beta-Blockers: Concomitant use of @DRUG$ with @DRUG$ should be avoided.", "LBL": "DDI-advise", "DRUGA": ["fenoldopam", "drug", "57-66"], "DRUGB": ["beta-blockers", "group", "73-85"]}
{"ID": "DDI-DrugBank.d488.s6.p6", "TEXT1": "Drugs Decreasing Heparin Effect: @DRUG$, tetracyclines, @DRUG$, or antihistamines may partially counteract the anticoagulant action of heparin sodium.", "LBL": "0", "DRUGA": ["Digitalis", "group", "33-41"], "DRUGB": ["nicotine", "drug", "59-66"]}
{"ID": "DDI-DrugBank.d94.s11.p699", "TEXT1": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "LBL": "0", "DRUGA": ["glucocorticoids", "group", "376-390"], "DRUGB": ["quetiapine", "drug", "609-618"]}
{"ID": "DDI-DrugBank.d531.s5.p0", "TEXT1": "Drugs which induce CYP3A4 activity (eg, @DRUG$, @DRUG$, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.", "LBL": "0", "DRUGA": ["phenobarbital", "drug", "40-52"], "DRUGB": ["rifampin", "drug", "55-62"]}
{"ID": "DDI-DrugBank.d567.s14.p0", "TEXT1": "However, another @DRUG$ has been found to produce a less than two-second increase in prothrombin time in healthy volunteers receiving low doses of @DRUG$.", "LBL": "DDI-effect", "DRUGA": ["HMG-CoA reductase inhibitor", "group", "17-43"], "DRUGB": ["warfarin", "drug", "168-175"]}
{"ID": "DDI-DrugBank.d558.s32.p25", "TEXT1": "Other Drugs: In healthy volunteers, amlodipine, phenytoin, @DRUG$, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), @DRUG$ (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.", "LBL": "0", "DRUGA": ["glyburide", "drug", "59-67"], "DRUGB": ["antacid", "group", "187-193"]}
{"ID": "DDI-DrugBank.d467.s2.p2", "TEXT1": "On the basis of the metabolism of @DRUG$ by cytochrome P450 3A4, ketoconazole, itraconazole, @DRUG$, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.", "LBL": "0", "DRUGA": ["bexarotene", "drug", "34-43"], "DRUGB": ["erythromycin", "drug", "97-108"]}
{"ID": "DDI-DrugBank.d263.s13.p97", "TEXT1": "Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, @DRUG$, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, @DRUG$, and vincristine.", "LBL": "0", "DRUGA": ["hydralazine", "drug", "186-196"], "DRUGB": ["ribavirin", "drug", "264-272"]}
{"ID": "DDI-DrugBank.d103.s3.p6", "TEXT1": "Monoamine Oxidase Inhibitors and @DRUG$: FORADIL should be administered with extreme caution in patients being treated with @DRUG$ or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.", "LBL": "0", "DRUGA": ["Tricyclic Antidepressants", "group", "33-57"], "DRUGB": ["monoamine oxidase inhibitors", "group", "143-170"]}
{"ID": "DDI-DrugBank.d196.s6.p9", "TEXT1": "Stavudine and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of @DRUG$ and @DRUG$ against HIV.", "LBL": "0", "DRUGA": ["stavudine", "drug", "85-93"], "DRUGB": ["zidovudine", "drug", "99-108"]}
{"ID": "DDI-DrugBank.d420.s5.p8", "TEXT1": "Iron Supplements and Foods Fortified With @DRUG$ Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental @DRUG$ (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.", "LBL": "0", "DRUGA": ["Iron", "drug", "42-45"], "DRUGB": ["iron", "drug", "151-154"]}
{"ID": "DDI-DrugBank.d211.s5.p2", "TEXT1": "Probenecid: May decrease renal tubular secretion of @DRUG$ resulting in increased blood levels and/or @DRUG$ toxicity.", "LBL": "0", "DRUGA": ["ampicillin", "drug", "52-61"], "DRUGB": ["ampicillin", "drug", "106-115"]}
{"ID": "DDI-DrugBank.d15.s0.p7", "TEXT1": "In clinical studies performed with @DRUG$, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.", "LBL": "0", "DRUGA": ["Fondaparinux", "drug", "35-46"], "DRUGB": ["fondaparinux sodium", "drug", "250-268"]}
{"ID": "DDI-DrugBank.d13.s0.p35", "TEXT1": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of Tricyclic antidepressants", "LBL": "0", "DRUGA": ["MAOI", "group", "104-107"], "DRUGB": ["Tricyclic antidepressants", "group", "260-284"]}
{"ID": "DDI-DrugBank.d210.s23.p1", "TEXT1": "Oral @DRUG$ Rofecoxib did not have any clinically important effect on the pharmacokinetics of @DRUG$ and norethindrone.", "LBL": "0", "DRUGA": ["Contraceptives", "group", "5-18"], "DRUGB": ["ethinyl estradiol", "drug", "102-118"]}
{"ID": "DDI-DrugBank.d537.s0.p30", "TEXT1": "Bentiromide may interact with acetaminophen (e.g., @DRUG$), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., @DRUG$ and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "LBL": "0", "DRUGA": ["Tylenol", "brand", "51-57"], "DRUGB": ["benzocaine", "drug", "125-134"]}
{"ID": "DDI-DrugBank.d558.s12.p6", "TEXT1": "Hydrochlorothiazide (@DRUG$) Alone or in Combination with Triamterene: Concomitant use of HCTZ alone or in combination with @DRUG$ is contraindicated.", "LBL": "0", "DRUGA": ["HCTZ", "drug", "21-24"], "DRUGB": ["triamterene", "drug", "122-132"]}
{"ID": "DDI-DrugBank.d94.s4.p194", "TEXT1": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, @DRUG$, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, @DRUG$, valproate(1), verapamil, zileuton.", "LBL": "0", "DRUGA": ["diltiazem", "drug", "232-240"], "DRUGB": ["troleandomycin", "drug", "451-464"]}
{"ID": "DDI-DrugBank.d546.s2.p1", "TEXT1": "Drug Interactions, General: Although there have been no formal interaction studies, intravenous @DRUG$ has been administered safely with drugs such as digitalis and sublingual @DRUG$.", "LBL": "0", "DRUGA": ["fenoldopam", "drug", "96-105"], "DRUGB": ["nitroglycerin", "drug", "180-192"]}
{"ID": "DDI-DrugBank.d86.s1.p55", "TEXT1": "Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), @DRUG$, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, @DRUG$, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.", "LBL": "0", "DRUGA": ["sparfloxacin", "drug", "163-174"], "DRUGB": ["lithium", "drug", "243-249"]}
{"ID": "DDI-DrugBank.d94.s11.p81", "TEXT1": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "LBL": "0", "DRUGA": ["Acetaminophen", "drug", "157-169"], "DRUGB": ["topiramate", "drug", "648-657"]}
